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Abstract 
Endothelial cell apoptosis IS an important process during vasculature remodelling, 
angiogenesis and inflammation. Medical interest in endothelial cell apoptosis as a 
target for arthritis and solid tumour treatment has prompted biochemical and 
pharmacological investigation into the mechanisms controlling endothelial cell survival 
and angiogenesis. In recent years it has been hypothesised that control of endothelial 
cell apoptosis and the induction of angiogenesis may in part be due to the enzyme 
cyclooxygenase (COX)-2. 
COX-2 is involved in the metabolism of arachidonic acid to prostaglandins in 
mammals. This pathway has been implicated in controlling inflammation and 
angiogenesis through prostaglandin (PG) pro~uction and more recently has been shown 
to inhibit endothelial cell death. It was the aim of this study to investigate endothelial 
cell apoptosis and angiogenesis focussing on the role of COX-2, prostaglandins and 
endogenous apoptotic inhibitors in these pathways. 
Endothelial cell apoptosis was assessed by chromatin condensation, DNA fragmentation 
and caspase activation. Angiogenesis was investigated by examining capillary-like 
tubule formation. Endothelial cell apoptosis induction and angiogenesis inhibition was 
observed using the selective COX-2 inhibitor 5-bromo-2-(4-fluorophenyl)-3-
(methylsulfonyl) thiophene (DuP-697) at a concentration 100 times lower than has 
previously been reported. Apoptosis was confirmed by induction of caspases 8, 9 and 3 
over 8 hr and DNA fragmentation and condensation over 24 hr. The effects observed 
may be due to a selective inhibition of COX-2 as apoptosis induction and angiogenic 
III 
inhibition only occurred when COX-2 was inhibited by selective and non-selective 
COX inhibitors. 
Induction of endothelial cell death was induced by treatment with two natural products 
that inhibit COX-2, namely curcumin and 6-shogaol (from turmeric and ginger 
respectively) although only at concentrations higher than were required to inhibit COX-
2. Both compounds induced chromatin condensation in endothelial cells and lurkat 
E6.1 cells with no DNA laddering or caspase induction. 
Further examination of the mechanisms of endothelial cell survival were investigated by 
assessing the endogenous expression of the apoptosis repressor with a caspase 
recognition domain (ARC) protein through examining reverse transcriptase CRT) - peR, 
native protein expression and transgenic over-expression in the endothelial cells. 
Endogenous expression of ARC was found in endothelial cells. However this 
expression declined during in vitro culture. Transgenic expression of ARC was found 
to increase levels of ARC in vitro. However it had no effect on apoptosis inhibition 
after 24 hr. 
The underlying mechanisms of cell death induction may be compound dependent in 
endothelial cells. Pharmacological inhibition of COX-2 and possibly PGE2 generation 
has detrimental effects on angiogenesis and endothelial cell survival. However 
inhibition of COX-2 by natural products at low concentrations may be advantageous in 
preventing tumour angiogenesis with no apoptosis induction. 
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1 Introduction 
1. 1 Endothelial cells and angiogenesis 
1.1.1 Endothelial cells 
Vascular endothelial cells are found as a monolayer in the internal surface of blood vessels 
in the body. In the vasculature of the arteries the endothelial cells are elongated forming a 
smooth luminal surface. Venous vessels however have endothelial cells that are rounded 
indented and bulge in to the lumen. Endothelial cells have three surfaces (i) a cohesive 
surface that adjoin endothelial cells to each other (ii) an adhesive surface which bind the 
cells to the basement membrane and (iii) a luminal surface that has specific binding 
proteins for the regulation of blood cells (Pasyk and lakobczak, 2004). Vascular 
endothelium is found to regulate blood pressure by releasing vasodilators such as nitric 
oxide and prostacyclin and vasoconstrictors e.g. thromboxane A2 and platelet activating 
factor. Endothelial cells are also found to secrete prostaglandins and numerous growth 
factors including vascular endothelial growth factor and basic fibroblast growth factor, 
which aid in the process of angiogenesis (Pasyk and lakobczak, 2004). 
1.1.2 Angiogenesis 
Hertig described angiogenesis originally in 1935 as the formation of new blood vessels 
from pre-existing blood vessels during physiological development. Angiogenesis occurs 
physiologically in the female reproductive system, embryogenesis and in normal 
1 
angiogenic turnover (Hertig, 1935; Paper, 1998; Carmeliet, 2000; Dor et al., 2003). In 
healthy adults angiogenic turnover is slow requiring 3 to 12 months (Paper 1998). 
Angiogenesis also occurs in pathological states such as wound healing, tumour formation, 
inflammation, and rheumatoid arthritis (Carmeliet, 2000; Cao, 2001; Chavakis and 
Dimmeler, 2002; Folkman, 2003). In 1971 Judah Folkman observed that angiogenesis was 
required for the growth of tumours beyond 1-3 cubic millimetres (mm) (Folkman, 1971). It 
is due to this that angiogenesis is the most studied form of blood vessel formation in adults. 
Initiation of angiogenesis is controlled by the balance of pro and anti angiogenic molecules 
in the surrounding cellular environment. Endothelial cells remain in the normal quiescent 
state due to anti-angiogenic factors out balancing the pro-angiogenic factors. The 
activation of angiogenesis is initiated by the turning on of the "angiogenesis master 
switch", which induces the production of pro-angiogenic inducers and the formation of new 
blood vessels (Carmeliet and Jain, 2000). Some of these inducing "switches" can include 
mechanical stress produced by proliferating cells, hypoxia, hypoglycaemia and 
inflammation (Carmeliet, 1999; Carmeliet, 2000; Lingen, 2001). 
Angiogenic stimuli cause the release of pro-angiogenic molecules such as vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and granulocyte 
macrophage colony stimulating factor (GM-CSF) (Rak et al., 2000; Folkman, 2003). The 
stimulated endothelial cells secrete proteases that breakdown the basement membrane of 
the parental blood vessels extracellular matrix (ECM). The endothelial cells then migrate 
through the gaps in the basement membrane toward the site of the chemotactic angiogenic 
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stimuli. Proliferation of the endothelial cells occurs and the endothelial cells form vessels 
by lining up bipolarly. The two sprouts of endothelial cells form a capillary and the 
basement membrane reform (Fig 1.1.1) (Paper, 1998; Chavakis and Dimmeler, 2002) 
3 
Endothelial cells 
...--
1---
...-
.--
o 
Chemotactic gradient of 
angiogenesis inducers are 
released from hypoxic tissue. 
• 
Basement membrane and 
ECM breaks down. 
D • 
Angiogenic sprouts loop and a lumen is formed 
and the basement membrane is formed. 
• ~ 
51 
Endothelial cells migrate 
toward the stimulus and 
angiogenic stimuli. 
1 
L 
~ 
Endothelial cells proliferate. 
Figure 1.1.1: The stages of angiogenesis showing breakdown of the basement membrane, migration and proliferation of the 
endothelial cells and the formation of the capillary (Paper,1998) 
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1.1.3 Breakdown of the extracellular matrix (ECM) 
Angiogenesis induction by VEGF in wounds or tumours begins with capillary 
vasodilatation and increased permeability allowing the migration of proteases to cleave the 
ECM to create space for the new vessels to grow into e.g. matrixmetalloproteases from 
endothelial or stromal cells (Egeblad and Werb, 2002). Plasma proteins invade the newly 
formed space and form a provisional scaffold for the migrating endothelial cells to grow 
onto. The increased protease activity also allows the redistribution of the adhesion 
molecules e.g. integrins, in the tissue priming the new space for the migration of the 
endothelial cells (Thurston et al., 2000; Kalluri, 2003). The proteolysis of the ECM 
releases bound growth factors e.g. VEGF, bFGF to cause a positive feedback effect of the 
angiogenic process and initiate endothelial cell migration (Carmeliet and Jain, 2000; 
Akarasereenont et al., 2002; Kalluri, 2003). 
1.lA Endothelial cell migration 
Extracellular matrix clearance allows the migration of proliferating endothelial cells 
forming long chains. Endothelial cells become elongated forming pseudopodia and up-
regulating integrin expression allowing binding to ECM adhesion molecules and adhesion 
molecules e.g. ICAM 1 and 2, VCAM-I on other cells (Varner, 1995). Integrin binding of 
endothelial cells to the ECM mediates cell movement and survival with avf33 integrin 
suppressing the mitochondrial! intrinsic pathway of apoptosis and promoting endothelial 
cell survival (Pluda, 1997). 
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1.1.5 Lumen/ormation and vessel maturation 
The new sprouting of endothelial cells into the tissue develops a lumen fonned from 
intercellular vacuoles and cellular surfaces in contact with the endothelial cells. This lumen 
finally contacts the existing vessels and fuses to give a new vessel. The endothelial cells 
then return to the original quiescent state (Canneliet, 2000). 
1.1.6 The effect o/VEGF on endothelial cells 
Vascular endothelial growth factor 165, or VEGF-A, is a member of a group of pro-
angiogenic molecules, which now includes VEGF-B, C, D, E and placental growth factor 
(PIGF) (Ferrara, 2001; Bates and Harper, 2003). VEGF is well documented as an inducer 
of vascular endothelial growth in vitro and in vivo as well as cellular migration and 
pezmeability seen in angiogenesis (Cazmeliet and Collen, 2000; Ferrara et ai., 2003). 
Expression of VEGF is regulated by oxygen tension e.g. hypoxia, where the hypoxia 
inducible factor-l (HIF-l) binds to the hypoxic response element mediates the expression 
(Canneliet, 2000; Giordano and Johnson, 2001; Ferrara et ai., 2003) and cytokine/ growth 
factor binding e.g. FGF, prostaglandins and IL-6 (Ferrara et al., 2003). 
VEGF binds to two tyrosine kinase receptors, VEGFR-l (jlt-l) and VEGFR-2 (KDRlflk-l) 
but it is the VEGFR-2 receptor that is required in the proliferation and migration of 
endothelial cells during angiogenesis (Neufeld et ai., 1999). The binding of VEGF to 
VEGFR-2 results in dimerisation of the two VEGFR molecules to activate a ligand 
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dependent tyrosine phosphorylation of signalling intennediates e.g. PI-3 kinase and 
mitogen activated protein (MAP) kinases (Ferrara et al., 2003, Neagoe et at., 2005). The 
activation of these pathways induces pleiotropic responses causing proliferation, tubule 
fonnation and survival of endothelial cells through a number of gene activations (Carmeliet 
and Collen, 2000; Ferrara et al., 2003). 
1.1.7 Induction of gene expression in endothelial cells by VEGF 
Upon stimulation with VEGF it has been shown that 139 genes are activated more than two 
fold within 24 hr (Abe and Sato, 2001). Only five of these genes are known to be related to 
the process of angiogenesis and include cyclooxygenase 2, heparin- binding epidermal 
growth factor like growth factor, early growth response 1 (EGRl), CYR61 a growth factor 
binding protein that aids the binding of endothelium to av~3 integrins, and angiopoietin-2. 
Other inducible genes have been found including transcription factors, EGR-2 and 3, 
nuclear receptors e.g. Nur77, Nurrl and Norl, MMPs, DNA replication licensing factor and 
VEGFR-2 (Abe and Sato, 2001; Akarasereenont et aI., 2002; Liu et al., 2003; Wary et al., 
2003). 
Of the angiogenic related genes that can be activated cyclooxygenase 2 (COX-2) was 
induced the greatest with a 4.7 fold increase in 0.5 hr, which decreases back to basal levels 
by 24 hr (Abe and Sato 2001). It can therefore be suggested that the activation ofCOX-2 is 
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important in the process of angiogenesis and has been seen to be up-regulated in tumour 
angiogenesis. 
8 
1.2 Cyclooxygenase enzymes 
The cyclooxygenase (COX) enzymes, also known as prostaglandin H synthase, are 
catalytically bifunctional enzymes with a cyclooxygenase and a peroxidase catalytic site 
(Pairet et al., 1999; Moore and Simmons, 2000). The COX enzyme is found in three 
isoforms in the body: the constitutive COX-I and the splice variant COX-3 (not discussed), 
and the inducible COX-2 enzymes. Cyclooxygenase-I, COX-2 and COX-3 are known to 
catalyse the conversion of arachidonic acid (AA) to prostaglandins (PG), thromboxanes 
(TX), and prostacyclins (PG 12) (Fig. 1.2.1) (Pairet et al., 1999; Moore and Simmons, 2000; 
Stack and Dubois, 2001; Steele et al., 2003). 
1 1 
PGF2a 
Arachidonic acid 
Cyclooxygenase 1 
Peroxidase 1 
PT ~l------'l 
PGEz PGIz 
Figure 1.2.1: A schematic representation of the catalysis of arachidonic acid to 
prostaglandins and thromboxanes indicating the points of catalysis by the cyclooxygenase 
and peroxidase enzymes (Iniguez et al., 2003). 
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1.2.1 Catalysis of arachidonic acid to prostaglandin H2 
Phospholipase-A2 catalyses the cleavage of the phospholipid bilayer to release AA into the 
cytosol of the cell (Masferrer, 200 I). A tyrosyl radical formed from the tyrosine285 amino 
acid residue in the cyclooxygenase active site catalyses the oxidation of arachidonic acid to 
the peroxyl radical precursor, which is then converted to PGG2 (Fig. 1.2.2). Once 
produced, PGG2 is reduced to PGH2 by the peroxidase catalytic site on the COX enzymes 
(Fig 1.2.3) (Marnett et al., 1999, Marnett, 2002). 
10 
(iii) 
H 00 • 
Haem iron oxidation 
ROOH ROH 
Felli ---J1"---_tL--. ... GelV=o 
AJ/ 
• 
Tyrosyl 
radical 
O2 ~ 
.o"o~ (ii~COO-
Tyr385 
OH 
H 
~~H ~~- Ar~chidonic 
aCid 
" COO-
OH (i) 
~ ~COO-
o Carbon-
centered 
radical 
Figure 1.2.2: The catalysis of arachidonic acid (AA) to prostaglandin G2 (PGG2) indicating 
the activation of COX by the formation of a ferryl-oxo complex by oxidising the haem 
group of COX to give a tyrosyl radical of Tyr385. The tyrosyl radical oxidises AA, 
allowing the binding of oxygen to form a carbon radical (i). The II-peroxyl radical 
cyclises with the oxygen (ii). Molecular oxygen binds to the radical and is subsequently 
reduced to prostaglandin G2 (iii) (Marnett, 2002). 
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Figure 1.2.3: A schematic representation of the catalytic conversion of arachidonic acid to 
prostaglandin H2 (PGH2) by COX and peroxides enzymes (Marnett, 2002). 
1.2.2 Cyclooxygenase 1 
Cyclooxygenase I isoform is an active homodimer of two 68-80 kDa proteins with four 
domains. These include a catalytic domain containing two catalytic sites; a cyclooxygenase 
and peroxidase domain used in the formation of prostaglandins (Fig 1.2.4a and b) (Marnett, 
et at., 1999; Stack and Dubois, 200 I; Lichenburger, 200 I; Masferrer, 200 I; Marnett, 2002). 
EGF MBD Catalytic PTEL 
COX-1 
Figure 1.2.4a: A schematic representation of cyclooxygenase I showing an epidermal 
growth factor (EGF)-like domain, a membrane binding domain (MBD) and a catalytic 
domain. The PTEL signalling peptide allows retention of the enzyme in a lipid membrane 
(Murakami and Kudo, 2004). 
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Figure] .2.4b: A ribbon diagram of ovine COX-I active homodimer showing the epidermal 
growth factor like domain (green), the membrane-binding domain (gold), and catalytic 
domain (blue) with the haem groups shown in red (Garavito et al., 2002). 
Cyclooxygenase ] is the constitutive isoform found in most tissues within the body. It is 
present at low basal levels, bound to the endoplasmic reticulum and nuclear membrane 
location (Morita et al. , 1995; Gilroy et aI. , ] 998; Ho et ai. , 1998; Stack and Dubois, 2001 ; 
Smith and Langenbach, 200 I ; Gately, 2003 ; Steele el aI. , 2003). It has been reported that 
COX-l can be induced under certain conditions. For instance Akarasereenont el al., (2002) 
reported that exposure of human umbilical vein endothelial cells and bovine aortic 
endothelial cells to VEGF I6S re ulted in increased COX-I expression. Murphy and 
Fitzgerald (200 I) also reported an increase in COX-I expression within 8-10 hr after 
expo ure of endothelial cells to VEGF I6S • 
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1.2.3 Expression and function of COX-J 
Of the three enzymes, COX-I is the most widely expressed with the COX-J gene (9q32-
9q33.3) ubiquitously expressed in most cells including platelets where COX-I is the 
predominant isoform and converts arachidonic acid to TXA2 (Fitzgerald, 2002). 
Cyclooxygenase-I is also the main isoform expressed in the gastric mucosa where it 
catalyses the formation of cytoprotective prostaglandins including PGh and PGE2 (Gilroy 
et al., 1998; Ho et al., 1998; Colville-Nash and Gilroy, 2000; Stack and Dubois, 2001; 
Steele et al., 2003). The effects of specific prostaglandins will be discussed later. However 
the prostaglandins produced in the gastric mucosa are required to maintain blood flow, 
mucosal integrity and secretions from the gastric mucosa (Riendeau et al., 1997; Gilroy et 
aI., 1998). The renal system is also affected by the activity of COX-J, which maintains 
homeostasis by ensuring the balance of electrolytes. Prostaglandins produced increase 
vasodilatation in the renal vascular bed and renal perfusion (Simon, 1999; Wallace, 1999; 
Weir et al., 2000; Lichenburger, 2001). Another important site of expression of COX-I is 
the vascular endothelium where it regulates blood pressure by producing prostaglandins 
such as prostaglandin hand E2 (Wallace, 1999; Willoughby et al., 2000; Fitzgerald, 2002). 
Apart from its physiological role there is growing evidence that COX-I may be involved in 
inflammatory conditions such as rheumatoid arthritis. Evidence in support of this was 
found when specific COX-2 inhibitors failed to inhibit the inflammatory process in 
rheumatoid arthritis even though prostaglandin levels were reduced in the inflamed area. In 
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contrast. dual inhibition of COX-I and 2 decreased the inflammation, indicating a role for 
COX-I (Wallace, 1999; Willoughby et ai., 2000, Fitzgerald, 2002). 
1.2.4 Cyclooxygenase 2 
Cyclooxygenase 2 is an active homodimer similar to COX-I and is made up of two 68-72 
kOa subunits depending on post-translational modifications. Similar to the COX-l protein, 
COX-2 has 4 domains that consist of a catalytic domain containing two catalytic sites, an 
epidermal growth factor like domain, a membrane binding domain and a signalling domain, 
which allows the retention of COX-2 in the lipid membrane (Fig 1.2.5) (Sakamoto. 1998; 
Gately, 2000; Masferrer, 200 I; Tanabe et ai., 2002). 
EGF MBD Catalytic STEL 
COX-2 
Figure 1.2.5: A schematic diagram of cyclooxygenase 2 showing an epidermal growth 
factor (EGF)-like domain, a membrane binding domain (MBO) and a catalytic domain. 
The STEL signalling peptide allows retention of the enzyme in a lipid membrane 
(Murakami and Kudo, 2004). 
The cyclooxygenase active site of COX-l and COX-2 were found to be 90% similar with 
only a single amino acid substitution of isoleucine5'10 for valine in the catalytic site of COX-
2. This is thought to result in a large side pocket in the substrate-binding site ofCOX-2 (Fig 
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1.2.6) (Simon, 1999; Emery, 200 I; Zha et al., 2004), which has been exploited in the 
design of specific COX-2 inhibitors. Some of these inhibitors will be discussed later 
(Section 1.2.8). 
Cyclooxy genase 
Figure 1.2.6: A cartoon of the cyclooxygenase 2 monomer indicating the peroxidase active 
site, membrane binding and dimerisation domain and the cyclooxygenase active site with 
the specific side pocket due to the substitution of isoleucine59o for valine (Taken from 
Moore and Simmons, 2000). 
COX-2 is predominantly inducible and generally absent in tissues under normal 
physiological conditions. The induction of COX-2 can be initiated by multiple stimuli, 
including inflammatory mediators such as lipopolysaccharide (LPS) and interferon- y, 
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angiogenic stimuli such as VEGF, and shear stress. The induction pathways of COX-2 and 
the effects of COX-2 in angiogenesis will be discussed later (Section 1.4.2). Constitutive 
expression of COX-2 at low levels is found in the brain tissue and renal system and has a 
diuretic and natriuretic effect (Smith et al., 1999; Weir el al., 2000; Stack and Dubois, 
200 I; Akarasereenont el al., 2002; Inoue et al.. 2002, Murakami and Kudo, 2004). 
1.2.5 Cyclooxygenase 2 induction 
The induction of COX-2 has been shown to occur early in inflammation, wound healing, 
hypoxia, and in normal and tumour angiogenesis. It appears to be induced in a biphasic 
manner with an early transient induction occurring at 0-8 hr and a delayed expression at 24-
48 hr after exposure to LPS (Willoughby et al., 2000; Stack and Dubois 2001). The initial 
COX-2 induction of 0-8 hr produces pro-inflammatory cytokines that includes PGE~ and 
PGb, while the second induction at 24-48 hr results in increased production of anti-
inflammatory prostaglandins such as PGD2 and 15-deoxy-~ 12J4_PGh (15d- PGh) 
(Willoughby et al., 2000). It has been suggested that the production of these anti-
inflammatory prostaglandins may have a regulatory effects on COX-2 expression and this 
will be addressed later (Sections 1.4.2 - 1.4.4) 
The promoter sequence of the COX-2 gene has many transcription control elements 
including nuclear factor-KB (NF-KB), cAMP response clement (CRE), GATA box, and 
TATA box (Fig 1.2.7) (Inoue el al., 1995; Yamamoto el al., 1995; Mestre et al., 2001; 
Perez-Sala and Lamas, 2001). The importance of these elements in the induction ofCOX-2 
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was elucidated in reporter gene assay following the deletion of the specific regions on the 
COX promoter (Kirtikawa el al., 2000). Different regions are vital for COX-2 expression 
depending on the stimuli used. However, it has been found that the upstream activation 
sequences could act in synergy to induce COX-2 and the TAT A box could independently 
induce COX-2. The control of COX-2 expression by these mechanisms allows for the 
induction of the enzyme under specific circumstances e.g. inflammation (Inoue et al., 1995: 
Yamamoto el at.. 1995; Mestre et al., 200 I; Perez-Sala and Lamas, 200 I). 
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Figure 1.2.7: A schematic representation of the COX-2 promoter sequence showing the 
regulatory elements present on the promoter region that could induce transcription of the 
COX-2 gene: nuclear factor-KB (NF-KB), nuclear factor-interleukin 6 (NF-IL6), specificity 
factor 1 (SP-I) cAMP response element (CRE), E-box, (Adapted from Perez-Sala and 
Lamas, 2001 and Murakami and Kudo, 2004). 
1.2.6 Induction of cyclooxygenase 2 during inflammation 
Induction of cyclooxygenase 2 during inflammation has been established to be controlled 
by many inflammatory mediators including IL-I~, IFN-y, and TNF-u. However the most 
documented inflammatory mediator ofCOX-2 activity is LPS. 
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Bacterial LPS induction of COX-2 is mediated through the toll-like receptor 4 that activates 
mitogen MAPK p38. MAPK p38 phosphorylates l-kappaB kinase (IKK) which in turn 
phosphorylates the inhibitor ofNF-KB, I-kappaB (lKB). The latter is normally in a complex 
with nuclear factor-KB (NF-KB) and upon phosphorylation is targeted for ubiquitination and 
degradation through the proteosomal pathway. This results in the release of NF-KB, which 
then translocates to the nucleus and initiates gene transcription (Bierhaus el al., 2000, Chen 
el al., 2003). A schematic representation of the potential involvement of NF-KB in the 
induction COX-2 is shown in Fig. 1.2.8. 
19 
Lipopolysaccharide 
~ 
TLR4 
MAP kinase p38 
( IKB 
NF- KBIIKB NF- KB 
.-----.. COX-2 
Promoter 
Figure 1.2.8: A schematic representation of lipopolysaccharide (LPS) signalling in the 
induction of COX-2. Lipopolysaccharide binds to the toll-like receptor 4 (TLR4) activating 
the phosphorylation of l-kappaB which in turn dissociates from its complex with NF-KB. 
NF-KB translocates to the nucleus where it binds to the NF-KB recognition site on the 
COX-2 promoter and activates the transcription and expression of COX-2 (Bierhaus el a/., 
2000, Chen el al., 2003). 
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1.2.7 Induction of cyclooxygenase 2 during angiogenesis 
The expression of COX-2 is an integral part of angiogenesis, and is expressed within 30 
minutes of cellular stimulation with VEGF (Abe and Sato. 200 I). Following its release 
during angiogenesis, VEGF binds to the protein tyrosine kinase receptor, flk-I IVEG FR-2 
and activates the mitogen activated protein (MAP) kinase pathway. The binding of VEGF 
to the VEGFR-2 activates MEK 112 which phosphorylates extracellular regulated kinase 
(ERK) 1/2 or p42/44. This eventually leads to the increase in cyclic adenosine mono-
phosphate (cAMP). Cyclic AMP (cAMP) then activates the COX-2 promoter inducing 
expression of COX-2 (Fig. 1.2.9) (Jones et ai., 1999; Tamura et al., 2002; Ruegg et al .. 
2004). VEGF also activates the production of GATA cis-binding elements that bind to the 
GA TA site on the promoter of the COX-2 gene. These elements are thought to be essential 
for the expression COX-2 (Akarasereenont et al., 2002; Tamura et al., 2002). 
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Figure 1.2.9: A schematic diagram of VEGF signalling in the induction of COX-2. VEGF 
(green) binds to the protein tyrosine kinase VEGFR-2 (blue) that activates the mitogen 
activated protein (MAP) kinase MEK 112. This then activates ERK 112 (P42/44), increasing 
the levels of cyclic adenosine mono-phosphate (cAMP) that binds to the COX-2 promoter 
increasing COX-2 expression. VEGF also activates GATA cis-binding transcription factor 
(TF), which binds to the GAT A box and activates the promoter (Jones et al. , 1999; 
Akarasereenont et aI. , 2002; Tamura et al. , 2002; Chun et al. , 2003; Ruegg et ai. , 2004). 
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1.2.8 Regulation of cyclooxygenase 2 expression 
The anti-inflammatory prostaglandins produced in the second phase of COX-2 induction 
have been found to be ligands for the peroxisome proliferator-activated receptor (PPAR)- y 
(Bishop- Bailey and Hla, 1999; Inoue et ai., 2000). Inoue et ai., (2000) have suggested that 
the binding of these anti-inflammatory prostaglandins to PPAR-y forms a negative 
feedback loop in the induction of COX-2, which acts in part through the inhibition of the 
NF-KB pathway (Fig 1.2.10). 
NF- KB 
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Figure 1.2.10: The regulation of COX- 2 expression by negative feedback loop mediated by 
PGD2 production and PPAR-y binding possibly interfering with NF-KB pathway and 
decreasing COX- 2 transcription (Inoue et al., 2000). 
It was also suggested that PGE2 would have a positive effect on COX-2 expression (Inoue 
et ai., 2000). During the initial expression of COX-2 pro-inflammatory prostaglandins such 
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as PGE2 are produced and are expelled from the cell. PGE2 binds EP 214 in an autocrine 
manner, increasing levels of cAMP. The increasing levels of cAMP activate the CRE 
binding protein (eREB), which binds the CRE region of the COX- 2 promoter and induce 
enzyme expression (Fig 1.2.11) (Inoue el at., 2000). 
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Figure 1.2.11: The positive feedback loop of COX- 2 expression by the increases in PGE2 
levels and autocrine binding to the EP 2 or 4 receptor. This increases cAMP levels within 
the cell and subsequently enhance COX-2 expression by activating the cAMP response 
element (Inoue e/ at., 2000). 
Other regulatory pathways similar to the positive feedback loop suggested above have been 
proposed. One such pathway involving VEGF during angiogenesis will be discussed in 
Section 1.4.2. 
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1.2.9 Prostaglandins 
Prostaglandins are paracrine and autocrine-acting hormones involved in numerous 
biological processes, including regulation of kidney function, reproduction, vascular tone, 
angiogenesis and inflammation (Smith et a/., 1986; Zhang et al., 1999; Stack and Dubois, 
200 I). Each prostaglandin is formed from arachidonic acid via the COX pathway to PGH2 
and then to specific prostaglandins via specific synthascs. Already stated earlier 
prostaglandins bind two types of receptors (i) G- protein coupled receptors (GPCR) and, (ii) 
PPAR, which cause differing effects on cell activity depending on the receptor that the 
prostaglandin binds (Smith et ai., 1986; Ide et ai., 2003; Hata and Breyer, 2004). The 
actions of the different prostaglandins are varied and some of the effects are summarised in 
Table I with PGE2 being discussed in further detail due to it being used in the current 
study. 
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Table I: The effects of different prostaglandins produced from arachidonic acid (modified 
from Smith et aI., 1986; Bishop-Bailey and Hla 1999; Uracz el al., 2002; Ward ef al., 2002; 
Ide el al .. 2003; Dong el al., 2004; Erl el al., 2004; Hata and Breyer, 2004). 
Prostaglandin Receptors Produced in Examples of effects , 
J 
PGh IP Endothelium, 
epithelium, smooth 
muscle. 
Vasodi latation, 
inflammation 
mediates acute I 
and oedema, 
PGh 
FP 
increases/decreases cellular cAMP, 
activates PP AR J3!£). 
Metabolite of PGb Increases intracellular CaL+, found 
In reproduction and menstrual 
cycle, used In renal 
haemodynamics. 
DP and Airways, skin, mast Increased bronchoconstriction, 
cells 
eosinophil and leukocyte 
infiltration, allergic 
vasoconstriction and 
reaction. 
dilation. I 
I 
Increase and decrease cAMP levels. 
Decreased platelet aggregation. 
CRTH2 and Endothelial cells, Increases apoptosis, p53 and p38 
PPAR y/ 8 epithelial cells, levels. Decreases IKB degradation 
(Though granulocytes. 
may be 
independent 
of PPAR y 
and 8). 
TPa and P 
and NF-KB binding to DNA. 
Possible effect In resolution of 
inflammation and damage of 
endothelium. 
Endothelial cells, Platelet aggregation, increased 
platelets, smooth smooth 
muscle cells. muscle cell proliferation, 
bronchoconstriction. Increases and I 
decreases cAMP levels. 
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1.2.10 Prostaglandin E] (PGE:J 
Prostaglandin E2 is produced in smooth muscle and endothelial cells by the membrane-
bound PGE-synthase (Uracz et al., 2002) and its production may be spontaneous (Soler et 
al., 2000). There are 4 GCPR specific for PGE2 and these are EP I, 2, 3 and 4. The effect 
produced by this prostaglandin may depend on which receptor is bound (Zhang et al., 
1999). Receptor I and 3 may cause constrictions but via different mechanisms. For 
instance. in smooth muscle, receptor I can cause constriction via an increase in intracellular 
Ca2+ concentration while in the same tissue, receptor 3 signals via an inhibitory G protein 
that decreases the level of cAMP (Zhang et ai, 1999; Purdy et aI., 2000). Receptor 2 and 4 
causes relaxation of vascular smooth muscle rings by increasing the level of cAMP. There 
may be coordinated regulation of systemic blood pressure by these receptors, with the 
actions of receptors I and 3 balanced by those of 2 and 4 to maintain the net pressure 
(Zhang et al., 1999; Purdy el al., 2000). PGE2 has an effect on inflammation due to the 
vasodilatation and constriction, and has an important role in the control of renal 
reabsorption of salt and water (Purdy et aI., 2000; Neisisus et al., 200 I; Hata and Breyer, 
2004). Importantly it has been found that PGEz has an etTect on angiogenesis by increasing 
VEGF expression, which is induced by acting through the MAPK pathway (Pai et al .• 
200 I). Apoptosis of cells is also affected by PGEz, which may decrease apoptosis and 
promoting cell proliferation by increasing cAMP and the expression of the anti-apoptotic 
protein BcI-2 (Ottonello et al., 1998; Sheng et al., 1998; Jabbour et al .• 2002; Davis et al .. 
2004). Cell adhesion by av~3 integrin binding may also be enhanced by PGEz acting 
through cAMP (Dormond et al., 2002). 
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1.2.111nhibitors of cyclooxygenase 2 
Inhibition of the COX-2 may be therapeutically beneficial In inflammation, where this 
enzyme is found to be expressed, resulting in the production of pro-inflammatory 
prostaglandins. Drugs that inhibit COX-2 can be segregated into non-specific inhibitors, 
which inhibit COX-I and COX-2 and specific inhibitors, which selectively block COX-2. 
The list of compounds both groups is increasing and now include some natural dietary 
compounds (e.g. curcumin), which inhibit COX-2 in certain cell types. 
1.2.11.1 Non-specific cyclooxygenase inhibitors 
Non-specific inhibitors of cyclooxygenase were first developed to inhibit COX-2 regulated 
inflammation but were found to inhibit COX-l and COX-2. Non-steroidal anti-
inflammatory drugs (NSAIDs) such as aspirin are widely used to treat inflammation and 
pain by decreasing the production of pro-inflammatory prostaglandins and have also been 
used to treat rheumatoid arthritis and cancer (Masferrer et al., 1994; Smith et al., 1998). 
Non-steroidal anti-inflammatory drugs have been found to have anti-pyretic, analgesic and 
anti-inflammatory actions preferentially inhibiting COX-l to decrease prostaglandin 
production. These drugs are grouped into 3 classes. Class I includes ibuprofen, naproxen 
and salicylic acid and are reversible competitive inhibitors, class 2 inhibitors such as 
indomethacin, are competitive inhibitors that can be reversed in a slow time dependent 
manner and class 3 inhibitors (e.g. aspirin), are irreversible inhibitors (Rosenstock el at.. 
1999). 
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Aspirin has been shown to bind transiently via the carboxyl group to arginine l20 of the 
active site of the COX enzymes. This weak interaction allows aspirin to diffuse and 
transfer the acetyl group to serine53o. The salicylate produced then diffuses out of the active 
site leaving the serine bound 2-carbon adduct close to tyrosine385. This is activated in the 
formation of PGG2 and has previously been discussed (Section 1.2.1) (Moore and 
Simmons, 2000). 
Unfortunately NSAIDs were found to have undesirable side effects, causing gastrointestinal 
toxicity and ulcer formation (Allison et al., 1992). Extended administration of NSAlDs 
inhibits the production of cytoprotective prostaglandins from COX-I in the gastric mucosa. 
The decrease in cytoprotective prostaglandins alters gastric homeostasis as discussed 
(Section 1.2.2.1). The induction of gastric ulcers by NSAID inhibition of COX- I led to 
the development of specific COX- 2 inhibitors to avoid the side effects ofNSAIDs. 
1.2.11.2 Specific cyclooxygenase 2 inhibitors 
Specific COX-2 inhibitors were designed to inhibit inflammatory prostaglandin formation 
by COX-2. The specific inhibitors are designed to bind the unique "side- pocket" found in 
the active site ofCOX-2. The selective COX-2 inhibitors inhibit COX-2 specifically in a 2 
step inhibition process where the first step involves an initial rapid reversible interaction of 
the drug with the enzyme and the second step involves the formation of a tight bond that 
allows a complex to form with a slow dissociation of the drug from the enzyme due to its 
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binding to the ' side-pocket" in the active ite of the COX- 2 enzyme (Fig. 1.2.12) 
(Rosenstock et aI. , 1999, Urban, 2000). 
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Figure 1.2.12: The inhibition of the COX- 2 enzyme identi fying the binding of the inhibitor 
to the "side-pocket" in the cyclooxygenase active site, preventing arachidonic acid entering 
the active site (Urban, 2000). 
There have been many specific COX-2 inhibitors developed, including celecoxib, 
rofecoxib, NS-398, and DuP-697. However, only a few of these will be di cussed. The 
structure of specific COX-2 inhibitors is very specific with certain chemical groups vital for 
OX inhibition. In the tricyclic inhibitor class, which includes celecoxib, rofecoxib and 
DuP-697, the exact spatial orientation of the aromatic rings is essentia l for inhibition of the 
OX enzymes. The aromatic rings must be adjacent to each other on the centre ring for 
OX-2 inhibition (Penning et ai. , 1997). Studies of the inhibitor and potential inhibitors 
were investigated using the rat carrageenan-induced footpad oedema assay and the most 
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potent inhibitors taken on for further analysis (Penning et af., 1997). It was found that the 
4-methyl analogue of the base compound was the most effective and thi lead to the 
discovery of celecoxib (Penning el af. , 1997). 
1.2.11.3 Celecoxib (Celebrex ®) 
Celecoxib is one of the specific COX-2 inhibitors approved for the treatment of 
inflammation in rheumatoid arthritis (Fig 1.2. 13) (Urban, 2000). Celecoxib has been found 
to be as effective in reducing prostaglandin formation as ibuprofen (800mg) at half the dose 
(400mg) in vivo and in vitro (Fitzgerald, 2002; Wu et al. , 2003), and has been shown to be 
anti-inflammatory and anti-analgesic in vivo (Smith el aJ., 1998). The additional advantage 
of celecoxib over traditional NSAIDs is the reduced gastrointestinal ulcer complications in 
the upper Gr tract as it is found to have an 8-fold lower incidence of ulceration compared to 
non-specific COX-2 inhibitors back to placebo levels (Goldstein el aJ. , 2000). 
Recently, it has been established that celecoxib has anti-cancer effects reducing cancer cell 
proliferation in vitro and in vivo. The administration of celecoxib has been shown to reduce 
the amount of polyps in familial adenopolyposis over a 6 month period (Blanke, 2002), and 
also decreases the number of prostrate cancer cells in treated cell lines (Hsu et ai. , 2000) 
and cholangiocarcinoma cells in treated cell lines (Wu el af. , 2003). Mostly the decrease in 
the proliferation of cancer cells is found to be due to the induction of apoptosis of the target 
cells (see Section 1.3.2 below). 
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Figure 1.2.13: The chemical structure of Celecoxib (Celebrex ®) indicating the two 
aromatic rings adjacent on the centre ring (Urban, 2000). 
1.2.11.4 Rofecoxib (Vioxx ®) 
Rofecoxib is the specific COX-2 inhibitor that has been approved for the treatment of 
osteoarthritis (Fig 1.2.14) (Urban, 2000). Rofecoxib specifically inhibits COX-2 derived 
prostaglandin production in vitro and in vivo (Chan et al .. 1999). Rofecoxib also is gastro-
protective as it maintains gastrointestinal integrity in rat models over 5 days (Chan et al., 
1999). Recently however rofecoxib has been found to increase the risk of cardiovascular 
disease resulting in the drug being removed from the market. There is now also increasing 
controversy over the cardiovascular safety of celecoxib as well (Mukherjee et al., 200 I; 
Niederberger et al., 2004). 
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Figure 1.2.14: The chemical structure of rofecoxib (Vioxx ®) indicating the two aromatic 
rings adjacent on the centre ring (Urban, 2000). 
1.2.11.5 5-bromo-2- (4-fluorophenyl)-3-(methylsulfonyl) thiophene (DuP-697) 
Structurally similar to celecoxib and rofecoxib, DuP- 697 is a tricyclic COX-2 inhibitor 
(Fig 1.2.15) (Penning et al., 1997). DuP-697 is an anti-inflammatory drug that promotes 
gastrointestinal safety similar to other specific COX- 2 inhibitors. Inhibition of 
inflammation was demonstrated using the inflamed rat paw model in non-established and 
established adjuvant arthritis (Gans et al., 1990). DuP-697 was also found to be non-
ulcerogenic in rat models at concentrations of up to 400mg/ kg and had no effect on renal 
vasculature prostaglandin production and on renal blood flow (Gans et al., 1990). 
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Figure 1.2.15: Chemical structure of DuP-697 showing the tricyclic structure of the 
inhibitor similar to celecoxib and rofecoxib, which is vital to the inhibition of COX- 2 
(Gierse et al., 1995). 
The specificity of DuP-697 for COX-2 is very high with the ICso for COX-2 inhibition 
being IOnM (Gierse et al., 1995). This concentration of DuP-697 (I OnM) has been shown 
to be ineffective against COX-I, with concentrations of I-I OO~M apparently being required 
for COX-I inhibition in bovine aortic endothelial cells (BAEC) (Rosenstock et al., 1999). 
At high concentrations, DuP-697 can act in synergy with non-specific COX inhibitors to 
irreversibly inhibit COX-I (Rosenstock el al., 200 I). The specific COX-2 inhibition has 
been attributed to the DuP-697 altering the enzymatic conformation via an interaction with 
a site, which is not the active site. This implies a non-competitive inhibition of COX-2 
activity by DuP-697, which may act by inhibiting the cleavage of the enzymes by trypsin 
(Rosenstock el al., 1999). 
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1.2.12. Dietary natural products 
Dietary products have been found to have many effects on the body, with many substances 
having anti-inflammatory properties. For instance, it has been established that turmeric 
(Curcuma longa) and ginger (Zingiber officinale) have anti-inflammatory effects and have 
been used in alternative therapies in the treatment of rheumatoid arthritis. These properties 
have been ascribed to certain chemicals found in the foods e.g. curcumin from turmeric and 
gingerols and shogaols from ginger. 
1.2.12.1 Curcumin (Diferuloylmethane) 
Curcumin is the yellow pigment of Turmeric (Curcuma tonga) (Fig 1.2.16), and an anti-
oxidant and anti-inflammatory properties have been known for many years (Singh et al., 
1996). 
o o 
HO OH 
Figure 1.2.16: The structure of curcumin from curcuma tonga, containing two aromatic 
moieties and a substituted functional group on an alkyl side chain (Zhang et al., 1999). 
The anti-inflammatory properties of curcumin are thought to be due to the inhibition of 
COX-2 at several levels including at the mRNA, protein expression and functional levels. 
35 
This occurs in a concentration-dependent manner (I/-lM to 25/-lM) after 8 hr (Zhang et al., 
1999; Chun el ai., 2003). Curcumin has been shown to repress thc activation of the NF-KB 
pathway by inhibiting the phosphorylation and degradation of IKBa subunit. This prevents 
the release ofNF-KB from its inhibitory complex with IKB and thus activation of the COX-
2 promoter and COX-2 gene transcription (Plummer el al., 1999; Surh el al., 200 I; Chun el 
al., 2003) (Fig 1.2.17). The MAPK pathway is also affected by curcumin with inhibition of 
the p38 and p42/ 44 pathways resulting in the inhibition of COX- 2 induction (Fig 1.2.17). 
These findings suggest that curcumin may block the induction of COX-2 by inhibiting the 
phosphorylation of the signalling molecules involved in the activation of the COX-2 
promoter (Chun el al., 2003). 
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Figure 1.2.17: The inhibition of the signalling pathways involved in COX-2 induction. 
Curcumin inhibits either the MAP kinase pathways or the dissociation of IKB from NF-KB, 
resulting in the inhibition ofCOX-2 induction (adapted from Chun et at., 2003). 
Curcumin has pro-apoptotic and anti-proliferative properties in certain cells. It is pro-
apoptotic in HL-60 cells and adenocarcinoma cell lines and anti-proliferative in human 
umbilical vein endothelial cells (Singh et at., 1996). The pro-apoptotic and anti-
proliferative effects in these cells may be due to the inhibition of COX- 2 and the 
correlation between apoptosis and COX- 2 inhibition is discussed in Section 1.4.4. 
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1.2.12.2 6-Shogaol 
6-Shogaol is one of the metabolites of the shogaol constituent of ginger (Zin~iher 
officina/e), and has been found to inhibit COX-I in rat cells (Tjendraputra et a/., 2001). 6-
shogaol has a similar structure to curcumin (Fig 1.2.18), and has been shown to inhibit 
prostaglandin production by COX-2 in lung epithelial cells, where it was the most effective 
of all ginger compounds tested (IC50 of 2.1 J!M). The inhibition of COX-2 generated 
prostaglandins may lead to an increase in apoptosis (see section 1.4.4). 
H OH H 
MeO 
HO 
Figure 1.2.18: The chemical structure of 6-shogaol indicating similarities to curcumin with 
the aromatic moiety, carbon chain and liphophilic alkyl side chain (Tjendraputra et aI., 
2001) 
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1.3 Cell death 
1.3.1 Necrosis 
Necrosis is the uncontrolled form of cell death. Induction of necrosis has been observed 
with viral infection, bacterial products such as LPS and immune defence components 
including the complement system (Proskuryakov et ai., 2003). During necrosis cells swell, 
lose membrane integrity and lyse causing an inflammatory reaction in the body 
(Proskuryakov et ai., 2003). Unlike apoptosis (discussed below) necrosis does not require 
adenosine triphosphate (A TP) and does not require the production of specific enzymes to 
occur (Proskuryakov et ai., 2003). A specific form of necrosis can occur during the process 
of apoptosis. This is referred to as "secondary necrosis" and occurs when ATP stores 
decrease during apoptosis thereby preventing the process of apoptosis to reach completion 
and the cell enters the process of necrosis instead (Proskuryakov et ai., 2003). 
1.3.2 Apoptosis 
Apoptosis was first described by Kerr, Wyllie and Currie in 1972 and is characterised as a 
set of morphological changes in a dying cell that contrast to a necrotic cell (Kerr et al., 
1972). The morphological changes included loss of contact with the ECM cytoplasmic 
shrinkage, membrane blebbing, the formation of apoptotic bodies, chromatin condensation 
and nuclear fragmentation resulting in 180bp multimer fragments of DNA (Gupta, 2001). 
Apoptosis is essential in embryonic development, the removal of dangerous or damaged 
cells, and for homeostasis of cellular turnover in adults (Kerr et al., 1972). However 
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uncontrollable apoptosis has been associated to some pathological states including 
Parkinson's and Alzheimer's disease, while a complete inhibition of apoptosis in unwanted 
or dangerous cells can result in an increase autoimmunity and tumour formation leading to 
canCer. 
Induction of apoptosis can begin with an insult to the cell (e.g. ultraviolet (UV) radiation, 
reactive oxygen species (ROS) or chemical damage), or following ligand-receptor binding 
(e.g. CD95 ligand binding to the CD95 receptor in T-cells (Ashkenazi and Dixit, 1998)), or 
by loss of contact with the extra-cellular matrix (e.g. anoikis (Frisch and Francis, 1994)). 
The inducers activate two major pathways, which control apoptosis: (1) the mitochondrial 
pathway and (2) the death receptor pathway, resulting in both pathways causing specific 
apoptotic morphological changes. 
1.3.2.1 Morphological changes associated with apoptosis 
The characteristic morphological changes associated with apoptosis were first described in 
1972 by Kerr, Wyllie and Currie (Kerr et al., 1972). These changes are still being used to 
define apoptosis with some of the changes being used as the hallmark by which the degree 
of apoptosis is judged. 
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l.3.2.2 Apoptotic bodies 
The formation of apoptotic bodies from a cell is one of the main features of apoptosis. The 
cell undergoes the blebbing off of "small spherical or ovoid cytoplasmic fragments 
containing remnants of the nuclei," (Kerr et ai., 1972). The apoptotic bodies have been 
found to contain not only cytoplasm but also condensed parts of the nuclei and densely 
packed organelles, which are intact but condensed, depending on the constituents of the cell 
at the time of the formation (Kerr et ai., 1972). This was found to be orchestrated by the 
cleavage and activation of gelsolin and p21-activated kinase-2 and fodrin in the cell (Martin 
et ai., 1995) 
1.3.2.3 Phosphatidylserine translocation 
As the membrane of the cells blebs, phosphatidylserine moves from its position in the inner 
membrane to the outer membrane in a calcium dependent manner (Blatt and Glick, 2001). 
The translocation of phosphatidylserine is required for the recognition of apoptotic cells by 
phagocytes, so that the apoptotic cells do not under go secondary necrosis and release their 
contents thereby causing an inflammatory reaction (Savill et al., 1993; Fadok et al., 2001). 
Recognition of the phosphatidylserine by phagocytes has been thought to be by a specific 
receptor that is expressed on macrophages 'and conserved throughout phylogeny of 
Caenorhabditis eiegans (c. eiegans) and Drosphophiia meianogaster (Fadok et al., 2000). 
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1.3.2.4 Cell shrinkage 
After the initiation of apoptosis the cell shrinks and loses volume of the cytoplasm (Bortner 
and Cidlowski; 1998). This is in contrast to necrosis in which the cells swell due to loss in 
homeostatic functions regulating cell volume. The loss of cellular volume is due to (1) the 
decrease in potassium ions within the cell causing an osmotic pressure to remove the water 
from the cytoplasm; (2) A degradation of the macromolecules in the cell due to 
fragmentation (Bortner and Cidlowski; 1998); (3) Blebbing and the formation of apoptotic 
bodies decreasing the volume of the cell as the bodies detach. 
1.3.2.5 Condensation of the chromatin and DNA cleavage 
The hallmark morphological change and the most severe change of apoptosis is the 
condensation and the cleavage of cells DNA into 180bp fragments (Sakahira et al., 2001). 
Caspase-3 activation causes the cleavage of the heterodimer of DNA fragmentation factor 
(DFF) 45 and DFF 40. This causes an activation of the intrinsic endonuclease function in 
DFF 40, which is now referred to as caspase activated DNase (CAD), by cleaving DFF 45, 
the inhibitor of CAD (iCAD) (Sakahira et at., 2001). The activation of CAD degrades 
chromatin into multimers of 180bp fragments, due to the cut happening in the linker 
fragment of the DNA between the histone protein complex, which normally folds the DNA 
into chromosomes. When resolved on an agarose electrophoresis gel, the fragmented 
chromatin forms a "DNA ladder" on the gel. This "DNA ladder" is considered the 
hallmark of apoptosis. This marker of apoptosis should not, however, be taken as the only 
definitive indicator of apoptosis, as it may not always appear. In some cases, a DNA smear 
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instead of a ladder may be produced even though the other biochemical changes of 
apoptosis may be observed (Collins et al., 1992). Drug or serum deprivation induced 
apoptosis may also cause a different pattern of DNA fragmentation where higher molecular 
weight fragments (300 and or 50kb fragments) are produced with no lower molecular 
weight fragments of DNA (Oberhammer et al., 1993; Rusnak et al., 1996; Steiman et al., 
1998). The higher molecular weight fragmentation may be inhibited by cyclohexamide, 
suggesting that the process is endonuclease dependent in a manner similar to other 
apoptosis mechanism (Rusnak et al., 1996). This indicates that not all inter-chromosomal 
DNA fragmentation during apoptosis gives the "hallmark" apoptotic biochemical change 
due to possible release of the chromatin loop domains before full cleavage of the DNA 
(Oberhammer et al., 1993). The DNA fragmentation has been dissociated from the other 
apoptotic changes and suggests that fragmentation is not necessary to indicate the induction 
of apoptosis (Taylor et al., 2001). 
These morphological changes associated with apoptosis are due to the activation of a 
family of cysteine proteases known as "Caspases" (Thornberry et al., 1997), which act in 
an enzyme activation cascade to target specific cellular proteins including DNases and 
proteases that result in the specific morphological changes. 
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1.3.3 Caspases 
The caspases are a highly conserved group of cysteine proteases, which initiate and execute 
the process of apoptosis. The name "Caspase" is derived from the conserved £),steine 
amino acid residue in the active site and the aspartic acid - xxx target cleavage site of this 
family of proteins (Nicholson and Thornberry, 1997; Thornberry et at., 1997). In all 14 
caspases have been identified, with 13 ofthem being mammalian (Van 100 et at., 2002), 12 
human (Shikama et al., 2001), and at least 8 of these are thought to be involved in 
apoptosis (Salvesen and Dixit 1997; Budihardjo et at., 1999; Earnshaw et at., 1999). As 
zymogens the pro-caspases are a single chain protein with 3 different domains: (i) N-
terminal prodomain (ii) the large subunit, and (iii) the small subunit (Krammer, 1999). 
Upon activation the small subunit is cleaved off from the peptide chain followed by 
cleavage of the large subunit from the prodomain. The two subunits heterodimerise and 
bind a second dimer by hydrophobic interactions to form an enzymatic active tetramer with 
two active sites (Fig 1.3.1) (Rotonda et at., 1996). 
t t Cleavage 
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Figure 1.3.1: A schematic diagram of the structural conversion of pro-caspase to active 
caspase indicating the cleavage of the pro-domain and small subunit from the large subunit 
and the formation of the tetramer after conversion. 
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The size of the pro domain for the zymogen is important for the function of the caspase in 
the activity of an "initiator" caspase or an "effector" caspase. The effector caspases have a 
shorter prodomain used just to inhibit the activity of the enzyme (Shen and White, 2001). 
The initiator caspases however have been found to have longer pro-domains in contrast to 
the effector caspases (90aa: 20-30aa), which can interact with signalling molecules such as 
death receptors or apoptotic protease activating factor (APAF-l) in apoptosis (Shi, 2002). 
The active site of the caspase recognises at least 4 amino acids: P4-P3-P2-Pl cleaving at 
the PI site, which is an aspartic acid residue (Nicholson and Thornberry, 1997). 
The caspase cascade induced in the death receptor pathway of apoptosis involves the 
activation of caspase 8 that cleaves pro-caspase 3 to active caspase 3 (as discussed in 
section 1.3.3.1 and 1.3.5.2). The mitochondrial pathway induces caspase 9 activation by 
the formation of the apoptosome (as discussed in section 1.3.3.2 and 1.3.5.1). Activated 
caspase 9 cleaves pro-caspase 3 to caspase 3, which targets cellular components (see 
section 1.3.3.3) to produce the morphological changes associated with apoptosis. Caspase 
3 activates caspases 6 and 7, which are possibly required in the amplification of caspase 
activation as will be discussed in section 1.3.3.4. 
1.3.3.1 Caspase 8 
Caspase 8 is the initiator caspase found in the death receptor pathway of apoptosis. It is 
found to bind to adaptor molecules (e.g. FADD), and is activated by auto-processing when 
many zymogens are bound to the adaptor molecules (Ashkenazi and Dixit, 1998) as 
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discussed below in the death receptor pathway of apoptosis. Caspase 8 activates caspase 3, 
which subsequently activates other caspases and causes the biochemical and morphological 
changes found in apoptosis (Nicholson and Thornberry, 1997). 
1.3.3.2 Caspase 9 
Caspase 9 is the initiator caspase in the mitochondrial pathway. It is activated when bound 
to the adaptor molecule APAF-1 by cytochrome-c (cyt-c) and adenosine triphosphate 
(ATP). Pro-caspase 9 binds APAF-1 by caspase recruiting domain (CARD)-CARD 
interactions and dimerises to other pro-caspase 9, forming a large complex called the 
"apoptosome". The c-terminal of the pro-caspase 9 inhibits the n-terminal, becoming 
active. Upon binding A TP and cyt-c a conformational change occurs exposing the n-
terminal of pro-caspase 9 allowing it to be activated into caspase 9. Caspase 9 then binds 
caspase 3 and proteolytic ally activates it (Zou et al., 1999). 
1.3.3.3 Caspase 3 
Caspase 3 is the general executioner/effector caspase in apoptosis. Activated through the 
death receptor and mitochondrial pathways by caspases 8 and 9 respectively, it has many 
targets for proteolytic degradation in apoptosis including cell cycle proteins (e.g. p21), 
signal transduction molecules (e.g. protein kinase C (PKC)), cytoskeleton proteins (e.g. 
actin), and anti-apoptotic proteins (e.g. Bcl-2) and iCAD (Enari et al., 1998; Fujita et al., 
1998; Kirsch et al., 1999). Caspase 3 also induces other caspases to become active and 
these include caspase 6 and 7 (Orth et al., 1996). 
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1.3.3.4 Caspases 6 and 7 
Classed as executioner/effector caspases downstream in their activation of caspase 3 (Orth 
et ai., 1996). Caspase 6 and 7 have distinct but overlapping substrate preferences and 
functions (Rao et ai., 1996; Zheng and Flavell, 2000), both breaking down lamins in the 
cytoskeleton. Caspase 7 however is almost synonymous with caspase 3 in its substrate 
preference, which gives some degree of redundancy in the action of these two caspases 
(Orth et ai., 1996). 
1.3.4 The Bcl-2 proteins 
The Bcl-2 superfamily of proteins is involved in the mitochondrial pathway of apoptosis 
(Gross et ai., 1998; Desagher et ai., 1999). The family of at least 19 proteins are split into 
four sub-groups based on their structure and function. Group 1 contains the anti-apoptotic 
Bcl-2 family members, with 3 or 4 Bcl-2 homology (BH) domains, and groups 2, 3 and 4 
contain the pro-apoptotic proteins, with 1 to 3 of the BH domains (Fig 1.3.2) (Zimmermann 
et a/., 2001). These two types of Bel proteins interact with each other and organelles within 
the cell to control the process of apoptosis via the mitochondrial pathway (Marsden and 
Strasser 2003; Shultz and Harrington 2003). 
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Figure 1.3.2: The structure of the Bcl-2 superfamily members showing the Bcl-2 homology 
(BH) domains and their arrangement in the protein and the transmembrane domain TM 
(Zimmermann et 01. , 200 I) 
The anti-apoptotic Bcl-2 proteins bind the mitochondrial outer membrane and prevent the 
release of cyt-c fro m the mitochondria and thus the induction of apoptosis. It has been 
suggested that the anti-apoptotic proteins may interact forming heterodimers, via the BH 
domains, with the pro-apoptotic proteins antagonising their effects on inducing apoptosis 
(Table 2). This implies that the ratio of anti-apo·ptotic to pro-apoptotic proteins is important 
in the induction of apoptosis, as a low ratio of the anti -apoptotic proteins to the pro-
apoptotic proteins would allow the induction of apoptosis due to a lack of antagonism from 
the Bcl-2 and Bcl-XL (Shimizu el 01., 2000) . 
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Table 2: The interactions of the anti-apoptotic Bc1-2 proteins with the pro-apoptotic Bc1-2 
proteins antagonising the induction of apoptosis. 
Anti -apoptotic protein 
Bel-2 
Bel-XL 
Interacting pro-apoptotic proteins 
Bax, Bid, Bak, Bel-XS, Bad 
Bcl-XS, Bak 
The other mechanism by which the Bcl-2 proteins prevent apoptosis is by the interaction of 
several anti-apoptotic Bcl-2 proteins with the adenosine nucleotide trans locator (ANT) and 
the voltage dependent anion selective channel (VDAC). The ANT and VDAC fonn the 
mitochondrial penneability transition pore (MPTP), which control the release of cyt-c and 
the transmembrane voltage gradient (Marzo et al., 1998; Shimizu et al., 1999; Shimizu et 
al., 2000). Upon binding Bcl-2 and Bel-XL the MPTP closes, preventing the contents of the 
inter-membrane space of the mitochondria to be released into the cell and initiating 
apoptosis (Shimizu et ai., 2000). 
The pro-apoptotic Bcl proteins all contain the BH3 domain that can be exposed or buried in 
the structure of the protein (Chou et al., 1999). This implies a requirement for some of the 
proteins to have to undergo post-translational modification to expose the BH3 domain and 
translocate to specific areas of the cell, thereby inducing apoptosis by the mitochondrial 
pathway. Some of the pro-apoptotic proteins only have the BH3 domain present in their 
structure and may activate the process of apoptosis by either forming pores and channels in 
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the mitochondrial membrane or by influencing the ANT and VDAC to open, releasing the 
contents of the inter-membrane space of the mitochondria in a pH and voltage dependent 
manner (Fig 1.3.3) (Green and Reed 1998; Gross et al., 1999; Shimizu, 2000). 
Insertion into 
Phospholipid 
membrane 
Pro-apoptotic 
Bel protein 
Pore formed 
/ 
'--
Mitochondrial contents 
Figure l.3.3: The potential action of the pro-apoptotic BcI-2 proteins on the mitochondrial 
membrane forming a pore in the membrane causing the loss of the intra-membrane 
contents. 
The BH3 domain proteins also form a heterodimer with some of the anti-apoptotic BcI-2 
proteins, inhibiting their anti-apoptotic function. This suggests that the ratio of the pro-
apoptotic:anti-apoptotic proteins are important in the induction of apoptosis (Shimizu et al., 
. 
2000). If the ratio of pro:anti is high then the anti-apoptotic proteins activity will be 
sequestered by the pro-apoptotic proteins with enough pro-apoptotic proteins to continue 
with the induction of apoptosis. Alternatively if the pro:anti ratio is low then the pro-
apoptotic proteins will be totally bound to the anti-apoptotic BcI-2 proteins and will fail to 
induce apoptosis (Shimizu et al., 2000). 
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1.3.5 The pathways of apoptosis 
1.3.5.1 The mitochondrial pathway of apoptosis 
The mitochondrial pathway of apoptosis is regulated by the changes in mitochondrial 
potential and permeability and is influenced by the Bcl-2 family of proteins. In a normal 
situation the anti-apoptotie proteins Bcl-2 and Bel-XL are inserted into the outer and inner 
membrane of the mitochondria. These two proteins maintain the mitochondrial potential by 
reducing the membrane permeability. Exposure of cell to insults such as UV radiation, 
ROS or chemicals, results in cell damage and an increase in p53 transcription (Chen et al., 
1996). Transcription of pro-apoptotic Bcl-2 family members (e.g. Bax and Bc1-XS) is 
attenuated by p53. These pro-apoptotic proteins undergo a conformational change by 
dephosphorylation (e.g. Bad) or by proteolytic cleavage (e,g. Bid) and transloeate into the 
mitochondrial membrane (Gross et al., 1998). When the ratio of anti-apoptotic:pro-
apoptotie members of the Bcl-2 protein family is too low the pro-apoptotic proteins cause 
an increase in mitochondrial membrane permeabilisation and release a number of pro-
apoptotic factors as discussed earlier (Zamzami and Kroemer, 2003). The permeabilisation 
of the outer mitochondrial membrane allows the release of pro-apoptotic factors (e.g. cyt-c 
and APAF-l) from the inter-membrane space. Upon release, APAF-l and pro-caspase 9 
bind via CARD dimerisation (Shi, 2001) forming the "apoptosome". Addition of ATP and 
cyt-c converts pro-caspase 9 to the active caspase 9 (Fig 1.1.4). Caspase 9 binds pro-
caspase 3 and proteolytically processes pro-caspase 3 to the active form (Fig 1.3.4). 
Caspase 3 then breaks down target proteins such as iCAD, which induce the morphological 
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changes associated with apoptosis (Thornberry et ai., 1998; Enari et al., 1998; Sakahira el 
al., 2001). 
Cellular insult 
J Cellular membrane 
.---... ~ p53 transcription 
1 
mitochondria t Pro-apoptotic Bcl2 
proteins e.g. Bax 0 
- .... ~ Cytochrome C, APAF-
1 and other intra-
cellular contents • 
Bax : Bcl2 ratio rises in 
the membrane and Bcb 
can't antagonise Bax 
effect. 
released. 
Activation of 
Cytochrome C 
ATP binds 
converting 
procaspase 9 
to caspase 9 
APAF-1 
1 
Apoptosis +--.. ... ------II '" caspase 311'" pro-1==:::111__ ~aspase 
Caspase 3 Caspase 9 
Cytochrome C binds 
APAF-1 to form 
apoptosome. 
Figure 1.3.4: The mitochondrial pathway of apoptosis induced by cellular stress or insult, 
increasing p53 expression. This results in increased production of pro-apoptotic BcI-
proteins (e.g. Bax). Binding of these proteins causes the release of cytochrome C that binds 
to the apoptosome converting pro-caspase 9 to active caspase 9. Caspase 9 proteolytically 
activates caspase 3 that causes the biochemical changes of apoptosis (adapted from Gupta 
2001). 
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1.3.5.2 The death receptor pathway of apoptosis 
Activation of apoptosis can be induced by the binding of death receptors to specific ligands 
(Boldin et al., 1996; Muzio et aI., 1996). The receptors are part of the tumour necrosis 
factor receptor (TNFR) superfamily, with conserved cysteine rich extracellular domain, 
intracellular death domain (DD; e.g. TNFR1, Fas (CD95» (Zimmermann et aI., 2001), and 
TNF related apoptosis inducing ligand (TRAIL). The death domain allows the activation of 
the signal cascade, which causes apoptosis (Boldin et al., 1996). 
To understand the death receptor pathway of apoptosis it is best to use the example of the 
Fas receptor (FasRJ CD95R) and Fas ligand (FasLi CD95) found on immune cells. FasR is 
a glycosylated cell surface molecule induced by cytokines including interferon gamma 
(IFN-y) , and TNF. FasL however is highly regulated, only being expressed on activated 
immune cells. Upon binding of FasL, FasR trimerizes via the death domain (DD) on each 
receptor. To this homo-trimer an adaptor protein, Fas-associated death domain (FADD), is 
recruited using the conserved DD on each protein. The death effector domain (DED) 
present on F ADD allows the recruitment of pro-caspase 8, which binds using homologous 
DEDs on each of the proteins, forming the death inducing signalling complex (DISC) 
(Gupta, 2001). In close proximity to each other the pro-caspase 8 autolytic ally activates 
each other to active caspase 8. Caspase 8 then catalyses the activation of pro-caspase 3 to 
caspase 3 (Fig 1.3.5), which then proteolytically destroys its cellular targets including 
iCAD, poly(ADP-ribose) polymerase (pARP), and lamin (Sakahira et al., 2001). 
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Fas L 
FasR --__ ~ __ ---------------------------------
DO 
OED 
DISC 
FADD 
Procaspase 8 
----------------. ~I ______ ~ 
Autolytic activation 
Active 
caspase 8 
1 
1 Activates caspase 3 
Apoptosis ...... __ Apoptotic targets .... _______ c~~~~ 
e.g. iCAD Caspase 3 
Figure 1.3.5: The death receptor pathway of apoptosis. The diagram indicates the fas li gand 
(FasL) and receptor (FasR) and the death domains (DD) on the receptor. Fas assoc iated 
death domain (FADD) with death effector domains (OED) bind pro-caspase 8 forming 
death inducing signalling complex (OJ C) and activat ing caspase 8 and sub equently 
caspase 3 (adapted from Gupta 200 1). 
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1.3.5.3 Interlinking of the apoptotic pathways 
The pathways of apoptosis induction are not as separate as they first appear. Both 
pathways working together can regulate the induction of apoptosis. This is controlled by the 
death receptor pathway activating the release of cyt-c through caspase 8 activating Bcl-2 
family protein Bid. 
Caspase 8 is activated by the fonnation of DISC and the autolytic cleaving of the pro-
caspase 8 zymogens (as described in Section 1.3.5.2). The active caspase 8 cleaves the Pro-
apoptotic Bid protein to its active t-Bid fonn, which binds to the mitochondrial outer 
membrane (Section 1.3.4 and 1.3.5.1). Binding t-Bid to the mitochondrial membrane 
increases the penneability of the membrane by possibly activating the VDAC, releasing the 
inter-membrane space contents including cyt-c and APAF-l (Cowling and Downward, 
2002). Cytochrome c and APAF-l, with pro-caspase 9 and ATP, fonn the apoptosome, 
which activates caspase 9 (Yoshida et al., 1998). This leads to the further conversion of 
pro-caspase 3 to caspase 3, which in tum causes the morphological changes associated with 
apoptosis e.g. DNA laddering, membrane blebbing and cellular shrinkage. 
It was however proposed by Cowling and Downward (2002) that a positive feedback loop 
may occur through this interaction of the pathways increasing the caspase activation in a 
cell. The positive feedback loop occurs through effector caspases cleaving the initiator 
caspases. The example being that caspase 8 is involved in the release of cyt-c from the 
mitochondria due to the cleaving of Bid to t-Bid. In tum the penneabilisation of the 
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mitochondrial membrane releases cyt-c into the cytosol , activating caspase 9, which then 
activates the executioner caspases 3. Caspase 3 activates caspase 6 and 7, which activate 
caspase 8 (Cowling and Downward, 2002) (Fig 1.3.6). 
Fas R 
DO 
OED 
Fas L 
FADD 
Procaspase 8 
1 Autolytic activation 
Active 
caspase 8 
1 ~aspase 6 + 7 
t 
Cleavage 
of Bid 
apoptosis ~ c:::;:~~~ Caspase 3 
t 
t-Bid 0 
\ ~inds 
\itochondria 
Caspase 9 activates caspase 3 Caspase 9 mitochondria 
Figure 1.3.6: The activation of caspase 6 by caspase 9 and the subsequent activation of 
caspase 8 causing a positive feedback loop in the activation of caspase 3, 6, 8 and the 
truncation of Bid to t-Bid (Cowling and Downward, 2002). 
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1.3.6 Endogenous inhibitors of apoptosis 
To inhibit apoptosis, signalling pathways are activated by stimuli such as extracellular 
matrix binding and growth factor binding. The signalling pathways increase the expression 
of anti-apoptotic proteins, which bind to the caspases and mitochondria. These include the 
well-documented Bcl-2 family of proteins discussed previously, and other anti-apoptotic 
proteins including survivin, cFLIP and the inhibitor of apoptosis proteins (xIAP) (Chavakis 
and Dimmeler, 2002; Duval et al., 2003). More recently a novel inhibitor of apoptosis has 
been identified and referred to as apoptosis repressor with caspase recruitment domain 
(ARC). 
1.3.6.1 Apoptosis repressor with caspase recruitment domain (ARC) 
The ARC gene found on human chromosome 16q22.1 produces an apoptotic inhibitor that 
contains a caspase recruitment domain fused to the c-terminal region rich in proline/ 
glutamic acid residues (Koseki et al., 1998; Abmayr et al., 2004). The CARD domain has 
been found to have high similarity to the pro-domains of the caspases and to the APAF-l 
and death domain containing molecules (Koseki et al., 1998). The ARC gene product 
interacts with caspase 2 and 8 and the pro-apoptotic protein Bax (Koseki et a!., 1998; 
Gustafsson et al., 2004). ARC has also been found to prevent apoptosis induced by Fas 
associated death FADD and trail associated death domain (TRADD) containing receptors 
(Koseki et al., 1998). This indicates that ARC induced inhibition of apoptosis occurs 
predominantly through the death receptor pathway and may be due to the binding of 
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caspase 8 at the mitochondria and the death domains (Koseki et al., 1998; Li et al., 2002). 
Binding of ARC to Bax however suggest that it can also suppress parts of the mitochondrial 
pathway of apoptosis and may include the suppression of cyt-c release from the 
mitochondria (Fig 1.3.7) (Neuss et ai, 2001; Chatterjee et al., 2003; Gustafsson et al., 
2004). Activity of ARC is controlled by phosphorylation of threonine 149 by protein kinase 
CK2 both in vitro and in vivo. This phosphorylation is required for its anti- apoptotic 
activity (Li et al., 2002). 
Expression of ARC has been found in the heart, skeletal muscle and some brain regions in 
both human and rats. Its expression however varies, depending on the cellular environment 
or experimental conditions (Koseki et al., 1998; Dowds and Sabban, 2001). For instance, 
cells cultured in serum-free medium are found to have elevated expression of ARC, which 
is localized to the nucleus (Dowds and Sabban, 2001). In areas of hypoxia and ischemia 
ARC levels in the cytosol may be decreased, allowing apoptosis to occur (Ekhterae et ai, 
1999; Hong et aI., 2003). Other pathological situations also alter the levels of ARC. 
Alzheimer's disease (AD) causes an increase in the expression of ARC, which may 
decrease the incidence of apoptosis in the affected cells (Engidawork et al., 2001). By 
comparison, in Duchenne muscular dystrophy there is no apparent change in levels of ARC 
but its distribution may be altered in affected muscle fibers (Abmayr et al., 2004). 
Moreover, ARC expression is decreased under conditions of enhanced caspase-3 
expression (Abmayr et al., 2004). 
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Over expression of ARC in cells has been shown to decrease the incidence of apoptosis and 
injury. Indeed over expression of ARC in rat heart ventricles decreased apoptosis in 
ischemic disease models (Chatterjee et al., 2003). Similarly, hypoxia induced apoptosis 
was reduced by over expression of ARC which also inhibited apoptosis induced by 
hydrogen peroxide in H9c2 cells (Ekhterae et ai, 1999; Neuss et aI., 2001; Gustafsson et al., 
2004). 
TNF Receptor family 
FADO 
Figure 1.3.7: Pathways of apoptosis and site of action of ARC protein. ARC can inhibit 
apoptosis by preventing the release of cytochrome c through binding to the pro-apoptotic 
protein Bax in the mitochondrial pathway, and by preventing the activation of caspase 8 in 
the death receptor pathway (Chatterjee et al., 2003). - - - -~ = inhibition. 
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1.4 Angiogenesis, Cyc[ooxygenase 2 and Apoptosis 
1.4.1 Angiogenesis and apoptosis 
The processes of angiogenesis and apoptosis are closely linked to each other. During 
angiogenesis, apoptosis of endothelial cells is reduced allowing the production of fresh 
blood vessels from existing vessels. Inhibition of apoptosis during angiogenesis is 
thought to be partially due to the increase in the anti-apoptotic protein Bcl-2 expression 
caused by VEGF in endothelial cells (Nor et al., 1999). The increase in expression of 
Bcl-2 was found to be pro-angiogenic in vascular cells, inducing sprouting and 
proliferation (Nor et al., 2001). Other anti-apoptotic molecules such as ARC have also 
been shown to inhibit apoptosis of skeletal and cardiac muscle cells (Koseki et al., 
1998). It is however not known if ARC is expressed in vascular endothelial cells or 
whether it can prevent apoptosis during angiogenesis and quiescence ofthe vasculature. 
1.4.2 Angiogenesis and cyclooxygenase 2 
Induction of angiogenesis during hypoxia by VEGF released from inflammatory cells 
and the ECM is associated with the induction of expression of COX-2. This occurs in 
endothelial cells within 30 min of treatment in vitro (Carmeliet and Jain, 2000; Abe and 
Sato, 2001; Akarasereenant et al., 2002; Tamura et al., 2002; Wary et al., 2003). 
Vascular endothelial cell growth factor binds to the VEGFR-2 activating protein 
tyrosine kinase and p42/44 (ERIOI2) MAPK. Induction of ERK1I2 increases the level 
of cAMP activating COX-2 gene expression (discussed in Section 1.2.5 and 1.2.7). The 
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ERK1I2 signalling messengers also directly translocate to the nucleus and increase 
expression of anti-apoptotic proteins including COX-2 (Jones et al., 1999; Ruegg et al., 
2004). 
Expression of the COX-2 gene by VEGF can cause a positive feedback loop of VEGF 
expression from endothelial cells (Leung et al., 2003). Prostaglandin E2, produced by 
COX-2 and PGE synthase, binds the cell in an auto or paracrine action and activates 
two possible signalling pathways. PGE2 stimulates the increase in the expression of 
VEGF by (i) activating the ERK 2 signalling messenger, which trans-activates JNK 1 
and increases levels of VEGF (Lin et al., 2001; Pai et al., 2001), (ii) binding the EP2 
receptor releasing HIF -1 a that binds to the hypoxic response element on the promoter of 
the VEGF gene increasing expression (Carmeliet, 2000; Giordano and Johnson, 2001; 
Gately and Li, 2004). The increase in VEGF concentration forms the positive feedback 
loop by inducing further COX- 2 expression (Fig. 1.4.1). 
Prostaglandin E2 has also been found to increase the levels of avp3 integrins that 
increases the activation ofVEGFR-2 and the binding ofVEGF possibly making the cell 
more sensitive to the VEGF produced thereby increasing angiogenesis (Soldi et al., 
1999; Gately and Li, 2004). Other prostaglandins have an effect on angiogenesis. For 
instance, PGI2 may increase endothelial cell permeability and sprouting and TXA2 
increases migration of endothelial cells (Gately and Li, 2004). 
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VEGFR2 
Figure 1.4.1: Schematic diagram of the positive feedback loop of vascular endothelial 
growth factor (VEGF) and COX-2 expression via PGE2 (Carmeliet, 2000; Giordano and 
Johnson, 2001; Lin et al., 2001; Pai et al., 2001; Gately and Li, 2004,). 
1.4.3 Angiogenesis and cyclooxygenase 2 inhibition 
Selective inhibition of COX- 2 activity has been found to inhibit angiogenesis dose 
dependently by decreasing growth factor (e.g. VEGF and bFGF) expression and 
inhibiting proliferation of endothelial cells in vitro and in vivo (Sawaoka et al., 1999; 
Leahy et al., 2002; Yazawa et al., 2005). Th,ese effects were reversed however by the 
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addition of PGE2, allowing endothelial cells to continue to proliferate (Yazawa et al., 
2005). 
1.4.4 Cyclooxygenase 2 and apoptosis 
Cyclooxygenase-2 is a key regulator of apoptosis and has been found to either inhibit or 
induce apoptosis depending on the type of prostaglandins produced. 
1.4.4.1 Cyclooxygenase 2 and apoptosis inhibition 
Induction of COX-2 during angiogenesis and inflammation has been found to reduce 
the incidence of apoptosis (Tsujii and Dubois, 1995; Leahy et at, 2002; King et at, 
2004; Lui et ai., 2004; Yazawa et ai., 2005). It may inhibit the activation of pro-
apoptotic proteins (e.g. p53) following drug and hypoxia induced apoptosis (Jabbour et 
ai., 2002; Leahy et al., 2002; Lui et ai., 2004). In addition, COX-2 may increase pro-
survival prostaglandins including PGE2. (Ottonello et al., 1998; Sheng et al., 1998; 
Murphy and Fitzgerald, 2001; Jabbour et al., 2002; Steele et al., 2003). Increase in 
PGE2 has been associated with intracellular increases of pro-survival factors (e.g. Bc1-
2) via the PI3K1Akt signalling pathway (Sheng et al., 1998; Parfenona et at., 2001; 
Gately and Kerbel, 2003). The induction of Bcl-2 inhibits the release of cyt-c from the 
mitochondria and prevents the activation of caspase 9 (Sun et at., 2002; Jendrossek et 
at.,2003). The synthesis ofPGE2 or treatment with PGE2 in vitro has also been shown 
to elevate the levels of cAMP intracellularly. This subsequently results in the activation 
of the cAMP response element (CRE) on many genes including VEGF and possibly 
anti-apoptotic proteins (Ottonello et at., 1998), and may also promote avp3 integrin 
binding of endothelial cells with cAMP signalling preventing cell dissociation from the 
ECM and subsequent anoikis (Dormond et al., 2002). 
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1.4.4.2 Cyclooxygenase 2 and apoptosis induction 
The production of the cyclopentenone prostaglandins during the second induction of 
COX-2 may be involved in the resolution of inflammation and in the control of 
angiogenesis. Cyclopentenone prostaglandins such as PGD2, PGh and 15-deoxy-~ 12.14 
- PGh, have been shown to induce apoptosis in many cell types including endothelial 
cells and granulocytes (Ward et al., 2002; Dong et al., 2004; Erl et al., 2004). These 
prostaglandins are ligands for PP AR-y, but may induce apoptosis independently of this 
receptor (Ward et al., 2002; Erl et al., 2004). Apoptosis induction is accompanied by an 
inhibition of NF-KB and AP-l DNA binding (Dong et al., 2004; King et al., 2004), and 
an increase in p53 and p38 activation that may be pro-apoptotic (Dong et al., 2004). 
1.4.4.3 Cyclooxygenase 2 inhibition and apoptosis induction 
Inhibition of COX-2 by non-steroidal anti-inflammatory drugs (NSAIDs), selective 
COX-2 inhibitors and other inhibitors of COX-2 such as curcumin, increase apoptosis 
and inhibit angiogenesis while decreasing PGE2 levels (Pang and Hoult 1997; Sawaoka 
et al., 1999; Leahy et al., 2002). The induction of apoptosis by COX-2 inhibitors may 
be due to the decrease in PGE2 production and decreasing VEGF production in 
endothelial cells. The decrease in PGE2 prevents the PI3K1 Akt signalling for the 
production of anti-apoptotic Bcl-2 proteins promoting the mitochondrial pathway of 
apoptosis, (Wheeler-Jones et al., 1997; Hsu et al., 2000; Williams et al., 2000; Wu et 
al., 2003; Zha et al., 2004). The inhibition of COX-2 causes the accumulation of 
unesterified arachidonic acid in the cell and this may also directly promote apoptosis 
(Cao et al. 2002; Zha et al., 2004). 
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Inhibitors of COX-2 have been shown to augment apoptosis independently of COX-2 
inhibition, suggesting a pro-apoptotic effect through other signalling pathways 
(Niederberger et al., 2004). COX-2 inhibitors e.g. NS-398, may promote apoptosis 
through the death receptor pathway independently of COX-2 inhibition (Totzke et al., 
2003; Niederberger et al., 2004). The selective COX-2 inhibitors celecoxib and 
rofecoxib have been found to induce apoptosis by interfering with multiple targets (e.g. 
Akt, ERK2), with no reversal of the induction ofCOX-2 (Hsu et al., 2000; Song et al., 
2002; Niederberger et al., 2004). These actions of the drugs are observed at 
concentrations much higher than the IC50 for the inhibition of COX-2, suggesting that at 
high concentrations COX-2 inhibitors may cause apoptosis in cells with no clinical 
inhibition of inflammation or angiogenesis. 
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2. Materials and Methods 
A full list of suppliers can be found in Appendix A. A full list of media recipes and 
solutions can be found in Appendix B. 
2.1 Cell Culture 
2.1.1. Isolation of Human Umbilical Vein Endothelial Cells (HUVECs) 
HUVECs were isolated using a modification of Morgan, 1999. Human umbilical cords 
were collected in a sterile container containing phosphate buffered saline (PBS) within a 
few hr of birth. The umbilical cord was placed on to tissue paper and small sections of the 
ends of the cord were removed to give a clear surface and unobstructed entry to the vein. 
To each end of the cord luers were placed into the vein and secured using strong thread. A 
20ml syringe containing 20ml PBS was attached to one end of the cord and the PBS 
flushed through the vein to wash out blood cells and also check for leaks or obstructions in 
the vein. Blood clots present were gently massaged to mechanically break down the clot. If 
the clot could not be removed the cord was cut beyond the obstruction and the luer 
reattached. A second 20ml syringe containing pre-filter sterilised collagenase solution 
(O.Smglml) was attached to the opposite end of the cord and the vein filled with the 
collagenase. The cord was wrapped in tin foil and placed in a 37°C incubator for 10 
minutes to facilitate dislodging of endothelial cells from the vessel wall. During these 10 
minutes a T25 flask was coated with 1 % (v/v) gelatin by adding 2ml of 1 % gelatin to the 
flask and incubating at room temperature for 5-10 minutes. Once the incubation was 
completed the excess gelatin was removed and the flask retained for further use. The cord 
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was removed from the incubator, gently massaged and the collagenase solution collected 
into a 50ml centrifuge tube. The cords were flushed with PBS and the wash collected into 
the same 50ml centrifuge tube. The solution was then centrifuged at 1000rpm for 5 
minutes. The supernatant was discarded and the cell pellet resuspended in 5ml of Medium 
199 supplemented with 20% foetal calf serum (FCS), 2mM I-glutamine and 100 units 
penicillin, 0.1 mglml streptomycin (complete MI99). The cell suspension was then placed 
into the gelatin-coated T25 flask and incubated for 24 hr at 37°C, 5% CO2 in a tissue 
culture incubator. The media was replaced after 24 hr with fresh medium containing 
endothelial cell growth factor (ECGF; 50l-lglml). Flasks were incubated for a further 2 days. 
2.1.2 Growth and Maintenance of HUVECs 
Maintenance of HUVECs was carried out by replacing the spent cell culture media with 
5ml fresh complete M199 containing ECGF. This process was repeated every two days 
until cells were confluent. 
2.1.3 Passaging and plating of HUVECs 
Confluent mono layers of HUVECs were detached with trypsin-EDTA solution (500 units 
trypsinll80/lglml EDTA). The culture medium was removed from the monolayer and 2ml 
of trypsin-EDTA added to each flask. The solution was gently swirled around the flask 
ensuring that the cell monolayer was covered in trypsin. The latter was removed and the 
process repeated but leaving approximately 200/l1 of solution in the flask. The flasks were 
continuously examined under the microscope until the cells rounded up. At this point the 
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flasks were gently tapped on the bench to dislodge the cells. 1ml of complete M199 was 
added to each flask to deactivate the trypsin-EDT A. Cells were counted with an improved 
Neubauer haemocytometer and calculated for plating into 12, 24 or 96 well plates pre-
coated with 1% (v/v) gelatin (only 12 and 24 well plates). Cells to be passaged had 2mls of 
fully supplemented Media 199 added into the flask and divided equally between 3 T25 or 
placed into a T75 tissue culture flask pre-coated with 1 % (v/v) gelatin (see section 2.1.1) 
and ECGF was then added to each well or flask and incubated at 37°C, 5% CO2 until ready 
for use. 
2.1.4 Growth and maintenance of J774 macrophages 
J774 macrophage cultures were maintained by removing spent Dulbeccos modified eagle 
media (DMEM) and replacing with 5ml fully supplemented DMEM every two days. 
Passaging of confluent cells was done by removing culture media and scrapping the cells 
into 1 ml of fully supplemented DMEM. Cells were counted and either plated into 12/24/96 
well plates for treatment or into fresh T25 culture flasks for growth and incubated at 37°C, 
5% CO2 until used. 
2.1.5 Growth and maintenance of Jurkat E6.1 cells 
Jurkat E6.1 cells were maintained in T25 tissue culture flasks in 2mM I-glutamine and 100 
units penicillin, 0.1 mglml streptomycin (complete RPMI 1640). Upon reaching confluence 
the media containing the cells was placed into' a 15ml centrifuge tube and centrifuged at 
1000rpm for 5 minutes. The supernatant was removed and the pellet resuspended into I ml 
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of fresh supplemented media for counting. Cells were distributed into 3 T25 flasks 
containing 4rnls of fresh supplemented media for passaging or plated into 12, 24 or 96 well 
tissue culture plates for experimentation. 
2.2 Matrigel HUVEC tubule formation assay 
Matrigel was defrosted at 4-8°C until liquid and 40~1 applied to each well of a -20oe pre-
cooled 96 well plate with -20°C pre-cooled tips ensuring a level covering of the well, 
followed by an incubation of the 96 well plate at 37°C for 30 minutes. To each well 100~1 
of a 2 x 105 cells/rnl suspension of HUVECs were added. Treatment was then spiked in to 
the media and the plate incubated to allow tubule formation at 37°C in a 5% CO2 tissue 
culture incubator. Tubules were counted and photographed after 8 hrs of incubation with 
only full tubules being counted as positive. 
2.3 Induction of apoptosis in HUVECs and Jurkat E6.1 cells 
Apoptosis was induced by removing the complete M199 and replacing it with 0% FBS 
M199. To the negative control wells the vehicle for the drug was added at the highest 
concentration used. In the treated wells the drug was added directly to give the final 
concentration required. The samples were incubated for up to 8 hr for caspase activation 
and for 24 hr when investigating caspase activity, DNA condensation and laddering. 
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2.4 Determination of induced cell apoptosis 
Floating cells in the culture medium were removed and counted. The cells were 
centrifuged at 13,000 rpm for 5 minutes in a microcentrifuge and resuspended in PBS at 1 x 
105/ ml. Adherent cells were trypsinised and counted. The percentage of floating cells was 
then worked out. The floating cells were subsequently used in chromatin condensation 
assays, determination of DNA laddering or analysis of caspase induction. 
2.4.1 Cytospinning and fluorescent staining of condensed chromatin 
Cell suspensions of lurkat E6.1 cells or HUVECs were pipetted into cytospin chambers 
(Fig 2.4.1) and centrifuged at 750rpm for 10 minutes to pellet cells onto a glass slide. 
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Cells 
Figure 2.4.1 The cartoon of a cytospin vessel. Cells were pipetted into the cytospin vessel 
and centrifuged to form a pellet of cells on the glass slide. The pellet was then fixed and 
stained 
Slides were fixed by pipetting 20~.t1 of 3.7% formaldehyde on to the cells for 10 minutes 
and washed 10 times in PBS to remove any excess formaldehyde. Acridine orange (4)lM) 
was added to the fixed cells and incubated in the dark for 3 minutes. Slides were again 
washed in PBS (10 times) to remove excess stain. 500 cells were counted at random, 
identifying and counting fluorescent stained cells which were taken as positives for 
condensed chromatin. The percentage of total cells that had condensed chromatin was then 
calculated using the equation below: 
Cells with condensed chromatin X 100 = % of floating cells with condensed chromatin 
Cells counted on slide (500) 
(% of floating cells/ 100) X % of floating cells with condensed chromatin 
= % of total cells with condensed chromatin. 
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These values were then plotted graphically and statistical analysed. 
2.4.2 DNA laddenng assay using a DNA suicide track ® kit 
The assay was performed according to the manufacturer's protocol. Cell pellet was 
resuspended in S00)11 of extraction buffer and incubated on ice for 30 minutes. The 
samples were centrifuged at 13,000rpm for S minutes and the supernatant retained. To the 
samples 20)11 of solution 2, an RNase solution, was added and incubated at 37°C for 60 
minutes. Twenty five microlitres of solution 3, used to aid isolation of the DNA from the 
cell lysate, was then added and mixed gently before incubating at SO°C for 60 minutes. To 
the solution 2)l1 of pellet paint TM, 60)l1 3M sodium acetate (pH S.2), and 6621 .. tl of 2-
propanol were added, mixed by inversion and incubated at room temperature for 2 minutes. 
Samples were centrifuged at 13,000rpm for 5 minutes, the supernatant removed and the 
pellet washed with 500 )11 70% ethanol and re-centrifuged. The supernatant was removed 
from the samples and the pellet was washed with 500)11 100% ethanol and centrifuged. The 
pellet was allowed to dry, resuspended in S0)11 of resuspension buffer and retained at 4°C 
until analysed by agarose gel electrophoresis. 
2.4.3 DNA ladden·ng assay following phenollchloroform DNA extraction 
Treated cells were lysed in lOO1l1 DNA lysis buffer (lOmM EDTA, 50mM Tris - HC1, 
O.S% SDS) for 30 minutes on ice. Proteinase K (O.Smg/ml) was added and the samples 
incubated for a further 1 hour at SO°c. Sill of Img/ml RNase A was added and again 
incubated at SO°C for 1 hour. An equal volume of phenol: chloroform: isomoyl alcohol 
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(24:25: 1) was added to the samples and gently mixed for 2 minutes. The samples were 
centrifuged at 13,000 rpm for 5 minutes. The aqueous top layer was transferred into a clean 
microcentrifuge tube. An equal volume of the phenol:chloroform mixture was added and 
centrifuged. The aqueous top layer was saved and 2.5 volumes of ice cold absolute ethanol 
plus 0.1 volumes of 3M sodium acetate (pH 5.8) added. The samples were incubated 
overnight at -70°C to precipitate the DNA. The precipitates were centrifuged for 5 minutes 
at 13,000 rpm and the supernatant discarded. Pelleted DNA was washed in 70% ethanol, 
centrifuged at 13,000 rpm for 5 minutes and left to air dry. The pellet was subsequently 
resuspended in 50111 of TE buffer and analysed by agarose gel electrophoresis. 
2.4.4 Analysis of caspase-3 activity 
Treated cell cultures were trypsinised and counted using a haemocytometer. The samples 
were centrifuged at 1000rpm for 10 minutes and resuspended in ice-cold lysis buffer 
(50mM HEPES, ImM Dithiothreitol (DTT), O.lmM EDTA, 10% (v/v) glycerol, 0.1% 
(w/v) CHAPS) (pH7.4) to the concentration of 1 x 107 cells/rnl before incubating on ice for 
5 minutes. The lysates were then centrifuged at 1000rpm for 10 minutes at 4°C. The 
supernatant was retained on ice or at -70°C until required. 
To determine caspase activity in samples, a conversion factor for sample activity was 
required and was determined by adding 100111 of 50llM p-nitroaniline to duplicate wells in 
a 96-well plate. Assay buffer added to other duplicate wells was used as blanks. The 
absorbance of each sample was read at 405nm using a Labsystems Multiscan RC 
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spectrophotometer. The blank values were subtracted from the p-nitroaniline readings and 
the conversion factor calculated as follows: 
Conversion factor (~MI AW5) = 50~Mlaverage A405 (of p-nitoaniline - blank) 
A 96-well assay plate was set up as follows using the cell supernatant derived from above: 
Table 3: Reagents required for the caspase 3 activity assay 
Sample Assay Cell extract Human Caspase-3 Substrate 
buffer (~I) (~I) recombinant inhibitor Ac-DEVD-
Caspase-3 Ac-DEVD- pNA (~l) 
(2U/1l1) CHO ().tl) 
Blank 90 0 0 0 10 
Cell sample 60 30 0 0 10 
Caspase-3 60 0 30 0 10 
positive 
control 
Caspase-3 + 30 30 30 0 10 
cell extract 
Cell extract 40 30 0 20 10 
+ inhibitor 
Prior to adding the substrate the 96 well plate was incubated at 3rC with the other reagents 
in order to alIow the inhibitor to interact with the enzyme. The substrate was subsequently 
added and the absorbance read at 405nm every 10 minutes for up to 2 hr. 
Following the absorbance readings the data for each sample was plotted against time 
(mins). The slope of the lines (aD at 405nm1lUin) was calculated from the linear portion 
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of the lines and the sample replicates mean averaged. Blank values were subtracted from 
the sample values. Activity of the samples (pmoll min) was calculated using the equation 
below; 
Activity (pmollrnin) = slope (Alrnin) x conversion factor (50IlMiaverage 405nm) x assay 
volume. 
Specific activity (pmollrninlnumber of cells) of the samples was calculated by dividing the 
activity (pmoll min) by the number of cells suspended in 30).1.1 of the lysis buffer and 
plotted for graphically analysis. 
2.5 Western blotting and protein analysis 
Culture media was discarded from treated wells. Treated cells were lysed in 20-100 ).1.1 20% 
(v/v) glycerol, lO%(v/v) SDS, and 0.1 M Tris-Hcl (pH6.8) on ice for 5 min. Protein 
samples were frozen (-200C) until required for protein concentration analysis or western 
blotting. 
2.5.1 BCA assay for protein concentration 
Stock solutions of protein standards (O-lOOO).l.gllll) were prepared from bovine serum 
albumin (BSA) in sterile distilled water (SDW). 0.1 ).1.1 of the lysis buffer used for western 
blotting was added to each stock solution. A protein standard curve was then constructed by 
adding IOll1 of each standard to duplicate wells in a non-sterile 96-well plate. 10).1.1 of a 
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1: 10 dilution of the samples were added into the sample wells of the same 96-well plate. 
The Bicinchoninic acid (BCA) reagent was prepared by mixing a 50: 1 ratio of solutions A: 
B. 200J.ll of the reagent was then added to each well and incubated for 30 mins at 37°C. The 
plate was read on a Labsystems Multiscan RC spectrophotometer at 595nm. The 
concentration of protein in each sample was determined from the standard curve 
constructed. 
2.5.2 Sample preparation 
Samples were thawed and aliquoted to give an equal concentration of protein for analysis. 
To the aliquot a volume of dithiothreitol (OTT) (1 M) was added to give a 1:5 dilution of 
OTT in the final sample (200 mM). This was used to reduce the proteins. ll-ll of 
bromophenol blue dye was also added. The samples were then boiled at 95°C for 5 mins to 
denature the proteins and then loaded immediately onto an SOS-PAGE gel in a mini-
protean II system (Biorad). 
2.5.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
The resolving gel solution was made (appendix B) and poured leaving approximately 2.5 
cm from the top of the glass (Fig 2.5.1). 
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2.5 em 1 Spacer 
Gel plate Clamps 
Figure 2.5. I: A cartoon of the gel forming equipment used to set the resolving gel in SDS-
PAGE. 
500J.l1 of isopropanol was applied to the top of the gel to stop oxygen preventing the 
polymerisation of the gel. Once set, the isopropanol was poured off of the resolving gel 
and any remaining isopropanol removed with a 3M Whatman filter paper. The stacking gel 
was prepared and poured on top of the resolving gel with the well forming comb placed 
into the top (Fig 2.5.2). 
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_+---+.-_ Well forming 
comb 
Spacer --+-->, Stacking gel 
f--+--- Resolving gel 
Clamps --+-
Figure 2.5.2: A cartoon of the stacking gel and well formation used in SOS-PAGE 
When the stacking gel was set the gel was placed into the electrode apparatus and then into 
the gel tank. The tank was filled with gel running buffer and the combs removed. The 
samples were pipetted into the wells and run at 200 volts for 45-60 mins, until the sample 
buffer had run through the gel. 
2.5.4 Western Blotting ofSDS-PAGE gel 
The gels were removed form the tank, the stacking gel cut and the resolving gel incubated 
in transfer buffer for 5 mins. Two Whatman filter papers and the nitrocellulose membrane 
were then cut to size and incubated in transfer buffer for 5-10 mins. After the incubation the 
nitrocellulose membrane and gel were placed into the transfer cassette as shown (Fig 2.5.3) 
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Cathode (+) 
/ 1 I 
] ,. 
Filter Pads (blue) 
Cassette Plates 
1 I ... Nitrocellulose membrane 
~ I ... Polyacrylamide gel ,III Whatman filter paper (orange) 
Anode (-) 
Figure 2.5.3: A schematic of the arrangement of the filter paper, nitrocellulose membrane, 
and gel for the western blot. 
Air bubbles were removed between the gel and the membrane by rolling them out. The 
cassette was then closed and placed into the transfer apparatus with cooling tubes used to 
maintain the temperature. The transfer was carried out at 350mA for 1 hour. Following 
completion of transfer, the nitrocellulose membranes was placed in blocking butfer for 2-3 
hr at room temperature on an orbital shaker. 
2.5.5 Immunodetection o/proteins on nitrocellulose membranes 
Blocked nitrocellulose membranes were incubated with primary antibody overnight. Each 
antibody used was diluted as required in 10mls of PBS-Tween 20. Incubations were 
followed by four washes with PBS-Tween 20 for 10 mins each wash. Horseradish 
peroxidase (HRP) conjugated secondary antibody was then incubated with the membrane in 
10mls of PBS-Tween 20 at a dilution of I :5000 for 30 mins. The secondary antibody was 
specifically targeted at the primary antibody to avoid cross reactivity with other non-related 
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proteins. After the incubation of secondary antibody the nitrocellulose membrane was 
again washed four times for 10 mins in PBS-Tween 20 to remove any excess antibody. 
2.5.6 Enhanced chemiluminescence detection of antibody bound proteins 
Protein bands were visualised using chemiluminescence detection. The two solutions 
obtained in the EeL kit were mixed in equal parts and incubated on the membrane for one 
minute. The excess solution was removed by tipping the membrane to its side and onto a 
paper towel. The membrane was then wrapped in clingfilm ensuring no air bubbles were 
present trapped. The membrane was exposed to Hyperfilm EeL (Amersham biosciences) 
for 5 to 20 mins depending on the intensity of the bands. The film was developed for 1-3 
mins until bands could be visualised, washed in water to remove any excess developing 
solution and fixed for 5 mins to prevent any further development of the film. 
2.5.7 Analysis ofimmunoblotting by densitometry 
Protein bands identified by specific antibodies and EeL detection were analysed using 
densitometry. Blots were analysed using the Gene Genius Bioimaging system and the 
Syngene Genesnap program. All blots were analysed and compared to control values 
before graphical representation. 
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2.6 Prostaglandin E2 enzyme linked immunosorbent assay 
(ELISA) 
2.6.1 Sample preparation 
HUVECs were treated with DuP-697 or indomethacin in serum free media (SFM) or 
complete media 199 and incubated at 37°C for 24 hr. Sample media was then removed from 
the tissue culture plate and retained for analysis of prostaglandin E2 (PGE2) or stored at -
70°C until required. 
2.6.2 Detection of PGE2 
Wash buffer was prepared by diluting 30ml of lOx buffered surfactant concentrate into 
270ml distilled water giving a 1: 10 dilution. Standards were serially diluted in cell culture 
media (CCM) to give a range of standards from Opg/ml to 2500pg/ml. The standards were 
then used within 60 mins of dilution. 
All samples and standards were analysed in duplicate. One hundred and fifty microlitres of 
CCM was added to the non-specific binding wells and 100/-11 of CCM was added to the zero 
standard wells. Samples and standards (100/-11) were added to the remaining wells. To each 
well, excluding the total activity and substrate blank wells, 50/-11 of PGE2 conjugate was 
added, followed by 50/-11 of PGE2 antibody, excluding the total activity, non-specific 
binding and substrate blank wells. The plate was then covered and incubated for 2 hr at 
room temperature on an orbital shaker at high speed. Wells were decanted and washed 
ensuring that all the liquid was fully removed. This was repeated 3 times. 5/-11 of PGE2 
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conjugate was added to the total activity wells. Two hundred micro-litres of pNPP substrate 
was added to all of the wells and the plate incubated for 1 hour at room temperature on the 
bench. After the incubation, 50~1 of trisodium phosphate stop solution was pipetted into 
each well and the optical density measured at 405nm immediately. 
Duplicates of samples and standards were averaged and the non-specific binding subtracted 
from the values. A standard curve was then produced and the concentration of PGE2 in the 
samples calculated from the curve. These values were then expressed as a percentage of 
the control concentration of PGE2 to allow for comparison of different treatments. The 
wells for total activity, non-specific binding and substrate blank were used for quality 
control of the assay. 
2. 7 Apoptosis repressor with CARD domain plasmid isolation 
and analysis 
2.7.1 Culture of competent cells 
A single DH5 a E.coli colony was use to inoc~late lOmls of tryptone-yeast extract media 
(TYM) and grown at 37°C for 3 hr. After the incubation Iml of the culture was added to 
100ml of fresh TYM and cultured for between 4 to 6 hr until the culture reached an optical 
density of 550 of 0.5-0.7. Cultures were centrifuged at 4000 x g for 15 mins at 4°C. The 
. 
supernatant was removed and the pellet resuspended in 30ml of Tfb 1 buffer (30mM 
potassium acetate, 50mM manganese chloride, 100mM potassium chloride, 10mM calcium 
chloride, 15% (w/v) glycerol), and then put on ice for 30 mins. The cells were then 
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centrifuged at 500 x g for 20 mins at 4°e and the supernatant discarded. The cell pellet was 
resuspended in 4m1 of cold Tfb 2 buffer (lOmM MOPS (pH7), 10mM potassium chloride, 
75mM calcium chloride, 15% (w/v) glycerol) and aliquoted into 200ul aliquots to be stored 
at -70°C. 
2.7.2 Preparation ofplasmid pCDNA3-ARC 
The filter paper holding the pcDNA3-ARe plasmid was placed into 100ui of sterile TE 
buffer for 10 mins at room temperature allowing the plasmid to transfer from the filter 
paper to the buffer. The plasmid in solution was stored at 4°e and -20oe until required. 
2.7.3 Transformation of the competent DH5 a E. coli cells 
A 200lli aliquot of DH5 a cells was defrosted on ice. The plasmid was added and the cells 
incubated for a further 30 mins on ice before subjecting to heat shock by incubating at 42°e 
in a water bath for 2 mins. The cells were then,placed back on ice and 800 ul of LB broth 
added before incubating at 37°e for lhour to allow the bacterial to recover. The 
transformed bacteria were spread onto an LB agar plate supplemented with ampicillin and 
incubated overnight at 37°e. The plate was stored at 4°e to be used as a transformed 
bacteria master plate from which all experimental bacteria would be grown. 
2.7.4 Bacterial growth and maintenance 
A single colony was selected at random from the transformed bacteria master plate and 
streak plated onto fresh LB agar plate containing ampicillin and was incubated overnight at 
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37°C. The fresh streak plate was used as the master plate of transformed bacteria and stored 
for 3-4 weeks at 4°C until a new master plate was produced. 
2.7.5 Isolation ofpCDNA3-ARC using Qiagen Miniprep plasmid isolation 
kit. 
Transfonned DH5a E. coli, with the pCDNA-ARC plasmid, were grown in 10 ml ampicillin 
containing LB on a rotary shaker at 37°C overnight. 1.5 m1 bacterial suspensions were 
transferred into a microfuge tube and centrifuged at 13,000 rpm for 5 mins. The 
supernatant was removed and the pellet resuspended in 250~1 of buffer PI (resuspension 
buffer containing RNase A 0.1 % (v/v) (Qiagen» followed by 250~1 of buffer P2 (alkaline 
lysis buffer containing sodium hydroxide (Qiagen». The suspension was inverted 5 times 
until clear. To precipitate the bacterial debris from the solution, 350111 buffer N3 
(neutralising guanidine hydrochloride and acetic acid buffer (Qiagen» was added and 
mixed by inversion 5 times followed by the tube being centrifuged at 13,000 rpm for 1 0 
mins. The supernatant was retained and passed through the QIA prep spin column by 
centrifuging at 13,000 rpm for 60 seconds with'the flow through discarded. The column 
was washed in 750)11 of buffer PE (Qiagen) and centrifuged 13,OOOrpm for 60 seconds and 
the flow through discarded. Centrifuging the column at 13,OOOrpm for 60 seconds dried the 
column membrane. Elution of the plasmid in a clean 1.5 microfuge tube was carried out by 
addition of 50Jll of buffer EB (High salt elution buffer (Qiagen» to the middle of the 
column membrane and incubating for I minute at room temperature followed by 
centrifuging at 13,OOOrpm for 1 minute. Plasmid suspensions were stored at 4°C until 
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required. The eluted DNA was quantified by spectrophotometry at 260run, using the 
equation: 
Absorbance value 1.000 = 50ng/~1 DNA. 
2.7.6 Digestion ofpCDNA3-ARCwith endonucleases 
The pCDNA3 plasmid was assessed for endonucleases digestion sites using webcutter 
program. The reaction mixtures for digestions were set up containing 2~1 plasmid, l~l lOx 
buffer mix, 1~1 of 5U/~1 restriction enzyme, 7~1 SOW. The reaction tubes were then 
placed at 37°C for 1 hour to allow restriction of the DNA to occur. The reaction was placed 
on ice and 2~1 of stop mix/loading buffer was added to each reaction. The digestions were 
visualised using a 1 % agarose gel and ethidium bromide staining. The sizing of the 
restricted plasmid was analysed by the Gene snap program (Syngene). 
2.7.7 Polymerase chain reaction (PCR) 
PCR amplification of DNA was carried out using a Master Cycler Gradient Thermocycler 
(Eppendorf) and specific PCR protocols for the target region of DNA. Standard PCR 
reactions were carried out in a total volume of 50~1 with the standard PCR mix consisting 
of; 0.2mM of each dNTP (dATP, dCTP, dTTP, dGTP) (Invitrogen Ltd.), ImM MgCl2 
(Invitrogen Ltd.), Ix Taq buffer (Invitrogen Ltd.), 1 Unit of Taq polymerase (Invitrogen 
Ltd.), 0.2~M forward primer, 0.21lM reverse primer, and DNA template. Nuclease free 
water (Promega) was used to make the total volUme to 50Il!. Amplified DNA was analysed 
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using 2111 PCR product + 8111 agarose gel loading buffer on 0.8% agarose gel 
electrophoresis at 100V until the dye front was 3cm from the end of the gel. 
2.7.8 Transfection of HUVECs using the JetPEI-HUVEC reagent 
HUVECs were plated into 24 well plates coated with 1 % gelatin using 35, 000 cells per 
well and incubated at 37°C in a tissue culture incubator. Plasmid DNA (2).lg) was diluted in 
50).l1 of 150mM sterile NaCI then briefly vortexed and centrifuged. The JetPEI-HUVEC 
reagent (4J.lI) was diluted in 50).l1 of sterile NaCI then briefly vortexed and centrifuged. 
Mixing the two solutions by gently vortexing them together and gathering the liquid to the 
bottom of the tube by centrifuging followed by an incubation at room temperature for 30 
min formed the DNA-JetPEI complex. During this time the 20% FCS medium 199 was 
removed from the HUVECs and replaced with 500).l1 2% FCS optiMEM. The DNA-JetPEI 
complex (100).l1) was added to the well and homogenized by gently swirling the plate then 
incubating the plate at 37°C in a tissue culture incubator for 4 hr. The transfection media 
was removed and replaced with lmI 20% FCS medium 199 for 24 hr. Transfections were 
photographed in the well and then prepared for western blot analysis. 
2.8 Agarose gel analysis and detection of DNA 
2.8.1 Agarose gel electrophoresis 
To 1 x TAE buffer 1-2 % (w/v) agarose was added and boiled to dissolve the agarose. The 
molten agarose was poured in to the gel cassette and the comb placed in the gel to form the 
sample wells. Once the gel was set 1 x T AE buffer was added to the tank to cover the 
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wells. Twenty-one micro-Iitres of the samples were transferred to new microcentrifuge 
tubes and to each of the samples 4).t1 of sample buffer was added. The samples were then 
loaded on to the gel and run at 60 - 80 volts until the dye front was 1-2cm from the bottom 
of the gel. 
2.8.2 Ethidium Bromide staining of an agarose gel 
Ethidiurn bromide was added to TAE buffer at a concentration of l).tglml. The agarose gel 
was then incubated in a tank containing 1 )lglml ethidium bromide for 20-30 mins. Once 
stained the gel was placed in distilled water for 2 mins and then visualised under UV light 
to detect the DNA. 
2.9 Statistical analysis of data 
All statistical analysis was conducted using Microsoft Excel and Graphpad Prism computer 
programs for all of the data used. 
2.9.1 Student's unpaired t-test 
Student's t-test was used for the statistical analysis of two independent sets of samples to 
conclude if the two sets of samples fell into two distinct populations. The two sets of 
samples that were tested were hypothesised to be under the null hypothesis and then 
underwent student's t-test to disprove the null hypothesis. Calculating t was done using the 
calculation below: 
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...j [1.!!I-l)S/ + (o,rl)si.I x [1 + 11 
[0]+02-2] 0] 02 
0] = number of values in set 1 
02 = number of values in set 2 
SI = standard deviation of set I 
S2 = standard deviation of set 2 
Comparing the value produced from the calculation and the degrees of freedom (dt) for the 
calculation (df= (0] + 02 - 2» to a t- table of values (Appendix C) gave a probability value 
(p value) of the null hypothesis being correct. If the t value was above the value stated for 
5% confidence the null hypothesis was discarded and the two groups of samples were 
considered significantly different. 
2.9.2 One way Analysis a/Variance (ANOVA) 
One way Analysis of Variance (ANOVA) was used to compare more than two sets of 
sample mean averages. The null hypothesis was again tested for the population of samples 
and rejected if at least any two of the samples were significantly different from each other. 
This was concluded by the variance between the mean values of the samples being greater 
than the variability between the individual sets of data. Analysis of the data was done by 
calculating the "within-samples sum of squares" (SSw); 
The overall mean of every sample to be compared was calculated and the total sum of 
squares (SSt) calculated using each sample value and the overall mean value using the 
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calculation above. Using the two values gained for the SSw and SSt the value for the 
"between samples sum of squares" (SSb) was calculated as below; 
The degrees of freedom of the "within samples" and "between samples" variance were 
calculated by; 
dfw = Number of samples in total- number of samples in the groups 
dfb = Number of sets of samples-1 
These values were then used to calculate the mean square of the "within samples" (MSw) 
and "between samples" (MSb) data; 
MSw = SSw / dfw 
A ratio of the two mean square values was the calculated to give F, which was then 
compared to the F-table (Appendix C): 
F=MSb 
MSw 
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If the value gained for F was greater than the value quoted for 5% confidence the null 
hypothesis was discarded and the data was significantly different. 
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3.0 Optimisation of apoptosis assays 
3.1 Introduction 
The morphological and biochemical changes associated with apoptosis are very specific. 
Identification of apoptosis within the cell is done by the assessment of the morphological 
changes that are associated with apoptosis. At present, apoptosis is identified by membrane 
blebbing, DNA condensation, DNA laddering, Bcl-2 family protein expression, caspase 
expression and caspase activation. 
3.1.1 Membrane blebbing 
Membrane blebbing is an early event after the initiation of apoptosis. The outer membrane 
of the cell undergoes translocation of phosphatidylserine from the inner membrane to the 
outer membrane of the cell due to inhibition of the aminophospholipid translocase and the 
activation of scramblase and the increase in f~drin cleavage by caspase 3 (Martin et aI., 
1995). The translocation of phosphatidylserine leads to the subsequent blebbing and 
budding off of the membrane to fonn small apoptotic bodies. Identification of membrane 
blebbing is assayed by binding of a biotin or fluorescein isothiocynate (FITe) labelled 
annexin V molecule, which binds highly specifically to phosphatidylserine in a calcium 
dependent manner and is analysed by fluorescent microscopy or flow cytometry (Martin et 
al., 1995; Clarke et al., 2000). Annexin V binding may give false positive results and 
therefore over estimation of the number of apoptotic cells as annexin V molecules will 
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enter necrotic cells and stain untranslocated phosphatidylserine (Callahan et ai., 2000; Bai 
et al., 2003). To counter this false staining of the cells it is required that a second stain be 
used to confirm that the cells have under gone apoptosis. This could be done using 
propidium iodide (Clarke et al., 2000). 
3.1.2 DNA condensation staining 
The DNA in cells that undergo apoptosis condenses in the cell due to the cleavage of the 
high molecular weight chromatin by the endonuclease CAD. This condensed form of 
chromatin can be visualised by light, fluorescent or electron microscopy or quantified 
directly by flow cytometry (Wilson and Potten, 1999). 
Light and fluorescent microscopy requires that the DNA must be stained for visualisation. 
In light microscopy, haematoxylin and thionin blue are used to stain fixed and wax 
embedded tissues. This method has good contrast in the tissue and stains the condensed 
chromatin heavily, but both stains also stain the mitotic cells in the sample giving false 
positives (Wilson and Potten, 1999). 
Fluorescent microscopy is usually used to identify cells that have undergone apoptosis in 
cell culture. Four main fluorescent stains are used, (1) 4' 6 - Diamino-2 phenyl indole 
(DAPI); (2) Hoechst stains 33258 and 33342 and (3) Acridine orange, (4) Terminal 
deoxynucleotide transferase mediated dUTP-biotin nick end labelling (TUNEL). Each 
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methodology has its own advantages and disadvantages (Table 4) (Wilson and Potten, 
1999). 
Table 4: Advantages and disadvantages of cell and DNA staining to identify apoptosis 
(Wilson and Potten, 1999). 
Staining method Advantages Disadvantages 
4' 6 - Diamino-2 Common, most used stain. Stains mitotic and necrotic 
phenylindole (DAPI). Accepted as identifying cells, making identification 
apoptotic cells. of apoptosis difficult. 
Hoechst stains Good at identifying the Stains non-apoptotic cells. 
differences of two types of 
tissue (e.g. human and 
mouse). 
Acridine orange Excluded from viable cells Stains necrotic cells making 
making it ideal for studies exclusive identification of 
on apoptosis. apoptotic cells difficult. 
TUNEL staining Terminal deoxynucleotide Gives approx. 18% false 
transferase (TDT) negative results. Altering 
TDT concentration can 
enzymatically labels all the produce false positive 
"nicked" DNA ends. results. 
Detection is by specific 
antibody, therefore very 
sensitive. 
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The quantification of the cells after preparation for microscopy is normally conducted by a 
tally count of 500-1000 cells per slide from 10 random fields of vision or by flow 
cytometry (Wilson and Potten, 1999). Consistent criterion for the scoring of apoptosis is 
essential with most researchers only scoring the definite apoptotic events. These data are 
then analysed to calculate the percentage of total cells undergoing apoptosis (Wilson and 
Potten, 1999). 
3.1.3 DNA cleavage and strand breaks 
DNA cleavage by CAD to form the ~200 bp fragments is the most recognisable 
morphological change seen in apoptosis. To analyse this, agarose gel electrophoresis is 
normally used after isolation of the DNA from the cell to see a ~200bp "DNA ladder" 
(Wilson and Potten, 1999). 
It has been noted however that different cells activate these biochemical changes at 
different time points during the induction of apoptosis. Therefore it was essential to 
optimise the assays that were to be used to assess apoptosis to gain a positive identification 
of apoptosis before moving onto further studies. lurkat E6.1 cells were used initially to 
optimise the apoptosis assays that were going to be used due to the fast growing phenotype 
and their ability to readily undergo apoptosis (Gajate et al., 2003, Handrick et al., 2005, 
Subhashini et al., 2005). To induce apoptosis in the lurkat E6.1 cells different treatments 
were used. Treatments that were used targeted specific cellular processes known to induce 
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apoptosis e.g. COX-2 inhibition as described in section 1.4.4, creation of reactive oxygen 
species (Kwon et aI., 2002), and cellular micro-tubule formation (Copland et at., 2005). 
Treated cells were cytospun and fluorescent microscopy, DNA ladder isolation, and 
caspase activation studies to assess apoptosis induction. Once this was achieved and 
apoptosis identified in the lurkat E6.1 cells the inducer of apoptosis was tested in 
HUVECs. 
3.2 Aims 
• To optimise methodology of apoptosis analysis in lurkat E6.1 cells and HUVECs. 
• To identify an inducer of apoptosis that yields the specific biochemical apoptotic 
changes in HUVECs to use as a positive indication of apoptosis. 
3.3 Methods 
• Cell culture was carried out as detailed in Section 2.1. 
• Condensation of chromatin was assessed following cytospinning of cells as 
described Section 2.3. 
• lurkat E6.1 cell DNA laddering was assayed using the DNA ladder Suicide track kit 
(Section 2.3.2) and caspase activation was measured as described in Section 2.3.4. 
• DNA was isolated from HUVECs using the phenol/chloroform extraction (Section 
2.3.3) and analysed by agarose gel electrophoresis (Section 2.8). 
• Trypan blue exclusion assay was used to assess cell viability of treated HUVECs. 
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3.4 Results 
3.4.1 The induction of apoptosis by multiple stimuli 
lurkat E6.1 cells were grown in fully supplemented media RPMI 1640 and treated with 
serum free medium with or without other stimuli. Serum free RPMI 1640 medium (SFRM) 
alone (Fig 3.1a), with hydrogen peroxide (20IlM) (Wagner et al., 2000) (Fig 3.1b), or 
staurosporine (0.1 IlM) (Cutolo et al., 2005) (Fig 3.lc) did not produce a significant 
increase in condensed chromatin after 24 hr or 48 hr. DNA laddering assays with these 
treatments gave no induction of DNA laddering with SFRM or staurosporine; however 
hydrogen peroxide did produce some DNA laddering (Fig 3.2). In parallel experiments 
treatments with curcurnin (50IlM) (Smith, 2004) (Fig 3.ld), paracetamol (300IlM) 
(Churchman et aI., 2001) (Fig 3.1e) and paclitaxel (500IlM) (Copland et aI., 2005) (Fig 
3.lf) were found to significantly induce chromatin condensation over 24 hr, which was 
slightly potentiated at 48 hr, and induced varying amounts of DNA laddering in the lurkat 
E6.l cells (Fig 3.2). However the DNA laddering observed with the curcumin and 
paracetamol were comparable to the DMSO controls. Caspase activation was confirmed by 
colorimetric assay with only pac1itaxel showing any increase above the DMSO control 
levels after 24 hr, which was reduced to control levels at 48 hr (Fig 3.3a and 3.3b). 
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Figure 3.1 a: Induction of chromatin condensation in lurkat E6.1 cells with serum free 
RPMI 1640 medium. lurkat E6. I cells were treated with serum free medium RPMI 1640 
(SFRM) over a 48 hr period prior to cytospinning and staining of the DNA with acridine 
orange. The data are the mean +/- s.e.m. of at least 3 experiments with 2 replicates in each. 
ANOYA was used to determine significance for all the data with Student's t-test 
identifying the individual points of significance. Significance is compared to SFRM 0 hr * 
p= <0.05. 
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Figure 3.1 b: Induction of chromatin condensation in lurkat E6.1 cells with hydrogen 
peroxide (20J.tM). Treated cells were also incubated at 37°C for up to 48 hr prior to 
cytospinning and staining of the DNA with acridine orange. Controls were treated with 
serum free RMPI 1640 medium (SFRM) with DMSO (0.06%) for 48 hr at 3rc. The data 
are the mean +/- s.e.m. of at least 3 experiments with 2 replicates in each. ANOV A was 
used to determine significance for all the data with Student's t-test identifying the 
individual points of significance. Significance is compared to SFRM + DMSO (0.06%) * 
p= <0.05. 
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Figure 3.1c: Induction of chromatin condensation in lurkat E6.1 cells with curcumin 
(50f.lM). Treated cells were also incubated at 37°C for up to 48 hr prior to cytospinning and 
staining of the DNA with acridine orange. Controls were treated with serum free RMPI 
1640 medium (SFRM) with DMSO (0.06%) for 48 hr at 37°C. The data are the mean +/-
s.e.m. of at least 3 experiments with 2 replicates in each. ANOYA was used to determine 
significance for all the data with Student's t-test identifying the individual points of 
significance. Significance is compared to SFRM + DMSO (0.06%) * p= <0.05. 
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Figure 3.1 d: Induction of chromatin condensation in lurkat E6.1 cells with paracetamol 
(300J.lM). Treated cells were also incubated at 37°C for up to 48 hr prior to cytospinning 
and staining of the DNA with acridine orange. Controls were treated with serum free RMPI 
1640medium (SFRM) with DMSO (0.06%) for 48 hr at 37°C. The data are the mean +/-
s.e.m. of at least 3 experiments with 2 replicates in each. ANOYA was used to determine 
significance for all the data with Student's t-test identifying the individual points of 
significance. Significance is compared to SFRM + DMSO (0.06%) * p= <0.05. 
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Figure 3.1 e: Induction of chromatin condensation in J urkat E6.1 cells with staurosporine 
(0.1~M). Treated cells were also incubated at 37°C for up to 48 hr prior to cytospinning 
and staining of the DNA with acridine orange. Controls were treated with serum free RMPI 
1640 medium (SFRM) with DMSO (0.06%) for 48 hr at 37°C. The data are the mean +1-
s.e.m. of at least 3 experiments with 2 replicates in each. ANDV A was used to determine 
significance for all the data with Student's t-test identifying the individual points of 
significance. Significance is compared to SFRM + DMSO (0.06%) * p= <0.05. 
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Figure 3.1 f: Induction of chromatin condensation in Jurkat E6.1 cells with paclitaxel 
(500JlM). Treated cells were incubated at 37°C for up to 48 hr prior to cytospinning and 
staining of the DNA with acridine orange. Controls were treated with serum free RMPI 
1640 medium (SFRM) with DMSO (0.06%) for 48 hr at 37°C. The data are the mean +1-
s.e.m. of at least 3 experiments with 2 replicates in each. ANOY A was used to determine 
significance for all the data with Student's t-test identifying the individual points of 
significance. Significance is compared to SFM + DMSO (0.06%) * p= <0.05. 
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Figure 3.2: Induction of apoptotic DNA fragmentation in lurkat E6.1 cells. Treatment with 
an apoptosis inducer were also incubated for 24hr at 37°C prior to DNA extraction using 
the DNA ladder Suicide track kit and visualised by 2% agarose gel electrophoresis and 
staining with ethidium bromide. Control cells ~ere incubated at 37°C for 24hr with DMSO 
(0.06%). Lane (I) DNA ladder (100 bp) (2) Non serum media (3) ClIrcumin (I~M) (4) 
Hydrogen peroxide (20~M) (5) Stallrosporine (0.1 ~M) (6) Paclitaxel (500~M) (7) 
Paracetamol (300mM) (8) DMSO (0.25%) (9) Untreated. The image is representative of 3 
separate experiments. 
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Figure 3.3a: Induction of caspase 3 activity by multiple stimuli in Jurkat E6.1 cells. 
Treated Jurkat E6.1 cells were incubated for 24 hr at 37°C prior to analysis of caspase 3 
activity. Controls were incubated in serum free RPMI 1640 medium (SFRM) with DMSO 
(0.06%) for 24 hr at 37°C. The data is the mean'2 experiments with 2 replicates in each. 
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Figure 3.3b: Induction of caspase 3 activity by multiple stimuli in lurkat E6.1 cells. 
Treated lurkat E6.1 cells were incubated for 48 hr at 37°C prior to analysis of caspase 3 
activity. Controls were incubated in serum free RPMI 1640 medium (SFRM) with DMSO 
(0.06%) for 48 hr at 37°C. The data is the mean 2 experiments with 2 replicates in each. 
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3.4.2 Effect of paclitaxel in Jurkat E6.1 cells 
Treatment of lurkat E6.1 cells for 24 hr with paclitaxel induced a significant dose 
dependent response on chromatin condensation between the concentrations of 1-IOOOnM 
(Fig 3.4a). Dose dependent DNA laddering was also observed in paclitaxel (50nM and 
500nM) treated lurkat E6.1 cells (Fig 3.4b). 
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Figure 3.4a: Induction of chromatin condensation in lurkat E6.1 cells with paclitaxel. 
Treated cells were also incubated at 37°C for up to 48 hr prior to cytospinning and staining 
of the DNA with acridine orange. Controls were treated with serum free RPMI 1640 
medium (SFRM) with DMSO (0.06%) for 48 hf at 37°C. The data are the mean +1- s.e.m. 
of at least 3 experiments with 2 replicates in each. ANOYA was used to determine 
significance for all the data with Student's t-test identifying the individual points of 
significance. Significance is compared to SFRM + DMSO (0.06%) * p= <0.05, ** 
p=<O.Ol. 
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Figure 3.4b: Induction of apoptotic DNA fragmentation in lurkat E6.1 cells. lurkat E6.1 
cells treated with paclitaxel (50/500nM) were also incubated for 24hr at 37°C. Control 
cells were incubated at 37°C for 24hr with DMSO (0.1 %). DNA extraction was completed 
using the DNA ladder Suicide track kit and visualised by 2% agarose gel electrophoresis 
and staining with ethidium bromide. Lane (1) DNA ladder (1 kB) (2) serum free media + 
DMSO (0.1 %) (3) Paclitaxel (50nM) (4) Paclitaxel (500nM). The image is repre entative 
of 3 separate experiments 
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3.4.3 Effects of paclitaxel on HUVECs 
Parallel experiments were carried out in HUYECs to assess the apoptotic effects of 
paclitaxel in these cells. A small but significant dose response was observed on chromatin 
condensation (Fig 3.5a). Interestingly, no DNA laddering occurred in any of the samples 
obtained from cells incubated with 10-5000 nM for 24 hr (Fig 3.5b). 
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Figure 3.5a: Induction of chromatin condensation in HUYECs. Cells treated with 
paclitaxel were incubated for 24hr at 37°C prior to cytospinning and staining of the DNA 
with acridine orange. Control cells were incubated at 37°C for 24hr in serum free medium 
(SFM) + DMSO (0.01 %). The data are the mean +/- s.e.m. of at least 3 experiments with 2 
replicates in each. ANOYA was used to determine significance for all the data with 
Student's t-test identifying the individual points of significance. Significance is compared 
to SFM + DMSO (0.01%) * p= <0.05. 
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Figure 3.5b: Induction of apoptotic DNA fragmentation in HUVECs. Paclitaxel (10-
5000nM) treated HOVECs were incubated for 24hr at 37°C. Control cells were incubated 
at 37°C for 24hr in serum free medium (SFM) 199 + DMSO (0.01 %). DNA was extracted 
using the DNA ladder Suicide track kit and visuali sed by 2% agarose gel electrophoresis 
and staining with ethidium bromide. Lane (1) DNA ladder (1 Kb) (2) (3) 0.5% FCS media 
(4) lOnM (5) 100nM (6) 200nM (7) 500nM (8) 1000nM (9) 5000nM (10) Adherent cell 
sample of serum free media + DMSO (0.01%) treated cells. (11) Adherent cell sample of 
5000nM treated cells. The image is representative of 3 separate experiments. 
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3.4.4 Effects of actinomycin-D on HUVECs 
Because of the lack of significant effects with paclitaxel, HUVECs were treated with 
actinomycin-D as a positive control for the induction of apoptosis in these cells (Grafe et 
al., 2001). In these studies, treatment of HUVECs with actinomycin-D for 24 hr induced a 
significant concentration-dependent (10-200 nM) increase in chromatin condensation (Fig 
3.6a). Actinomycin-D (200 nM) also caused marked DNA laddering compared to the 
DMSO controls (Fig 3.6b). Trypan blue exclusion assays indicated that actinomycin-D 
decreased cellular membrane integrity in a dose dependent response (10-200 nM) when 
exposed to cells over a 24hr period (Fig 3.6c). 
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Figure 3.6a: Induction of chromatin condensation in HUVECs with actinomycin-D (10-
200nM). Treated cells were incubated for 24hr at 37°C. Control cells were incubated at 
37°C for 24hr in serum free medium (SFM) 199+ DMSO (0.0002%). HUYECs were 
cytospun and the DNA stained with acridine orange. The data are the mean +/- s.e.m. of 3 
experiments with 2 replicates in each. ANOY A was used to determine significance for all 
the data with Student's t-test identifying the individual points of significance. Significance 
is compared to SFM + DMSO (0.01%) * p= <0.05, ** = p< 0.01. 
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Figure 3.6b: Tnduction of apoptotic DNA fragmentation in HUVECs. Control cells were 
incubated at 37°C for 24hr with DMSO (0.0002%). HUVECs treated with actinomycin-D 
(200nM) were also incubated for 24hr at 37°C prior to DNA extraction using the 
phenol/chloroform method and visualised by 2% agarose gel electrophoresis and staining 
with ethidium bromide. Lane (I) Apoptotic positive HL-60 cells (2) DNA ladder (IOObp) 
(3) Serum free media + DMSO (0.0002%) (4) Serum free media (5) Actinomycin-D 
(200nM). Arrows indicate darker DNA fragmentation in the sample. The image is 
representati ve of 3 separate experiments. 
112 
40 
Q) 
** ::I 
.Q 
C 30 CIS 
c. 
~ 
.... 
.: -
.... 
.- J9 ~ 0 20 'tI .... 
Q)~ 
.5 ~ 
S 
f/) 
f/) 
0 
10 W 
> 
::J 
~ 
0 
0 50 100 150 200 
Actinomycin-D (nM) 
Figure 3.6c: Trypan blue staining of HUYECs treated with actinomycin-D (1 0-200nM). 
Treated cells were incubated for 24hr at 37°C. Control cells were incubated at 37°C for 
24hr with serum free medium (SFM) 199 + DMSO (0.0002%). HUYECs were stained 
with trypan blue and counting by haemocytometer. The data are the mean +/- s.e.m. of 3 
experiments with 2 replicates in each. ANOYA was used to determine significance for all 
the data with Student's t-test identifying the individual points of significance. Significance 
is compared to SFM + DMSO (0.01%) * p= <0.05, ** = p< 0.01. 
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3.5 Discussion 
This chapter of experiments was involved in the optimisation techniques to be used for 
measuring apoptosis and identifying a suitable inducer of apoptosis in HUVECs. The 
present work indicates that actinomycin-D was a suitable inducer of apoptosis in 
HUVECs due to the induction of the characteristic morphological changes associated 
with this process e.g. DNA fragmentation and chromatin condensation. 
Apoptosis was identified usmg chromatin condensation as the technique allows 
quantitative analysis of apoptotic and normal cells, which was confirmed by DNA 
fragmentation analysis. Initial studies of the different compounds investigated on Jurkat 
E6.1 cells gave varying amounts of chromatin condensation. Curcumin, paracetamol 
and paclitaxel were all shown to significantly increase chromatin condensation over 24 
and 48 hr. Curcumin did not induce DNA fragmentation in to ~200 bp mulitmers in 24 
hr or induce caspase 3 activity over 24 hr or 48 hr. Similar to the present study, 
Piwocka et al. (1999, 2001, and 2002) indicated that curcumin treatment of Jurkat E6.1 
cells did not activate caspase 3 or induce lower molecular weight fragmentation of the 
DNA. Consequently combined with our studies this suggests that curcumin induces cell 
death through a caspase independent pathway and may he due to high glutathione levels 
in cells preventing caspase activation (Piwocka et al., 2001). 
In parallel studies, paracetamol induced chromatin condensation after 24 hr. However 
no further increase was seen at 48 hr. Paracetamol treatment of Jurkat E6.1 cells did not 
cause the activation of caspase 3 but did induce some slight DNA fragmentation to 
produce a characteristic DNA ladder associated with apoptosis. Similar to these 
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findings, Elder and Paraskeva (1999) indicated that traditional NSAIDs induced 
apoptosis in colorectal carcinoma cells in vitro with full DNA fragmentation. However, 
very high concentrations of the NSAIDs were used to induce apoptosis e.g. ImM (Elder 
and Paraskeva, 1999) and therefore the dose of paracetamol used in the present 
experiments may not have been high enough to induce the full apoptotic morphological 
changes in Jurkat E6.1 cells. 
Several studies have indicated paclitaxel may induce apoptosis through an increase in 
microtubule formation (Copland et al., 2005; Markman et al., 2005). In the present 
study, paclitaxel (0-500nM) did induce a dose dependent caspase-3-related chromatin 
condensation and DNA fragmentation at 24 hr in Jurkat E6.l cells before caspase 3 
activity declined back to control levels at 48 hr. Interestingly 24 hr treatment of 
HUVECs with paclitaxel (O-5000nM) did only cause a small significant increase in 
chromatin condensation but there was no DNA fragmentation. This finding is 
supportive of studies with paclitaxel in ARO and KAT-4 thyroid cancer cell lines in 
which paclitaxel did not induce caspase activation, DNA fragmentation or release cyt-c 
from the mitochondria (Pan et al., 2001). Together with the current study this suggests 
clinically paclitaxel may not have an effect on the vasculature in the treatment of cancer 
prevention, but this is to be confirmed. 
Further studies into actinomycin-D treatment of HUVECs resulted in a significant dose-
dependent increase of apoptosis within 24 hr. Actinomycin-D treated HUVECs 
exhibited the characteristic morphological changes associated with apoptosis including 
chromatin condensation and DNA fragmentation in to the -200 bp multimer DNA 
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"ladder", which was consistent with previous studies that indicated an increase in 
TUNEL positive cells and DNA fragmentation in actinomycin-D treated HUVECs after 
24 hr (Grafe et ai., 1999). The apoptotic mechanism proposed by Grafe et at. (1999) 
suggested a stimulation of free radical production which in tum activated the caspase 
cascade, but may be independent of protein synthesis as cycloheximide has been shown 
not to have an effect on the induced apoptosis (Grafe et ai., 1999). 
Taken into consideration with our study it would suggest that treatment of endothelial 
cells with actinomycin-D does induce a caspase-dependent apoptosis. However, 
analysis of the DNA fragmentation by actinomycin-D (100-200nM) revealed smearing 
of some DNA in the phenol: chloroform extraction and agarose gel electrophoresis. 
These data implied that actinomycin-D may induce necrosis of the cells, which was 
confirmed by the membrane permeability study. Actinomycin-D (l00nM-200nM) was 
shown to induce membrane permeability in ~20 % and ~30% of the cells respectively 
, 
and therefore indicate a significant increase in necrosis at these concentrations. 
It has been suggested that necrosis observed in an in vitro population of apoptotic cells 
may be due to cell culture being deficient in phagocytotic cells and therefore not 
clearing away apoptotic cells (Fadok et ai., 2001; Proskuryakov et ai., 2003). In this 
instance the apoptotic cells burst and undergo necrosis (Proskuryakov et ai., 2003). It 
may be in the present study that high doses of actinomycin-D may decrease the time 
taken to induce apoptosis in HUVECs and cause the cells to undergo post-apoptotic 
necrosis within the 24 hr studied and therefore appear necrotic, but this would require 
further time-dependent studies of caspase activation, chromatin condensation and DNA 
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fragmentation over 24 hr to confinn this hypothesis. However, actinomycin-D was 
selected as the positive control for the activation of apoptosis in HUVECs due to the 
reliable induction of the morphological changes associated with this process. 
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4.0 Effects of curcumin and 6-shogaol on VEGF 165 
induced cyclooxygenase-2 expression and apoptosis in 
HUVECs 
4.1 Introduction 
Dietary compounds e.g. curcumin and 6-shogaol, have been found to exhibit anti-
inflammatory properties and have been used in alternative therapies for certain 
inflammatory diseases such as rheumatoid arthritis. The anti-inflammatory properties of 
curcumin are thought to be due to the inhibition of the NF-KB activation pathway of 
inflammatory enzymes including COX-2 and inducible nitric oxide synthase (iNOS) as 
described in section 1.2.12.1 (Fig. 1.2.17). However it has also been identified that the 
MAP kinase (P42/p44) pathway may also be inhibited by curcumin (Section 1.2.12.1). 
Recently compounds of similar structures have been identified and purified from ginger e.g. 
shogaols and gingerols, with 6-shogaol being most effective at inhibiting COX-2 specific 
prostaglandin production in lung epithelial cells (Section 1.2.12.2). It is not known if 6-
shogaol acts in a similar way to curcumin by preventing signal transduction and 
transcription of the COX-2 gene. 
Apoptosis induction by curcumin has been shown in human melanoma cells (Bush et al., 
2001) potentially through the inhibition of COX-2 expression. COX-2 expression is an 
important factor in angiogenesis and HUVEC survival but it is not clear if curcumin has 
any effect on the inhibition of VEGFl65 induced COX-2 expression or if any inhibition of 
118 
COX-2 in HUVECs would induce apoptosis. Studies with 6-shogaol have indicated an 
inhibition of prostaglandin production (section 1.2.10) however no studies have been done 
to identify any pro-apoptotic affects on cells in vitro or if there are any effects on the 
inhibition ofVEGF165 induced COX-2. 
4.2 Aims 
• To investigate the effects of curcumin and 6-shogaol on VEGF165 induced COX-2 
expressIOn. 
• To investigate if curcumin and 6-shogaol induce apoptosis in HUVECs. 
4.3 Methods 
• Western blotting of COX-2 was carried out as described in section 2.4 using 
selective anti-COX-2 goat polyclonal IgG and anti-p-actin rabbit IgG at a 
concentration of O.2llg/ml (a 1: 1000 dilution of stock antibody). COX-2 antibody 
was detected by donkey anti-goat IgG-HRP at O.OSllg/ml (1 :5000 dilution of stock 
antibody) and then visualised by ECL detection. 
• Condensation of chromatin was assessed using the cytospinning technique 
described in Section 2.3. 
• HUVEC DNA isolation was performed using the phenol/chloroform extraction of 
DNA (Section 2.3.3) and analysed by agarose gel electrophoresis (Section 2.S); 
lurkat E6.1 DNA analysis was carried out by DNA ladder Suicide track kit ® 
(Section 2.3.2). 
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4.4 Results 
4.4.1 Induction of COX-2 with VEGF/ 65 in HUVECs 
HUVECs grown in fully supplemented medium 199 were quiesced for 16 hr in 1% FC 
medium 199 and treated with 50ng/ml VEGF I65 for up to 24 hr. This resulted in the 
induction of COX-2 protein which was increased in a time-dependent manner, peaking at 8 
hr and continuing until 24 hr (Fig 4.1). 
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Figure 4.1: Induction of COX-2 expression in HUVECs with VEGF 165 (50nglml). Control 
cells were treated with 1 % FCS medium 199 for 24 hr in a 37°C tissue culture incubator. 
VEGF165 treated cells were incubated for up to 24 hr prior to cell lysis and western blotting 
of the samples. Lane (1) molecular weight marker, (2) 1774 murine macrophages treated 
with LPS for 24 hr, (3) 0 hr, (4) 2 hr, (5) 4 hr (6) 6 hr (7) 8 hr (8) 24 hr VEGF I65 . p-actin 
levels were assessed to show equal protein loading. The images are representative of 3 
separate experiments 
4.4.2 Inhibition of COX-2 by curcumin and 6-shogaol in HUVECs 
VEGF 165 induced COX-2 expression was inhibited by curcumin in a dose independent 
manner with concentrations of I. 78~M, 3.12~M, 25~M and 50~M blocking VEGF 
J20 
stimulated COX-2 expression (Fig 4.2a, c). However, 6.25)lM and 12.S)lM curcumin 
treatment had no effect on VEGF l65 induced COX-2 expression in HUVECs (Fig 4.2a, c). 
6-shogaol induced a dose dependent response in the inhibition of VEGF l65 induced COX-2 
in HUVECs. Expression of COX-2 was inhibited to unstimulated levels by low 
concentrations of the 6-shogaol and with the higher concentrations (12.5)lM, 2S)lM and 
SO)lM) reduced the expression below unstimulated levels by ~ 40% (Fig. 4.2b, c). Analysis 
of cell viability in 6-shogaol treated HUVECs using the MTT assay produced a dose 
dependent decrease in cell viability down to 33% of control values (Fig. 4.3). 
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Figure 4.2a and b: Inhibition of VEGF l65 induced COX-2 expression in HUVECs by 
curcumin and 6-shogaol. VEGF l65 treated ~UVECs in the presence or absence of 
curcumin (a) and 6-shogaol (b) were incubated at 37°C for 24 hr. Control cells were 
incubated with 1% FCS medium 199 + 0.2 % methanol (MeOH) for 24 hr at 37°C. Cells 
were lysed and western blotted. Lane (I) 1774 murine macrophages treated with LPS for 
24 hr, (2) 1% FCS medium 199+ MeOH (0.2%), (3) VEGF l 65 (50ng/ml), (4) 50llM 
curcumin/6-shogaol, (5) 251lM, (6) 12.5 IlM, (7) 6.25 IlM, (8) 3.125IlM, (9) 1.78)lM. The 
image is representative of2 separate experiments. 
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Figure 4.2c: Inhibition of VEGF165 induced COX-2 expression in HUVECs by curcumin 
and 6-shogaol. VEGF 165 (50nglml) treated cells in the presence or absence of curcumin and 
6-shogaol were incubated at 37°C for 24 hr. Control cells were incubated in 1% foetal calf 
serum (FCS) medium 199 + 0.2 % methanol for 24 hr at 37°C. Cells were lysed and 
. 
western blotted and analysed by densitometry. The data is the mean of 2 experiments. 
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Figure 4.3: Mitochondrial activity in HUVECs treated with 6-shogaol. VEGF l65 (50ng/ml) 
and 6-shogaol treated cells were incubated at 37°C for 22 hr prior to addition of MTT and 
further incubation for 2 hr at 37°C. Control cells were treated with 20 % foetal calf serum 
medium 199 (complete medium) + methanol (MeOH) (0.002%) for 24 hr at 37°C. Crystal 
formation was assessed by colour change at 595nm. The data are the mean of 3 
experiments +/- s.e.m with 2 replicates in each experiment. ANOV A was used to determine 
significance for all the data with Student's t-test identifying the individual points of 
significance. Significance is compared to complete medium 199 + MeOH (0.002%) * p= 
<0.05, ** p=<O.Ol. 
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4.4.3 Induction of HUVEC apoptosis with curcumin and 6-shogaol 
In parallel studies curcumin was found to dose dependently induce significant chromatin 
condensation over 24 hr at 50J.lM (Fig 4.4a-d). 6-shogaol also induced a significant dose 
dependent increase in chromatin condensation over 24 hr peaking at 60% total cells with 
chromatin condensation (Fig 4.4a, e, and f). However treatment with 6-shogaol did not 
produce any HUVEC DNA fragmentation (Fig 4.5). 
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Figure 4.4a: Induction of chromatin condensation in HUYECs with curcumin and 6-
shogaol. Treated cells were incubated in at 37°C for 24 hr. Control cells were treated with 
serum free medium (SFM) 199 + methanol (MeOH) (0.2%) for 24 hr at 37°C. HUYECs 
were cytospun and the DNA stained with acridine orange. The data are the mean +/- s.e.m. 
of at least 3 experiments with 2 replicates in each. ANOYA was used to determine 
significance for all the data with Student's t-test identifying the individual points of 
significance. Significance is compared to SFM 199 + MeOH (0.2%) * p= <0.05, ** p= 
<0.01. 
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Figure 4.4b-f: Induction of chromatin condensation in HUVECs with curcumin and 6-
shogaol. Controls were treated with serum free medium ( FM) 199 with methanol 
(MeOH) (0.2%) for 24 hr at 37°C (b). Curcumin (50/lM) treated cell were also incubated 
at 37°C for 24 hr prior to cytospinning, staining of the DNA with acridine orange and 
viewed x 100 (c) and x400 (d). 6-shogaol (50/lM) treated cells were also incubated at 37°C 
for up to 24 hr prior to cytospinning, staining of the DNA with acridine orange and viewed 
x 100 (e) and x400 (t). The images are representative of 3 separate experiments with 2 
replicates in each. 
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Figure 4.5: Induction of apoptotic DNA fragmentation in HUVECs treated with 6-shogaol. 
Untreated cells were incubated in 20% foetal calf serum medium (complete medium) for 24 
hr at 37°C. Treated cells were incubated for 24h'r at 37°C in serum free medium (SFM) 199 
in the presence of 6-shogaol. Control cells were incubated at 37°C for 24hr in SFM + 
methanol (MeOH) (0.2%). DNA was extracted using the phenol: chloroform method and 
visualised by 2% agarose gel electrophoresis and staining with ethidium bromide. Lane (I) 
DNA ladder (100 bp) (2) complete medium 199 (3) SFM + MeOH (0.2%) (4 - 9) 6-shogaol 
l.78~M, 3.12~M, 6.25~M, 12.5~M, 25~M, 50~M. The image is representative of 3 
separate experiments. 
4.4.4 Effects of PGE2 on curcumin and 6-shogaol induced HUVEC chromatin 
condensation 
Induction of HUVEC chromatin condensation by curcumin and 6-shogaol was not inhibited 
by exogenous PGE2. Treatment of HUVECs with 50~M curcumin and 6-shogaol induced 
significant chromatin condensation (Fig 4.4, 4.5). To prevent this exogenous PGEz (J O~M) 
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was added to the HUVECs simultaneously with the curcumin or 6-shogaol. Exogenous 
PGE2 did not reduce the chromatin condensation induced by curcumin or 6-shogaol (Fig 
4.6a, b, c, d, e). 
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Figure 4.6a: Induction of chromatin condensation in HUVECs by curcumin and 6-shogaol. 
HUVECs treated in serum free medium (SFM) 199 with 6-shoagol (50IlM) and curcumin 
(50IlM) in the presence or absence of PGE2 (lOIlM) were incubated at 37°C for 24 hr 
Controls were treated with SFM + methanol (MeOH) (0.2%) for 24 hr at 37°C. HUVECs 
were cytospun and the DNA stained with acridine orange. The data are the mean +/- s.e.m. 
of at least 3 experiments with 2 replicates in each. ANOVA was used to determine 
significance for all the data with Student's ~-test identifying the individual points of 
significance. Significance is compared to SFM + MeOH (0.2%) * p= <0.05, ** p= <0.01. 
128 
Figure 4.6b-e: Induction of chromatin condensation in HUVECs by curcumin and 6-
shogaol. Controls were treated with serum free medium ) 99 with methanol (MeOH) 
(0.2%) for 24 hr at 37°C. 6-shoagol and curcumin with or without PGE2 (] O~M) treated 
cells were also incubated at 37°C for 24 hr prior to cytospinning and staining of the DNA 
with acridine orange. (b) curcumin (50~M) + PGE2 (1 O~M) xlOO, (c) curcumin (50~M) + 
PGE2 (JO~M) x400, (d) 6-shogaol (50~M) + PGE2 (lO~M) xlOO, (e) 6-shogaol (50~M) + 
PGE2 (I O~M) x400. 
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4.4.5 Induction of apoptosis in Jurkat E6.1 cells with curcumin and 6-shogaol 
lurkat E6.1 cells treated with curcumin (50)..lM) did not induce significant chromatin 
condensation (Fig 4.7). The lack of chromatin condensation was accompanied by no 
significant DNA laddering in treated lurkat E6.1 cells (Fig 4.8). In contrast 6-shogaol 
induced significant condensed chromatin at 50)..lM (Fig 4.7). Similarly to curcumin 6-
shogaol did not produce any DNA fragmentation when examined by agarose gel 
electrophoresis (Fig 4. 7b). 
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Figure 4.7a: Induction of chromatin condensation in lurkat E6.1 cells by curcumin and 6-
shogaol. 6-shoagol (2-50IlM) and curcumin (50IlM) treated cells were also incubated at 
37°C for 24 hr prior to cytospinning and staining of the DNA with acridine orange. 
Controls were treated with serum free RPMIl640 medium (SFRM) + methanol (MeOH) 
(0.002%) for 24 hr at 37°C. The data are the mean +/- s.e.m. of at least 3 experiments with 
2 replicates in each. ANOV A was used to determine significance for all the data with 
Student's t-test identifying the individual points of significance. Significance is compared 
to SFM + MeOH (0.002%) * p= <0.05, ** p= <0.01. 
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Figure 4.7b: Induction of apoptotic DNA fragmentation in lurkat E6.1 ce ll s by curcumin 
and 6-shogaol. lurkat E6.1 cel ls treated with paclitaxel, 6-shogaol or curcumin were 
incubated for 24hr at 37°C. Control cells were incubated at 37°C for 24hr with methanol 
(0.002%). DNA extraction was completed using the DNA ladder Suicide track kit and 
visualised by 2% agarose gel electrophoresis and staining with ethidium bromide. Lane (I) 
DNA ladder (100 bp) (2) complete Medium RPMII640 (3) serum free medium (SFM) + 
methanol (0.002%) (4) paclitaxel (500IlM), (5) curcumin (50IlM), (6) 6-shogaol (50IlM) . 
The image is representative of 3 separate experiments. 
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4.5 Discussion 
The results presented in this chapter indicate that curcumin and shogaol induce a 
caspase-independent cell death in HUVECs. These effects were observed at 
concentrations higher than required to inhibit COX-2 possibly indicating a possible 
COX-2 independent mechanism of cell death. 
Curcumin and 6-shogaol were found both to inhibit VEGF-induced COX-2 expression 
at low concentrations. Curcumin gave a bi-phasic effect of inhibition of COX-2. The 
western blot and densitometry data indicates no inhibition of VEGF induced COX-2 
expression at 6.25 and 12.5 )lM. Furthermore, the inhibition seen at 1.78)lM seems to 
be greater than at 3.125)lM. However, the densitometry analysis of the two replicate 
blots indicates and dose dependent effect at these two concentrations with 3.125)lM 
inhibiting COX-2 expression more than 1.78)lM. This inconsistency may be explained 
through the methodology. Densitometry analysis is a semi-quantitative method and 
may not give fully accurate quantitative data. Densitometry computer programs 
compare the density of the band chosen to the surrounding background. However, 
western blots may not have a uniform background behind the image of interest and this 
would interfere with the comparison of the band to the background producing a lesser or 
greater quantitative value than is seen elsewhere on the blot. Furthermore, the data is an 
average of two blots and again the background of different blots may vary no matter 
how similar the change in protein expression. This would also affect the data produced 
by computer program further altering the final results. It is therefore required that any 
inhibition suggested here must be confirmed by further experimentation. Moreover, any 
data produced by densitometry may need to be confirmed by more than by three 
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replicates if the changes in protein expression seen are not very clear. The curcumin 
data are comparable to other studies in mouse skin that show an inhibition of induced 
COX-2 expression by curcumin at both low (l-5IlM) and at higher concentrations 
(25IlM ) (Chun et al., 2003), though no studies were completed at intermediate 
concentrations. In contrast studies by Zhang et al., (1999) indicated that curcumin had a 
dose dependent effect on phorbol 12-myristate 13 acetate induced COX-2 expression in 
human gastrointestinal epithelial cells and dose dependently inhibited PGE2 formation. 
These studies indicate a possible curcumin inhibition of COX-2 expression and activity 
in HUVECs in a dose dependent mechanism though this remains to be confirmed by 
further experimentation. 
6-Shogaol inhibited COX-2 expression at low concentrations < 10ilM with a slight dose 
response effect. Similarly 6-shogaol was found to inhibit COX-2 activity in A459 cells 
with an IC50 = 2.11lM (Tjendraputra et al., 2001), possibly indicating a similar COX-2 
inhibitory effect to that of curcumin. However the dose response effect on COX-2 
expression by 6-shogaol in the current study was found to be due to cytotoxicity as 
determined by the MTT assay. The increase in cytotoxicity indicated a possible increase 
in apoptosis of the cells. 
Curcumin and 6-shogaol both induced dose dependent chromatin condensation in 
HUVECs giving a maximum chromatin condensation of approximately 25% and 70% 
chromatin condensation respectively. Further studies with 6-shogaol did not induce 
DNA laddering in HUVECs or Jurkat E6.1 cells after 24 hr. Curcumin was also found 
not to induce DNA fragmentation in Jurkat E6.1 cells, which was similar to other 
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previous studies (Piwocka et at., 1999; Piwocka et at., 2000; Piwocka et at., 2001 and 
chapter 3) that indicated a caspase independent cell death with no DNA 1addering. In 
contrast to this Wei et aI., (2005) indicated an increase in DNA laddering upon 
treatment with 70 JlM 6-shogaol. However, the data presented by Wei et at., (2005) 
does not appear to substantiate this suggestion with no apparent DNA laddering, but 
some smearing, on the agarose gel suggesting a caspase-independent fragmentation of 
the DNA. It has been suggested that the effects seen with curcumin may be due to a 
prevention of glutathione depletion and no cyt-c release (Piwocka et aI., 1999; Piwocka 
et at., 2000; Piwocka et aI., 2001). 
The investigation into the induction of chromatin condensation matches previous work 
by Smith (2004) that showed that similar concentrations of curcumin and 6-shogaol 
inhibited thymidine incorporation during DNA replication in HUVECs and therefore 
prevented HUVEC growth and replication. It is possible therefore that the inhibition of 
HUVEC replication seen in cells treated with curcumin and 6-shogaol is caused by the 
induction of cell death. Similarities in the effects observed with both curcumin and 6-
shogaol treatments and the subsequently induced apoptotic morphology may be due to 
the comparable structures of the compounds. 
As the structure of6-shogaol is similar to curcumin (Tjendraputra et at., 2001) it may be 
that cell death induced by 6-shogaol is through a similar mechanism. However, Wei et 
at., (2005) have suggested that it is not the conserved phenyl ring seen in structures of 
6-shogaol and 10-shogaol, and in curcumin (Zhang et at., 1999), but the a,~-unsaturated 
ketone moiety. Together with the present study this would suggest that the enhanced 
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induction of chromatin condensation observed with 6-shogaol, compared to curcumin, 
may not be caused by the phenyl ring in both structures but by the a,p-unsaturated 
ketone moiety present in the structure of 6-shogaol and curcumin. However the phenyl 
ring may contribute to the activity of both 6-shogaol and curcumin. A hypothesis of 
how the two comparable structures may induce different effects in HUVECs may be 
due to the overall structures of the molecules. Curcumin consists of two phenyl rings 
connected by an alkyl chain (Zhang et al., 1999). In contrast 6-shogaol does not have 
the second phenyl ring (Tjendraputra et ai., 2001) and therefore the free alkyl chain 
associated with 6-shogaol may be the cause of the enhanced levels of chromatin 
condensation. Mechanisms behind this effect would have to be confirmed but may be 
due to the increased lipophilicity ofthe 6-shogaol alkyl side chain making it possible for 
the molecule to enter cells easier than curcumin. 
Chromatin condensation induced by 6-shogaol and curcumin also appears to be COX-2-
independent. Simultaneous treatment of HUVECs with PGEz and 6-shogaol or 
curcumin did not prevent the chromatin condensation after 24 hr indicating that a 
prevention of PGEz formation was not the cause of apoptosis, though inhibition of 
another COX-2 product may have been the cause of the cell death. However, when 
considered with other studies, which indicate that curcumin and 6-shogaol inhibit COX-
2 activity at lower concentrations than were used in this study (Zhang et aI., 1999, 
Tjendraputra et ai., 2001, Chun et ai., 2003), it may suggest that curcumin and 6-
shogaol do not need to inhibit COX-2 to induce apoptosis. Furthermore, the current 
observations indicate that a 50% inhibition of COX-2 expression at low concentrations 
of curcumin and 6-shogaol did not induce chromatin condensation. This also supports a 
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caspase-independent mechanism as PGE2 has been shown to increases Bcl-2 
concentration and therefore prevent the mitochondrial apoptosis pathway being induced 
(Ghosh et al., 2000, Hsu et al., 2000, Johnson et al., 2001, Basu et al., 2005). 
Nevertheless this does not rule out the activation of the death receptor pathway of 
apoptosis or the activation of necrosis. 
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5.0 Comparison of selective and non-selective COX-2 
inhibitors on angiogenesis and induction of 
apoptosis in HUVECs. 
5.1 Introduction 
Extended administration of non-steroidal anti-inflammatory drugs (NSAIDs) is implicated 
in the topical injury of the gastrointestinal (GI) tract e.g. gastric ulcers. Non-selective 
inhibition of the COX enzymes was found to be responsible with the decline in 
cytoprotective prostaglandins e.g. PGh and PGE2, causing the GI tract to become 
unregulated in secretions and blood flow, eventually leading to topical injury of the area. 
To prevent the GI damage induced by NSAIDs, selective COX-2 inhibitors were designed 
to prevent inflammation but spare COX-l activity by binding to a "side-pocket" in the 
active site of the enzyme (described in section 1.2.8.2) therefore allowing the production of 
cytoprotective prostaglandins in the GI tract and maintain GI mucosal integrity. Rofecoxib 
and celecoxib are two selective COX-2 inhibitors that were approved for the treatment of 
osteoarthritis and rheumatoid arthritis respectively, and have been investigated for anti-
cancer activity through the induction of apoptosis in the tumour cells (Hsu et al., 2000; 
Blanke, 2002; Wu et al., 2003) (discussed in section 1.2.8.3). However recent reports 
indicated that high concentrations of these two selective COX-2 inhibitors may produce 
apoptosis in cells in vitro and promote heart disease and vascular injury in vivo after 
extensive use. It is currently not known if this class of drugs induce apoptosis in 
endothelial cells at low concentrations in vitro or in vivo, or by what mechanisms they may 
induce apoptosis. Furthermore it is not known whether the specific inhibition of COX-2 
alone could be responsible for the induction of apoptosis. Effects of selective COX-2 
inhibitors on endothelial cell migration and tubule formation after potential damage to 
endothelial cells are also unknown. 
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5.2 Aims 
• To compare the effects of the selective COX-2 inhibitor DuP-697 and of the non-
selective COX inhibitor indomethacin on the induction of apoptosis and tubule 
formation in HUVECs. 
• To determine if the induction of any apoptosis is due to selective COX-2 inhibition 
in the cells. 
• To elucidate the pathways associated with the induction of apoptosis in HUVECs 
and if this induction can be inhibited by reversing COX-2 inhibition. 
5.3 Methods 
• Western blotting of COX-2 was carried out as described in section 2.4 usmg 
selective anti-COX-2 goat polyclonal IgG at a concentration of 0.2Jlg/rnl (a 1 :1000 
dilution of stock antibody). COX-2 antibody was detected by donkey anti-goat 
IgG-HRP at 0.08Jlg/rnl (1 :5000 dilution of stock antibody) and then visualised by 
ECL detection. 
• Western blotting of caspases was carried out using specific anti-caspase 3, 8 and 9 
mouse monoclonal IgG at the concentration of 0.1 Jlg/rnl (1: 1000 dilution of stock 
antibody). 
• Condensation of chromatin was assessed using the cytospinning technique 
described in Section 2.3. 
• HUVEC DNA isolation was perfonned using the phenol/chloroform extraction 
(Section 2.3.3) and analysis by agarose gel electrophoresis (Section 2.8). 
• Matrigel tubule assay was carried out as described in Section 2.6. 
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5.4 Results 
5.4.1 Expression ofCOX-2 in HUVECs 
HUVECs grown in 20% serum-containing medium expressed low levels of COX-2 protein 
which did not change over a 24 hr incubation period as detennined by western blot analysis 
(Fig 5.1). When quiesced cells were subsequently stimuJated with VEGF there was a time-
dependent increase in COX-2 expression with maximal expression occurring by 8 hr and 
maintained for 24 hr after the addition ofVEGF (Fig 5.1). 
2 3 4 5 6 7 8 
Figure 5.1: Cyc1ooxygenase-2 expression in HUVECs. HUVECs were quiesced for 16 hr 
in 1 % FCS Medium 199 and then treated with VEGF for 0 - 24 hr. Lane (1) 1774 murine 
macrophage treated with LPS for 24 hrs; (2) HUVECs cultured in 20% FCS Medium 199 
for 24 hr; lanes (3)-(8) VEGF treated for Ohr, 2hr, 4br, 6hr, 8br and 24br respectively. The 
blot is representative of 3 separate experiments. 
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5.4.2 Inhibition of prostaglandin E2 production in unstimulated and VEGF/ 65 
stimulated HUVECs by DuP-697 
Treatment of cells with DuP-697 caused a dose dependent inhibition of PGE2 production in 
unstimulated and VEGF treated HUVECs cultured in serum free medium (SFM), 
completely inhibiting PGE2 production at 1/-lM (Fig 5.2). DuP-697 (in 20% foetal calf 
serum medium 199 (complete medium» gave a small but significant inhibition (20%) of 
PGE2 levels when compared to control values (Fig 5.3). Activation of HUVECs with 
VEGF was shown to increased PGE2 production (23%) in complete medium which was 
inhibited by DuP-697 to 80% of control levels (Fig 5.3). In parallel studies, indomethacin 
caused a dose dependent inhibition of PGE2 production, with complete inhibition obtained 
at concentrations of 3/-lM and above (Fig 5.4). 
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Figure 5.2: Inhibition of prostaglandin (PG) E2 production in HUVECs by DuP-697 in 
serum free medium (SFM) 199. Treated cells were incubated for 24 hr at 37°C. VEGF 
treated cells were quiesced in 1 % foetal calf serum (FCS) medium 199 for 16 hr prior to 
VEGF treatment in the presence or absence of DuP-697. Control cells were incubated with 
DMSO (0.01 %) for 24 hr at 37°C. PGE2 levels were determined by ELISA. The data are 
the mean +/- s.e.m. of at least 3 experiments with 3 replicates in each. ANOV A was used to 
determine significance for all the data with Student's t-test identifying the individual points 
of significance. Significance was compared to SFM + DMSO (0.01%) +/- VEGF. 
*p=<0.05, ** p=<O.Ol and *** p= <0.001. 
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Figure 5.3: Inhibition of prostaglandin (PG) E2 production in HUVECs by DuP-697 in 20% 
foetal calf serum medium (complete medium) 199. Treated cells were incubated for 24 hr at 
37°C. VEGF treated cells were quiesced in I % foetal calf serum (FCS) medium 199 for 16 
hr prior to VEGF treatment in the presence or absence of DuP-697. Control cells were 
incubated with DMSO (0.01 %) for 24 hr at 37°C. PGE2 levels were determined by 
ELISA. The data are the mean +/- s.e.m. of 3 experiments with 3 replicates in each. 
ANOVA was used to determine significance for all the data with Student's t-test 
identifying the individual points of significance. Significance was compared to complete 
medium + DMSO (0.01 %) +1- VEGF. *p===<O.05. 
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Figure 5.4: Inhibition of prostaglandin (PG) E2 production in HUYECs cultured in serum 
free medium (SFM) by indomethacin. Treated cells were incubated at 37°C for 24 hr. 
Control cells were incubated with 0.01 % ethanol (EtOH) for 24 hr. PGE2 levels were 
determined by ELISA. The data are the mean +/- s.e.m. of at least 3 experiments with 3 
replicates in each. ANOY A was used to determine significance for all the data with 
Student's t-test identifying the individual points of significance. Significance was 
compared to serum free media (SFM) + OM SO (0.01%) +/- YEGF, *p=<0.05, ** p=<O.Ol 
and *** p= <0.001. 
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5.4.3 Effects of DuP-697 on chromatin condensation in HUVECS 
Treatment of HUVECs in SFM with 10 nM DuP-697 increased the amount of chromatin 
condensation in a dose dependent manner at concentrations of 0.0001-0.1 11M (Fig. 5.5a-g). 
DuP-697 (lOnM) caused high molecular weight DNA fragmentation as well as apoptotic 
DNA laddering after 24 hr (Fig. 5.6). 
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Figure 5.5a: Induction of chromatin condensation in HUVECs. Treated cells were 
incubated for 24 hr at 37°C. Control cells were incubated at 37°C for 24 hr with DMSO 
(0.01 %). HUVECs were cytospun and the DNA stained with acridine orange. The data are 
the mean +/- s.e.m. of 3 experiments with 2 replicates in each. ANOV A was used to 
determine significance for all the data with Student's t-test identifying the individual points 
of significance. Significance is compared to serum free media (SFM) + DMSO (0.0 I %) * 
p= <0.05 ** P == <0.01. 
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Figure 5.5b-g: Induction of chromatin condensation in HUVECs. Untreated cells were 
incubated in 20% foetal calf serum medium 199 (complete medium) for 24 hr (b). Control 
cells were incubated at 37°C for 24hr in serum free medium (SFM) + DMSO (0.0 I %) (c). 
HUVEC treated with DuP-697' 0.01 (d), 0.1 (e), 1 (f) and IOflM (g) were incubated for 24 
hr at 37°C. HUVEC were cytospun and the DNA stained with acridine orange. The 
images are representative of3 experiments with 2 replicates in each. 
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Figure 5.6: Induction of apoptotic DNA fragmentation in HUVECs. Treated HUVECs 
were incubated for 24 hr at 37°C. Control cell~ were incubated at 37°C for 24hr in serum 
free medium (SFM) + DMSO (0.01 %). DNA was extracted using the phenol/chloroform 
method and visualised by 2% agarose gel electrophoresis and staining with ethidillm 
bromide. Lane (1) DNA ladder (100bp) (2) SFM + DMSO (0.01%) (3) Actinomycin- D 
(200nM) apoptosis positive control (4) DuP-697 (IOnM). The image is representative of3 
separate experiments. 
5.4.4 Induction of apoptosis in HUVECs by indomethacin 
Indomethacin induced a dose dependent chromatin condensation at concentrations of 31l M 
and above (Fig. 5.7 and 5.8a-g). These concentrations of indomethacin have been shown to 
inhibit COX-2 as well as COX-I in whole cell systems (Mitchell et al., 1994) and 
completely inhibited PGE2 production in our studies (Fig. 5.4). 
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Figure 5.7a: Induction of chromatin condensation in HUVECs. Cells treated with 
indomethacin (0.01-1 OIlM) were incubated for 24 hr at 37°C. Control cells were incubated 
at 37°C for 24hr with ethanol (EtOH) (0.01 %). HUVECs were cytospun and stain with 
acridine orange. The data are the mean +/- s.e.m. of at least 3 experiments with 2 
replicates in each. ANDV A was used to determine significance for all the data with 
Student's t-test identifying the individual points of significance. Significance is compared 
to serum free media (SFM) + EtOH (0.01%) * p= <0.05, ** p= <0.01. 
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Figure 5.8a-g: Induction of chromatin condensation in HUVECs. Untreated HUVECs 
were incubated in 20% foetal calf serum medium 199 (complete medium) (a) . Control cells 
were incubated at 37°C for 24m in serum free medium (SFM) + ethanol (EtOH) (0.01%) 
(b). Cells treated with indomethacin; 0.01 (c) 0.1 (d), 1 (e), 3 (f) and 10 /lM (g) were also 
incubated for 24hr at 37°C. HUVECs were cytospun and the DNA stained with acridine 
orange. The images are representative of 3 experiments with 2 replicates in each. 
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5.4.5 Effects of DuP-697 on caspase activation 
Induction of caspase-8 (Fig 5.9a and d) and 9 (Fig 5.9b and d) occurred within 1 hr 
following DuP-697 treatment and peaked at 2 hrs, declining thereafter. By comparison, 
caspase 3 induction occurred at 2 hrs and remained elevated for up to 8 hr (Fig 5.9c and d). 
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Figure 5.9a-c: Caspase expression in HUVECs. Cells treated with DuP-697 (10nM) were 
incubated at 37°C for 0-8 hr. Caspase 8 (a) Lane (I) = molecular weight marker, (2) 20% 
foetal calf serum medium 199 (complete medium) (3) serum free medium (SFM) + DMSO 
(0.01%), (4) 0 hr ,(5) 1 hr, (6) 2 hr, (7) 4 hr, (8) 6 hr, (9) 8 hr. Caspase 9 (b) Lane (I) = 
molecular weight marker, (2) SFM + DMSO (0.01%) (3) 0 hr ,(4) I hr, (5) 2 hr, (6) 4 hr, 
(7) 6 hr, (8) 8 hr, (9) complete medium. Caspase 3 (c) Lane (I) lurkat E6.1 cells treated 
with 50~M paclitaxel positive control for 24 hr, (2) molecular weight marker, (3) SFM + 
DMSO (0.01%), (4) 0 hr, (5) 1 hr, (6) 2 hr, (7) 4 hr, (8) 6 hr, (9) 8 hr. The images are 
representative of 3 experiments. 
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Figure 5.9d: Caspase expression In HUVECs. HUVECs were treated with DuP-697 
(lOnM) and incubated at 37°C for 0-8 hr. Control cells were incubated at 37°C for 8 hr in 
serum free medium (SFM) + DMSO (0.01%). HUVECs were lysed and analysed for of 
caspase expression by western blotting and densitometry. The data are the mean +/- s.e.m. 
of 3 experiments. ANOV A was used to determine significance for all the data with 
Student's t-test identifying the individual points of significance. Significance is compared 
to serum free media (SFM) + DMSO (0.01%) * p= <0.05. 
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5.4.6 Effects o/indomethacin on caspase activation 
Induction of caspase 9 (Fig 5.IOa and c) occurred within I hr following indomethacin 
treatment and peaked at 4 hrs, declining thereafter. Similarly caspase 3 induction occurred 
at I hr and levels declined to control levels over an 8 hr incubation period (Fig 5.1 Ob and 
c). 
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Figure 5.10a and b: Caspase expression .m HUVECs treated with indomethacin . 
HUVECs were treated with indomethacin (3IlM) and incubated at 37°C for 0-8 hr. Control 
cells were incubated at 37°C for 8 hr in serum free medium (SFM) + ethanol (EtOH) 
(0.01%). Caspase 9 (a); lane (1) molecular weight marker, (2) SFM + EtOH (0.0 1%), (3) 0 
hr, (4) I hr, (5) 2 hr, (6) 4 hr, (7) 6 hr, (8) 8 hr, (9) 20 % foetal calf serum medium 
(complete medium). Caspase 3 (b); lane (I) lurkat E6.1 cells treated with 50llM paclitaxel 
positive control , (2) molecular weight marker, (3)complete medium, (4) SFM + EtOH 
(0.01%), (5) 0 hr, (6) I hr, (7) 2 hr, (8) 4 hr, (9) 6 hr, (10) 8 hr. The images are 
representative of 3 experiments. 
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Figure 5. 10c: Caspase expression in HUVECs treated with indomethacin. HUVECs were 
treated with indomethacin (311M) and incubated at 37°C for 0-8 hr. Control cells were 
incubated at 37°C for 8 hr in serum free medium (SFM) + ethanol (EtOH) (0.0 I %). The 
data are the mean +/- s.e.m. of 3 experiments (caspase 9) and 2 experiments (caspase 3). 
ANOVA was used to determine significance for all the data with Student's t-test 
identifying the individual points of significance. Significance is compared to SFM + EtOH 
(0.01 %) * p= <0.05. 
5.4.7 Effects of PGE2, VEGF/ 65 and CHO-DEVD on DuP-697 induced 
apoptosis in HUVECs 
Prostaglandin E2 (lOIlM) reversed chromatin c(;mdensation (Fig 5.1 I and 5.12), caspasc 8 
and 9 activation (Fig 5.13) and DNA laddering (Fig 5.14) in HUVECs induced with DuP-
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697 (lOnM). A similar reversal was also observed following treatment of HUVECs with 
the specific caspase-3 inhibitor CHO-DEVD (12.5JlM) as demonstrated by chromatin 
condensation (Fig. 5.11) and DNA laddering (Fig. 5.14). VEGF (50ng/ml) also reversed 
chromatin condensation (Fig. 5.15) and DNA laddering (Fig. 5.16). 
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Figure 5.11: Reversal of DuP-697 induced chromatin condensation by PGE2 and caspase 3 
inhibitor (CHO-DEVD) in HUVECs. DuP-697 (10nM) treated cells were incubated at 
37°C for 24 hr. In parallel experiments PGE2 (lOJlM) or the caspase 3 inhibitor (CHO-
DEVD) (l2.5JlM) were added to the HUVECs simultaneously with DuP-697 and incubated 
at 37°C for 24 hr. Cells were cytospun and stained with acridine orange. The data are the 
mean +1- s.e.m. of at least 3 experiments with 2 replicates in each. ANOVA was used to 
determine significance for all the data with Student's t-test identifying the individual points 
of significance. Significance is compared to serum free media (SFM) + DMSO (0.0 I %) * 
p= <0.05. 
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Figure 5.12: Reversal of DuP-697 induced chromatin condensation by PGE2 and caspa e 3 
inhibitor (CHO-DEVD) in HUVECs. HUVECs were treated with DuP-697 (I OnM) and 
incubated at 37°C in a tissue culture incubator for 24 hr (b) + (c). In parallel experiments 
PGE2 (lO~M) (d) or CHO-DEVD (12.5~M) (e) were added to the HUVECs simultaneously 
with DuP-697 and incubated at 37°C for 24 hr. Control cells (a) were incubated at 37°C for 
24 hr in erum free medium ( FM) with DMSO (0.01%). HUVECs were cytospun and 
stained with acridine orange. The image are representative of3 separate experiments. 
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Figure 5.13: Caspase expression in HUVECs treated with DuP-697 and PGE2• HUVECs 
were treated with DuP-697 (lOnM) + PGE2 (10~) and incubated at 37°C for 24 hr. 
Control cells were incubated at 37°C for 24 hr with in serum free medium (SFM) + DMSO 
(0.01%). HUVECs were lysed and caspase expression was analysed by western blotting 
and densitometry. The data are the mean +/- s.e.m. of 3 experiments (caspase 9) and 2 
experiments (caspase 8) respectively. ANDV A was used to determine significance for all 
the data with Student's t-test identifying the indjvidual points of significance. Significance 
is compared to SFM + DMSO (0.01%) * p= <0.05. 
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Figure 5.14: Induction of apoptotic DNA fragmentation in HUVECs. Control cells were 
incubated at 37°C for 24hr with DMSO (0.01%). DuP-697 (IOnM) treated cells were 
incubated at 37°C for 24 hr. In parallel experiments PGE2 or CHO-DEVD treatments were 
added simultaneously with DuP-697 and incubated for 24 hr at 37°C. Control cells were 
incubated at 37°C for 24 hr in serum free medium (SFM) with DMSO (0.0 I %). DNA was 
extracted using the phenol/chloroform method and visualised by 2% agarose gel 
electrophoresis stained with ethidium bromide. Lane (I) SFM + DMSO (0.01%) (2) 
Actinomycin- D (200nM) positive control (3) DuP-697 (IOnM) (4) DuP-697 + PGE2 (10 
llM) (5) DuP-697 + CHO- DEVD (12.5 llM) (6) IKb Ladder. The image is representative 
of 3 separate experiments. 
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Figure 5.15a: Reversal of DuP-697 induced chromatin condensation by VEGF in 
HUVECs. DuP-697 (lOnM) treated cells were incubated at 37°C for 24 hr. In parallel 
experiments VEGF (50nglml) was added to the HUVECs simultaneously with DuP-697 
and incubated at 37°C for 24 hr. Control cells were incubated at 37°C for 24 hr in serum 
free medium (SFM) + DMSO (0.01 %). HUVECs were cytospun and stained with acridine 
orange. The data are the mean +/- s.e.m. of 3 experiments with 2 replicates in each. 
ANOV A was used to determine significance for all the data with Student's t-test 
identifying the individual points of significance. Significance is compared to SFM + 
DMSO (0.01%) * p= <0.05. 
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Figure 5.15b-e: Reversal of DuP-697 induced chromatin condensation by VEGF in 
HUVECs. DuP-697 (lOnM) treated cells were incubated at 37°C in a tissue culture 
incubator for 24 hr (c) and (d). In parallel experiments VEGF (50ng/ml) was added to the 
HUVECs simultaneously with DuP-697 and incubated at 37°C for 24 hr (e). Control cells 
were incubated at 37°C for 24 hr in serum free medium (SFM) + DMSO (0.01%) (b). 
HUVECs were cytospun and stained with acridine orange. The images are representative of 
3 eparate experiments. 
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Figure 5.16: Induction of apoptotic DNA fragmentation in HUVECs. HUVECs treated 
with serum free medium (SFM) + DuP-697 (lOnM) and/ or VEGF I65 (50nglml) were 
incubated for 24hr at 37°C. Control cells were incubated at 37°C for 24hr in SFM + 
DMSO (0.01 %). HUVECs were lysed and DNA was extracted using the 
phenol/chloroform method and visualised by 2% agarose gel electrophoresis and staining 
with ethidium bromide. Lane (1) DNA Ladder (100 bp) (2) SFM + DMSO (0.01%) (3) 
Actinomycin- D (200nM) positive control (4) DuP-697 (10nM) (5) DuP-697 + VEGF I65 
(50nglml). The image is representative of 3 separate experiments. 
5.4.8 Induction of HUVEC membrane permeability by DuP-697 
Cellular membrane permeability was assessed to assess cell viability using the trypan blue 
exclusion assay. Treatment for 24 hr with DuP-697 caused a dose dependent increase in 
the permeability of the HUVEC membrane to approximately 40% of all cells being stained 
(Fig 5.17). 
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Figure 5.17: Induction of HUVEC membrane permeability by DuP-697. HUVECs treated 
with DuP-697 (0.01- 10 /lM) were incubated at 37°C for 24 hr. Control cells were 
incubated at 37°C for 24 hr in serum free medium (SFM) + DMSO (0.01%). HUVECs 
were counted by haemocytometer. The data are the mean +/- s.e.m. of 3 experiments with 
2 replicates in each. ANOV A was used to determine significance for all the data with 
Student's t-test identifying the individual points of significance. Significance is compared 
to SFM + DMSO (0.01%) * p= <0.05, ** p= <0.01. 
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5.4.9 Effects o/DuP-697and indomethacin on tubule/ormation 
Matrigel gel assays were used to assess angiogenic tubule formation of unstimulated and 
VEGF stimulated HUVECs (Fig 5.18). DMSO (0.01 %) controls formed tubules in ECM 
gel (Fig 5.18a and b). DuP-697 (lOnM) significantly inhibited the tubule formation of 
unstimulated HUVECs (Fig 5.18a and c). Prostaglandin E2 (lOJlM) had no effect on tubule 
formation (Fig 5.18a and d) but significantly reversed the DuP-697 inhibition of tubule 
formation (Fig 5.18a and e). Activation of the HUVECs with VEGF (SOng/ml) increased 
the formation of the tubules relative to control levels (Fig 5.18a and f) and this increase was 
significantly reduced by DuP-697 (lOnM) (Fig 5.18a and g). Addition of VEGF, PGE2 and 
DuP-697 to HUVECs significantly increased tubule formation above control levels (Fig. 
5.18a and h). The non-selective COX-2 inhibitor indomethacin only inhibited tubule 
formation at 311M and above (Fig. 5. 19a and 5.19b-i). 
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Figure 5.18a: Tubule formation ofHUVECs treated with DuP-697. Treated HUVECs were 
incubated at 37°C for 8 hr. In parallel experiments PGE2 (10~M) and/ or VEGF (50ng/ml) 
were added simultaneously with the DuP-697. Control cells were incubated at 37°C for 24 
hr in 20% foetal calf serum medium 199 + DMSO (0.01 %). The data are the mean +/-
s.e.m. of at least 3 experiments with 2 replicates in each. ANOVA was used to determine 
significance for all the data with Student's t-test identifying the individual points of 
significance. Significance is compared to complete medium 199 + DMSO (0.01%) * p= 
<0.05, ** p= <0.01. 
163 
Figure S.18b-h: Tubule formation of HUVECs treated with DuP-697. Control cells were 
incubated at 37°C for 24 hr in complete medium 199 + DMSO (0.01%) (b). Treated cells 
were incubated at 37°C for 8 hr. HUVECs were treated with DuP-697 (IOnM) (c) or in the 
absence (d) or presence (e) of PGE2 (lOflM). HUVECs were treated VEGF (SOnglml) in 
the absence (f) or presence (g) of DuP-697 and with a combination of all treatments (h). 
The images are representative of 3 separate experiments with 2 replicates in each 
experiment. 
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Figure 5.19a: Inhibition of HUVEC tubule formation by indomethacin. HUVECs were 
treated with indomethacin (0.0 I-I 00 11M) and incubated at 37°C for 8 hr. Control cells 
were incubated at 37°C for 24 hr in 20 % foetal calf serum medium (complete medium) 
with ethanol (EtOH) (0.0 I %). The data are the mean +/- s.e.m. of at least 3 experiments 
with 2 replicates in each. ANOV A was used to determine significance for all the data with 
Student's t-test identifying the individual points of significance. Significance is compared 
to complete medium 199 + EtOH (0.01%) * p= -:-0.05, ** p= <0.01, *** p= <0.001. 
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Figure 5.19b-i: Inhibition of HUVEC tubule formation by indomethacin. Untreated cells 
were incubated with 20 % foetal calf serum mydium (complete medium) at 37°C for 8 hr 
(b). HUVECs treated with indomethacin 0.01 (d), 0. 1 (e), 1 (t),3 (g), 10 (h) and 100 ~M 
(i) were incubated at 37°C for 8 hr. Control cells were incubated at 37°C for 24 hr in 
complete medium + ethanol (EtOH) (0.01%) (c). The images are representative for 3 
separate experiments with 2 replicates in each. 
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5.5 Discussion 
The present studies show that DuP-697 induced apoptosis and inhibited capillary-like 
tubule formation in HUVECs. These effects were observed at a concentration of 10 nM 
DuP-697, the concentration equalling the ICso value for inhibition of COX-2 activity in 
vitro (Gierse et al., 1995). 
COX-2 expression in HUVECs was induced by VEGF treatment over 8 hr and being 
maintained to 24 hr. However, expression of COX-2 was also seen in the untreated 
cells. This may be caused by the increased stress by trypsinisation of the cells or the 
incubation of the cells in SFM or 1% FCS medium 199 for 16 hr (Wheeler-Jones, 2005, 
personal communication). DuP-697 inhibited PGE2 production dose dependently in 
SFM with an ICso = 0.01 11M. However, in 20% FCS medium 199 DuP-697 only 
inhibited ~ 20% of PGE2 production in HUVECs. Similarly, indomethacin totally 
blocked PGE2 production in SFM at the IC50 for COX-2 (311M) (Mitchell et aI., 1994). 
At this concentration of indomethacin 50% of COX-2 should still be active and capable 
of producing PGE2. Further analysis of the PGE2 concentrations from the SFM and 
20% FCS medium studies indicate a 27% decrease in total PGE2 production when 
HUVECs were incubated with SFM. This may possibly suggest that the enhanced 
inhibition of PGE2 production seen in SFM by DuP-697 may be caused by a change in 
the expression levels of both COX-l and COX-2. Incubation with SFM may increase 
COX-2 expression and decrease COX-l expression. The change in expression profiles 
would decrease the production of COX-l derived PGE2 and make the majority of PGE2 
in the cells produced via COX-2. The effects seen by DuP-697 mediated inhibition of 
COX-2 would therefore be seem greater than the ~ 20% inhibition that was observed in 
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the 20% FCS medium studies. Parallel studies with DuP-697 on the inhibition of PGI2 
production gave no significant inhibition of PGI2 levels in non-VEGF stimulated cells. 
However, in VEGF-stimulated cells a significant reduction of 20% was shown by 10 
nM DuP-697. This indicates that in basal conditions COX-I is responsible for the 
production of PGI2 with COX-2 only producing PGh under VEGF-stimulated 
conditions. Furthermore, this suggests that PGh and PGE2 production is regulated by 
the varying expression levels of COX-I and COX-2 (Churchman et al., 2006). To 
confirm this further research into the expression of COX-l and COX-2 under stress 
conditions is required. 
Results from various cell types indicate that inhibition of COX-2 is associated with the 
induction of apoptosis whereas the inhibition of COX-l may not be involved. For 
instance, in U397 cells, inhibition of COX-I did not induce apoptosis whereas 
inhibition of COX-2 was required to induce apoptosis in vitro (Riendeau et al., 1997, 
Johnson et al., 2001). In addition, COX-2 over-expression in endothelial cells has been 
shown to promote cell survival (Leahy et al., 2002). In our studies we have found that 
the non-specific COX inhibitor indomethacin induced caspase activation and chromatin 
condensation only when used at concentrations known to inhibit COX-2 c:: 3 J.lM; 
Mitchell et ai., 1994). This supports the notion that COX-2 may indeed be associated 
with cell survival and protection against apoptosis. 
DuP-697 induced caspase dependent HUVEC chromatin condensation and DNA 
laddering. Similarly other selective COX-2 inhibitors, celecoxib and NS-398, have 
been shown to induce chromatin condensation and DNA fragmentation in vitro and in 
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vivo although at concentrations far higher than those reported to inhibit COX-2 in vitro 
(Wu et al., 2003, Niederberger et al., 2004, Zhang et aI., 2005). 
In parallel with the above observations, the studies also revealed that PGE2 or VEGF 
prevented the induction of chromatin condensation and DNA laddering in HUVECs by 
10 nM DuP-697. Moreover, treatment of cells with VEGF stimulated PGE2 production 
and resulted in a time-dependent induction of COX-2 protein which was only expressed 
at minimal basal levels in cells not stimulated with VEGF. These findings indicate that 
both PGE2 and VEGF may protect against DuP-697 induced apoptosis in these cells. 
DuP-697 was able to inhibit PGE2 production in HUVECs cultured in SFM and 20% 
FCS medium 199 by 50% and 23% when used at the concentrations that induced 
apoptosis, further suggesting a critical role for PGE2 in cell survival. Previous studies 
have shown that exogenous PGE2 can prevent apoptosis in HCA-7 human colon 
carcinoma cells induced by selective COX-2 inhibition (Sheng et al., 1998). VEGF can 
induce expression of anti-apoptotic proteins Bcl-2 and Al in HUVECs (Gerber et aI, 
1998), which together with the actions of PGE2 would suggest a pro-survival and anti-
apoptotic actions of these two molecules. 
Several studies implicate caspases as mediators of apoptosis induced by COX-2 
inhibitors. Caspases 3, 8 and 9 were induced by DuP-697 in HUVECs and the apoptosis 
proved to be caspase 3 dependent as a selective caspase 3 inhibitor (CHO-DEVD) 
inhibited chromatin condensation and DNA fragmentation. Similarly, in several other 
studies, the induction of caspase dependent apoptosis by selective COX-2 inhibitors has 
been identified. For instance, Basu et al. (2005) and Dandekar et al. (2005) have 
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reported that 48 h treatment of MDA-MB-231, MDA-MB-468 breast cancer cells and 
PC3-MC prostrate cancer cells respectively with celecoxib resulted in caspase 3, 7 and 9 
activation during apoptosis. 
Three possible pathways of caspase activation have been suggested in cells treated with 
selective COX-2 inhibitors. Selective COX-2 inhibitors (NS-398, celecoxib, rofecoxib) 
have been shown to inhibit cell signalling e.g. Akt and ERK, prevent production of 
PGE2 and inhibit anti-apoptotic Bcl-2 protein expression (Ghosh et al., 2000, Hsu et al., 
2000, Johnson et al., 2001, Basu et al., 2005). Nor et al. (1999) and Pai et al. (2001) 
have suggested that this inhibition of PGE2 may lead to decreases in Bcl-2 protein 
expression and promote the mitochondrial pathway of apoptosis. 
PGE2 is also an important mediator in integrin binding to the ECM. Inhibition of PGE2 
decreases the expression of avp3 integrin (Dormond et al., 2002). The inhibition of 
avp3 integrin binding to the ECM may result in two pathways being activated (1) 
inhibition of anti-apoptotic Bcl-2 protein expression, which precedes the activation of 
mitochondrial pathway apoptosis (Pollman et al., 1999, Dormond et al., 2002). (2) Fas 
receptor (Fas R) trimerisation and the activation of caspase 8 through the death receptor 
pathway of apoptosis (Aoudjit et al., 2001). 
It has also been shown that COX-2 sequesters p53 inhibiting apoptosis. Selective 
inhibition of COX-2 prevented the binding of p53 and increasing active caspase 9 
expression (Choi et a/., 2001). Furthermore, in other studies Li et al. (2001) identified 
the mechanism for selective COX-2 inhibitor induced caspase activation in SW480 and 
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SW620 colon carcinoma cells as cyt-c and caspase 9 dependent. These two findings 
imply that COX-2 may be important in preventing mitochondrial permeability. 
In relation to these three possible mechanisms of caspase activation, our findings that 
both caspase 8 and 9 were induced within 1 hr of DuP-697 treatment can support all of 
the mechanisms suggested. However, disruption of the av~3-ECM binding appears to 
promote the induction of both caspase 8 and 9 at the same time, which is similar to the 
current data. The decrease in integrin binding may induce an inhibition of anti-
apoptotic Bcl-2 protein expression and promote Fas R trimerisation increasing the 
activation of caspase 9 and caspase 8 respectively. This suggestion would explain the 
activation of dual initiator caspases in the present study with no predominant apoptotic 
pathway being obvious. 
Caspase activation may also be caused by the other possible mechanisms as stated 
above. Inhibition of COX-2 by DuP-697 is non-competitive (Rosenstock et al., 1999), 
possibly changing the conformation of the enzyme by allosterism and preventing AA 
from entering the active site. If the conformation ofCOX-2 was changed this may also 
prevent COX-2 binding other proteins, for instance p53. The prevention of COX-2 
binding would leave p53 to act as a transcription factor for the pro-apoptotic Bcl-2 
proteins and increase mitochondrial pathway of apoptosis and activating caspase 9 
(Choi et al., 2001; Li et aI., 2001). Furthermore, this pathway would be promoted by a 
decrease in anti-apoptotic Bcl-2 proteins caused by a loss ofPGE2 production (Ghosh et 
al., 2000, Hsu et al., 2000, Johnson et al., 2001, Basu et al., 2005). However, this 
would possibly lead to a large increase in caspase 9 expression, which is not seen in the 
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current work. Further research would have to be conducted into the expression ofBcI-2 
proteins and p53 sequestering to confinn the involvement of these pathways. 
Selective COX-2 inhibition may promote the induction of HUVEC apoptosis as was 
further confinned with indomethacin. In these studies indomethacin induced apoptotic 
chromatin condensation and caspase activation only at concentrations that inhibited 
COX-2 (> 3)lM) (Mitchell et al., 1994). However whether PGE2 inhibition is the cause 
of the induction of apoptosis is unclear since indomethacin (0. 125)lM) inhibited PGE2 
production by 50% without inducing apoptosis. This concentration of indomethacin 
does not inhibit COX-2 activity (Mitchell et al., 1994). It therefore may be suggested 
that PGE2 may not be the only contributing factor in HUVEC survival, but it is clear 
that COX-2 activity is very important in cellular homeostasis. 
COX-2 has been shown to be important in angiogenesis whereas COX-l has no effect 
on this process (Bryant et al., 1998; Pentland ·et al., 2004). Treatment of HUVECs with 
DuP-697 (10 nM) prevented capillary-like tubule formation in vitro whereas the non-
specific COX inhibitor indomethacin only inhibited angiogenesis at concentrations 
known to inhibit COX-2 (2: 3 /-lM). These data suggest that COX-2 is required for 
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tubule formation. This action may be related to PGE2 production since inhibition of 
tubule formation by DuP-697 was reversed by exogenous PGE2 in our studies. 
Similarly, Leahy et al., (2002) found that PGE2 prevented the inhibition of in vivo rat 
cornea angiogenesis by celecoxib. PGE2 has been shown to increase binding 
endothelial cells to the ECM through av~3 dependent mechanism (Leahy et al., 2002; 
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Yazawa et al., 2005). Together with the present study these findings suggest a strong 
link between angiogenesis and PGE2 production. 
PGE2 may induce VEGF expression through binding to the EP4 receptor and activating 
the JNK and HIF-la pathways (Ghosh et al., 2000, Kuwano et ai., 2004, Huang et ai., 
2005). Once induced, VEGF enhances COX-2 expression forming a positive feedback 
loop that regulates both VEGF production and COX-2 induction (Caughey et al., 2001). 
The products of COX-2, including PGE2 and TXA2 may then play an important role in 
cellular migration and tubule formation and specific inhibition of PGE2 and TXA2 
prevents proliferation and angiogenesis (Wu et al., 2003, Jantke et al., 2004). However, 
the induction of tubule formation by PGE2 is probably independent of VEGF induction 
since there was no reversal of the inhibition of tubule formation in the presence of DuP-
697 by VEGF. This suggests that PGE2 may have a separate signalling pathway to 
affect tubule formation. 
Similarly, previous studies with selective COX-2 inhibitors e.g. celecoxib and NS-398 
have shown an inhibition of COX-2 activity, prostaglandin and thromboxane production 
and capillary-like tubule formation in vitro and angiogenesis in vivo by decreasing avp3 
integrin expression and binding to the ECM (Pollman et ai., 1999, Ghosh et al., 2000, 
Dormond et ai., 2002, Leahy et al., 2002, Yazawa et al., 2005). Furthermore the 
inhibition of avp3 integrin expression and binding to the VEGFR-2 decreased receptor 
phosphorylation upon VEGF 165 activation (Soldi et aI., 1999) preventing VEGFR-2 
signalling; supporting our findings that VEGF165 did not reverse DuP-697 inhibition of 
angiogenesis without PGE2 treatment. 
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In summary, the selective COX-2 inhibitor DuP-697 has been found to induce apoptosis 
and prevent capillary-like tubule fonnation in vitro at pharmacologically relevant 
concentrations. The effects observed have been shown to be probably caused by the 
specific inhibition of COX-2. The induction of apoptosis is possibly caused by the 
inhibition of PGE2 and avp3 integrin binding to the ECM. However this has to be fully 
established by further experimentation. The inhibition of capillary-like tubule 
fonnation does appear to be strongly linked to the expression of COX-2 derived PGE2 
possibly through a mechanism of avp3 integrin binding. The importance of other COX-
2 metabolites that are expressed and the effects on angiogenesis must not be ruled out 
and further study must be done to confinn the role of PGE2 and other COX-2 
metabolites in tubule formation. 
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6.0 Isolation, growth and transfection of the apoptosis 
repressor with caspase recruitment domain (ARC) 
6.1 Introduction 
Apoptosis repressor with caspase recruitment domain (ARC) is a novel endogenous 
apoptosis inhibitor found to have high sequence similarity to some caspase binding proteins 
e.g. APAF-l and FADD. The structural similarity observed by ARC causes interaction 
with pro-caspases and pro-apoptotic proteins e.g. Bax and AP AF -1 preventing the 
activation of caspases and therefore apoptosis as described in section 1.3.5.1. Expression 
of the ARC gene has been characterised in heart and brain tissue in humans and varies in 
expression levels depending on cellular environment and experimental conditions. 
Expression in heart tissue may indicate that the vascular system may express ARC; 
however the vascular system beyond the heart tissue has not been tested for ARC. Possible 
ARC expression in endothelium may explain the slow cellular turnover rate and would give 
insight in to the mechanisms of endothelial cell apoptosis. 
Transfection of primary HUVECs has been found to be difficult with cells not recovering 
from the procedure or not taking up sufficient plasmid to express the protein. Methods for 
the transfection of primary HUVECs therefore will have to be optimised before ARC 
transfection takes place. 
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6.2 Aims 
• To isolate the plasmid containing the ARC gene. 
• Transformation of competent bacteria with the ARC gene. 
• To assess the size of ARC gene insert. 
• To transfect primary HUVECs with the ARC gene. 
6.3 Methods 
• Plasmid pCDNA-3 containing the ARC gene was given as a gift from Professor 
Chen Xi (Division of Biochemistry, Cardiovascular Institute and Fu Wai Hospital, 
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 
China) on filter paper and was regenerated as described in Section 2.7.2. 
• Preparation of competent cells and the pCDNA3-ARC and the transformation of 
competent DH5a E.coli have all been described in Section 2.6. 
• Restriction analysis (Section 2.6.6) was designed using the webcutter program and 
completed using Hine II, Xba I, Not I, Hind III and Shb I digestions in a 10111 
reaction with a concentration of 0.5 units/JlI of restriction enzyme and analysed on a 
1 % agarose gel. 
• Transfection methods used were as described in Section 2.7 and were optimised 
using green fluorescent protein and UV microscopy then ARC was transfected in to 
HUVECs. 
• ARC expression in HUVECs was confirmed using western blotting (Section 2.4) 
with an anti-ARC rabbit polyclonal antibody (Merck biosciences) at a concentration 
of 1 Jlg/ml. 
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6.4 Results 
6.4.1 Expression of the ARC protein in HUVECs 
Freshly isolated HUVECs from umbilical cords were lysed and different amounts of protein 
loaded on polyacrylamide gel during western blotting. Freshly isolated HUVECs were 
found to express ARC protein as determined by western blotting (Fig 6.1). Parallel 
samples from HUVECs grown in 20% FCS media over time (pO-p5) did not express the 
ARC protein (Fig 6.2- 6.4). HUVECs treated over 24 hr with serum free media also did not 
express the ARC protein (Fig 6.5). 
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Figure 6.1: The expression of ARC in freshly isolated HUVECs. Lane (I) Molecular 
weight marker, (2) Freshly isolated HUVECs 20)lg protein, (3) 40)lg protein, (4) 60)lg 
protein, (5) 80j.lg protein. The blot is representative of 3 separate experiments. 
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Figure 6.2: The expression of ARC in passage 0 HUVECs grown in 20% FCS medium 199 
for up to 24 hr. Control cells were treated with 20% FCS medium 199. All other cells 
were quiesced for 16 hr with 1% FCS medium 199 for 16 hr before treatment with 20% 
FCS medium 199. Lane (1) Molecular weight marker, (2) Freshly isolated HUVECs, (3) 
control, (4) 0 hr, (5) I hr, (6) 2 hr, (7) 4 hr, (8) 8 hr, (9) 24 hr. The blot is representative of 
3 experiments. 
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Figure 6.3: The expression of ARC in passage I HUVECs grown in 20% FCS medium 199 
for up to 24 hr. Control cells were treated with 20% FCS medium 199. All other cells 
were quiesced for 16 hr with 1% FCS medium 199 for 16 hr before treatment with 20% 
FCS medium 199. Lane (1) Molecular weight marker, (2) control, (3) 0 hr, (4) 1 hr, (5) 2 
hr, (6) 4 hr, (7) 8 hr, (8) 24 hr. The blot is representative of 3 experiments . 
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Figure 6.4: The expression of ARC in passage 5 HUVECs grown in 20% FCS medium 199 
for up to 24 hr. Control cells were treated with 20% FCS medium 199. All other cells 
were quiesced for 16 hr with 1% FCS medium ] 99 for] 6 hr before treatment with 20% 
FCS medium 199. Lane (1) Molecular weight marker, (2) control, (3) 0 hr, (4) I hr, (5) 2 
hr, (6) 4 hr, (7) 8 hr, (8) 24 hr. The blot is representative of 3 experiments. 
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Figure 6.5: The expression of ARC in passage 5 HUVECs grown in 0% FCS medium 199 
for up to 24 hr. Control cells were treated with 20% FCS medium 199. Lane (I) Molecular 
weight marker, (2) control, (3) 0 hr, (4) I hr, (5) 2 hr, (6) 4 hr, (7) 8 hr, (8) 24 hr. Image is 
representative of 3 experiments. 
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6.4.2 Analysis of ARC RNA transcription in HUVECs 
Due to HUVECs not expressing the ARC protein in cultured cells RNA was extracted, as 
identified by the 18s and 28s rRNA bands, (Fig 6.6) and analysed to assess whether control 
of ARC gene expression is between transcription of the gene and translation of the protein . 
Following on from previous work (McKay, 2004) the reverse transcription-PCR (RT-PCR) 
of the HUVEC RNA at 55°C gave a 400 bp fragment of cDNA (Fig 6.7). Optimisation of 
the RT-PCR with different annealing temperatures, 50°C, 55°C and 60°C only produced a 
similar 400 bp cDNA band at the 50°C PCR rea~tion (Fig 6.8). 
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Figure 6.6: Isolation of passage 5 HUVEC RNA. Lane (I) I Kb DNA ladder, (2) 1:5 
dilution of RNA, (3) I: 1 dilution of RNA. Samples were analysed on 1.2 % Agarose gel 
electrophoresed at 80v. The image is representa,tive of 3 separate experiments. 
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Figure 6.7: Reverse transcriptase (RT)-PCR of passage 5 HUVEC RNA for the ARC gene. 
Lane (I) 100 bp DNA ladder, (2) positive control (McKay, 2004) (3) Reaction - AMV-
reverse transcriptase, (4) Reaction - RNA template, (5) 5SoC reaction. Samples were 
analysed on 1.2 % Agarose gel electrophoresed at 80v. The image is representative of 3 
separate experiments. 
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Figure 6.8: Reverse transcriptase (RT)-PCR of passage 5 HUYEC RNA using a gradient of 
annealing temperature. Lane (1) 1 Kb DNA ladder, (2) positive control (McKay, 2004) (3) 
SO°C reaction - AMY-reverse transcriptase, (4) 50°C reaction - RNA template, (5) 50°C 
reaction, (6) 55°C reaction - AMY-reverse transcriptase, (7) 55°C reaction - RNA 
template, (8) 55°C reaction, (9) 60°C reaction - AMY-reverse transcriptase, (10) 60°C 
reaction - RNA template, (11) 60°C reaction . . Samples were analysed on 1.2 % Agarose 
gel electrophoresed at 80v. The image is representative of 3 separate experiments. 
6.4.3 Transformation of competent DH5a E.coli with ARC 
The plasmid pCDNA3-ARC was soaked from t~e filter paper in TE buffer and transformed 
into competent DH5a E.coli. After 24 hr incubation in ampicillin supplemented Luria-
Bertani (L8) broth and mini prep isolation the plasmid was found to be amplified in the 
bacteria. Agarose gel analysis was run with 4: 1 dilution of samples with loading buffer 
(Fig 6.9). 
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Figure 6.9: Isolation of pCDNA3-ARC from transfected DH5a E.coli indicating the 
presence of the plasmid. Lane (1) IKb DNA ladder (2) Isolation I (0.161lg/1l1 DNA), (3) 
Isolation 2 (0.241lg/1l1 DNA), (4) Isolation 3 (0.241lg/1l1 DNA), (5) Isolation 4 (0.241lg/1l1 
DNA). The image is representative of 3 experiments. 
6.4.4 Restriction of pCDNA3-ARC isolated from transformed DH5a E. coli 
Treatment with Hinc II resulting in fragments of 200 bp, 661 bp, 840 bp, 1500 bp, 2274 
bp, 3199 bp, and 3825 bp and possibly cut the ARC insert. Digestion with Xba J failed to 
restrict the plasmid as no bands except the control plasmid were visible on the ge l. The 
Not I enzyme cut the plasmid giving two fragments of 7396 bp and 6000 bp. Hind III 
restriction gave 6000 bp and 820 bp fragments. Shb J restricted the plasmid resulting in 
fragments of 5233 bp, 804 bp and 583 bp (Fig 6.] 0). The Not r restriction digest indicated 
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that the size of the complete pCDNA3-ARC was approximately 7396 bp and with the size 
of pCDNA3 being 5446 bp (Invitrogen Life Technologies) estimated the size of the ARC 
gene insert as 1950 bp. 
To confinn the presence of the ARC gene and to further confirm the size of the ARC gene 
insert the mini-prep isolated pCDNA3-ARC was amplified using ARC specific primers by 
PCR. Agarose gel analysis of the PCR products gave one major DNA band of 
approximately 2 Kb (Fig 6.11). 
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Figure 6.10: The digestion of pCDNA3-ARC with restriction enzymes to size the ARC 
gene insert in the pCDNA3.1 plasmid. Lane (1) lKb ladder, (2) pCDNA3-ARC, (3) Hinc 
fI digestion, (4) Xba I digestion, (5) Not I digestion, (6) Hind III digestion , (7) Shb I 
digestion. The image is representative of 3 separate experiments. 
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Figure 6.11: The PCR amplification of ARC gene insert from the isolated pCDNA3-ARC 
plasmid, indicating the presence of the ARC gene. Lane (I) 1 Kb ladder, (2) Plasmid 
isolation I, (3) Plasmid isolation 2 (4) Plasmid isolation 3, (5) Plasmid isolation 4. Image 
is representative of 3 separate experiments. 
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6.4.5 Transfection of HUVECs with pCDNA3-ARC 
Following the successful identification of the ARC gene in the pCDNA3-ARC construct 
cultured HUVECs (passage 1-4), which do not express ARC, were optimised for 
transfection with ARC using a number of techniques and the pCDNA3.1-GFP plasmid. 
HUVEC transfection using the JetPEI-HUVEC transfection reagent (Section 2.7.8) gave a 
transfection efficiency of approximately 20-30% of the cells plated (Fig 6.12). Following 
recombinant green fluorescent protein (GFP) expression in HUVECs the GFP expression 
was used as a positive control for successful transfection of following experiments. 
HUVECs were subsequently transfected with pCDNA3-ARC (Fig 6.13). Further analysis 
of the transfected HUVECs by western blotting gave a single protein band using a specific 
monoclonal anti-ARC antibody at approximately 30 kDa in size (Fig 6.14). 
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Figure 6.12: Transfection of HUVECs (passagel-4) with pCDNA3.I-GFP to assess 
tran fection efficiency. Control cells were transfected with no plasmid or DNA. Treated 
cells were transfected with vehicle plasmid and pCDNA3.I-GFP. Picture (a) control cells 
under light microscopy, (b) control cells under fluore cent microscopy, (c) HUV C + 
pCDNA3.1 under light micro copy, (d) HUVECs + pCDNA3.1 under fluorescent 
microscopy (e, g) pCDNA3. J -GFP transfected HUVECs 1 and 2 under light and 
fluore cent micro copy, (f, h) pCDNA3.I-GFP transfected HUVEC 1 and 2 under 
fluorescent micro copy. Images are representative of3 separate experiments. 
188 
-(c) 
, 
Figure 6.13: Transfection of HUVECs (Pl-p4) with pCDNA3.1-GFP. Control cells were 
transfected with no plasmid or DNA. Treated cells were transfected with vehicle plasmid 
and pCDNA3.I-GFP. Picture (a) control cells under light microscopy, (b) control cells 
under fluorescent microscopy, (c) HUYECs + pCDNA3.1 under light microscopy, (d) 
HUVECs + pCDNA3.l under fluorescent microscopy (e) pCDNA3.I-GFP transfected 
HUVECs under light microscopy, (f) pCDNA3. I -GFP transfected HUVECs under 
fluorescent microscopy. Images are representative of3 separate experiments. 
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Figure 6.14: Expression of recombinant ARC protein in HUVECs. Lane (I) pCDNA3-
ARC + JetPEI-HUVEC, (2) pCDNA3-ARC - JetPEI-HUVEC, (3) pCDNA3. I + JetPEf-
HUVEC, (4) pCDNA3.1 - JetPEI-HUVEC, (5) pCDNA3.I-GFP + JetPEI-HUVEC, (6) 
pCDNA3.1-GFP - JetPEI-HUVEC, (7) - pla,smid + JetPEI-HUVEC, (8) - plasmid -
JetPEJ-HUVEC, (9) Molecular weight marker. The image is representative of 3 separate 
experiments. 
6.4.6 Inhibition of DuP-697 induced apoptosis in pCDNA3-ARC transfected 
HUVECs 
After successful transfection with the pCDNA3-ARC (Fig 6.13 and 6.14) HUVECs were 
treated with DuP-697 (0.01-1 )lM) for 24 hr, HUVECs treated with DuP-697 signi ficantly 
induced ~ 27% chromatin condensation. Parallel studies with over-expression of the 
recombinant ARC protein and pCDNA3.I-GFP did not affect the levels of DuP-697 
induced chromatin condensation (Fig 6.15). However, DMSO controls were also found to 
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induce significant (~20%) chromatin condensation when transfected with either 
pCDNA3.1-GFP or pCDNA3-ARC compared to the non-transfected cells. 
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Figure 6.15: Induction of chromatin condensation by DuP-697 in HUVECs transfected 
with pCDNA3-ARC. Untransfected HUVECs were treated with serum free medium 
(SFM) + DuP-697 (lOnM) for 24 hr at 37°C. HUVECs transfected with pCDNA3-ARC/ 
pCDNA3.1 were incubated in 20% foetal calf serum medium (complete medium) for 24 hr 
prior to induction of chromatin condensation with DuP-697 (lOnM) in SFM for 24 hr at 
37°C. Control cells were treated with SFM + DMSO (0.01 %). The data are representative 
of 3 separate experiments. ANOVA was used to determine significance for all the data 
with Student's t-test identifying the individual points of significance. Significance was 
compared to SFM + DMSO (0.01%) * p= <0.05. 
, 
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6.5 Discussion 
This chapter of results indicates that the apoptosis repressor with a CARD domain is 
endogenously expressed in HUVECs but is down regulated in tissue culture by possible 
transcriptional control of the ARC gene. Exogenous transfection of the ARC gene was 
shown to increase the expression of ARC in cultured HUVECs with little effect on 
DuP-697 induced chromatin condensation. 
Several studies have shown that ARC is expressed in many different tissues e.g. cardiac 
tissue, skeletal muscle and some brain regions (Koseki et at., 1998, Dowds and Sabban, 
2001). Isolation of fresh HUVECs and immediate western blot analysis indicated that 
HUVECs in vivo endogenously express the ARC protein at low levels. The 
identification of a protein band of approximately 20 kDa proteins as ARC is consistent 
with Koseki et at. (1998) reporting that heart tissue transcribed the ARC gene with a 
predicted protein molecular weight of 22.6 kDa. This is however the first study to 
possibly identify the expression of the ARC protein in the vasculature. 
The expression of ARC protein may be highly regulated and may require elements in 
vivo which are not present in our cell culture medium or the additional growth factors 
provided e.g. ECGF. This conclusion is based on the fact that expression of ARC 
rapidly disappeared when freshly isolated cells were incubated in vitro with the protein 
becoming undetectable even just after 24 hr in culture. Similarly it has been reported 
that the addition of growth factors into culture medium did not enhance ARC expression 
in PC12 cells (Dowds et at., 2001), supporting the suggestion that culture medium does 
not contain the required supplements to induce ARC. Contrary to the study in PC12 
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cells by Dowds et aI., (2001) the present findings indicated that growth in serum free 
medium did not induce the expression of the ARC protein in tissue cultured HUVECs. 
This possibly suggests that the ARC protein may be expressed through stress activation, 
but incubation with serum free medium did not caused enough stress in HUVECs to 
activate transcription of the gene. Cell survival in HUVECs may be due to other 
possible mechanisms e.g. avp3 integrin-ECM binding (Section 5.5). 
Analysis of the transcription of the ARC gene (l6q22.1) in cultured HUVECs did not 
indicate a clear and consistent cDNA band following RT-PCR analysis. These results 
possibly indicate that transcription of the ARC gene has been down regulated during 
tissue culture. 
These findings suggest that down regulation of the ARC transcript and protein 
expression is not due to the presence of growth factors in the media. However at the 
moment the mechanism behind the down regulation of the gene transcription and 
protein expression is unclear. 
The presence of the ARC insert in the pCDNA3 plasmid was confirmed by enzymatic 
restriction of the plasmid and by PCR. Restriction of the plasmid using different 
restriction enzymes indicated the total size of the plasmid was 7396 bp with the insert 
being ~1950 bp in size. This was confirmed by PCR which gave a product of ~ 2 Kb 
indicating the ARC gene was present in the plasmid. 
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Transfection of HUVECs with the pCDNA3-ARC plasmid produced a single protein 
band at -30 kDa. The estimated molecular weight identified for the ARC protein is 
22.6 kDa (Koseki et al., 1998), however other studies have identified the transfected 
protein molecular weight in H9c2 cells at approximately 32 kDa (Neuss et aI., 2001), 
which supports our expressed protein in transfected HUVECs as ARC. Furthermore no 
protein of similar weight is expressed in any of the cells not transfected with the ARC 
gene indicating that the protein expressed in HUVECs is probably ARC. 
Transfection of HUVECs with pCDNA3-ARC and the vector pCDNA3.1 induced a 
significant increase in chromatin condensation with further treatment of DuP-697 not 
having any additional effect. This is similar to levels of chromatin condensation seen in 
transfected HEK293 cells, SK-N-BE cells and H9c2 cells, which all indicate a 10-15% 
increase in condensed chromatin and cell death after transfection with ARC or empty 
vector (Li et ai.. 2002, Gustafsson et ai.. 2004, Jo et aI., 2004). This indicates that 
transfection of the HUVECs may have increased intracellular stress levels inducing 
some chromatin condensation without requiring DuP-697. The explanation for this may 
be possible starvation of the cells after transfection. It has been noted that transfection 
of bacteria increases the requirement of ATP to maintain the cells (Brown, 1998). This 
may also be the case in the transfected HUVECs and incubation in SFM may have 
induced chromatin condensation due to the lack of supplements in the medium. 
In contrast to our findings, previous studies show that ARC transfected cells inhibited 
the all activation of chromatin condensation through preventing caspase dependent 
apoptosis (Koseki et al.. 1998, N euss et aI., 2001, Li et al., 2002, Gustafsson et al., 
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2004, Jo et al., 2004). However, treatment with DuP-697 did not give any additional 
induction of chromatin condensation above control levels for pCDNA3-ARC or 
pCDNA3.1-GFP transfected cells. This suggests that further chromatin condensation 
was possibly inhibited due to the transfection of the cells decreasing intracellular ATP 
levels and preventing the activation of the caspase cascade. Alternatively, it may be the 
chromatin condensation observed in the study is not due to apoptosis but necrosis and 
further confirmation of apoptosis by DNA fragmentation and caspase activation is 
required. 
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7 General Discussion 
In recent years induction of endothelial cell apoptosis and inhibition of angiogenesis 
have been seen as a target for tumour treatment, rheumatoid arthritis and other 
inflammatory diseases (Carmeliet, 2000; Cao, 2001; Chavakis and Dimmeler, 2002; 
Folkman, 2003). The processes of angiogenesis and apoptosis are closely linked to each 
other with COX enzymes being influential in both pathways (Leahy et aI., 2002; 
Yazawa et al., 2005 and results chapter 5) (Fig 7.1). The COX pathway has been 
identified as important in endothelial cell apoptosis with specific interest being given to 
COX-2. Increased expression of COX-2 by VEGF binding to endothelial cells has been 
shown to decrease apoptosis through the formation of COX-2 metabolites e.g. PGE2 
(Tsujii and Dubois 1995; Leahy et ai, 2002; King et ai, 2004; Lui et al., 2004; Yazawa 
et al., 2005). Furthermore, in this study it has been suggested that the expression profile 
of the COX enzymes may vary during cellular stress. Total PGE2 production was 
shown to be decreased in HUVECs incubated with SFM compared to cells incubated in 
20% FCS medium. This may possibly be caused by a decrease in the expression in 
COX-l and increase COX-2 expression as explained previously (Section 5.5), 
suggesting further importance for COX-2 in cell homeostasis and survival. 
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Figure 7.1: Schematic diagram of the role of COX-2 in the apoptosis and angiogenesis pathways. COX-2 involvement in angiogenesis and 
apoptosis is mediated through prostaglandin production specifically PGE2, which may cause a positive feedback loop of VEGFR 
phosphorylation, cell survival, proliferation and migration (Nor et al., 1999; Carmeliet, 2000; Aoudjit et a!., 2001; Choi et a!., 2001: 
Giordano and Johnson 2001; Lin et al., 2001; Pai et al., 2001; Gately and Li, 2004; Basu et al., 2005). 
197 
Specific inhibition of COX-2 in endothelial cells induces a caspase-depcndent apoptosis 
and inhibits in vitro and in vivo angiogenesis with no effect observed when only COX-l 
is inhibited (Leahy et af., 2002; Basu et af., 2005; Yazawa et af., 2005 and results 
chapter 5). Studies with paracetamol further indicated the induction of apoptosis 
through the inhibition of COX-2. Paracetamol used at a concentration known to inhibit 
COX-2 expression (300 11M) (Churchman et af., 2000) induced chromatin condensation 
and some DNA laddering without caspase 3 induction at 24 or 48 hr (results chapter 3). 
However, this may be that the treatment activated the caspase cascade transiently as 
seen in the DuP-697 and indomethacin studies. Therefore, caspase activation should 
have been identified as early as 1 hr for the samples that caused DNA laddering in the 
initial studies. 
COX-2 specific effects have been shown to be reversed by exogenous PGE2 indicating a 
role for PGE2 in the prevention of apoptosis, as has previously been seen, and a specific 
role in angiogenesis other than increasing VEGF expression (Ghosh et af., 2000;, Hsu et 
af., 2000; Johnson et a/., 2001; Basu et a/.,2005). 
Previously proposed mechanisms to the induction of apoptosis through PGE2 inhibition 
(Nor et af., 1999; Pollman et af., 1999; Choi et af., 2001; Pai et af., 2001; Dormond et 
a/., 2002) and the data acquired in this study do indicate a strong possibility that PGE2 
inhibition may be the cause of endothelial cell apoptosis in this case. However to 
assume that the mechanism of apoptosis activation is the inhibition of the anti-apoptotic 
effects of PGEz may be misleading as PGEz was only fractionally inhibited by DuP-697 
and that other anti-apoptotic COX-2 metabolites e.g. TXA2 would have been inhibited 
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by the selective COX-2 inhibitor (Wu et al., 2003; lantke et al., 2004). The effects seen 
by treatment of endothelial cells with PGE2 may be acting through a parallel pathway to 
reverse apoptosis and not solely reversing the specific inhibition of COX-2 caused by 
DuP-697. Similarly the effect of PGE2 on selective COX-2 inhibited angiogenesis may 
be through a parallel pathway and inhibition of another COX-2 metabolite may be 
responsible for the decrease in capillary-like tubule formation e.g. TXA2 . 
Further work could be completed to inhibit COX-l and the specific PGE2 synthase to 
identify whether induction of the endothelial cell apoptosis is a COX-2-PGE2 specific 
effect or if the expression of the other prostaglandins and COX-2 metabolites are 
important in endothelial cell survival. The individual PG synthases may then be 
inhibited (Wheeler-Jones et al., 2005, personal communication) to identify which of the 
COX-2 metabolites or which combination of metabolites is more important in the 
survival of endothelial cells. Studies into the inhibition of other prostaglandins e.g. 
PGIz by COX-2 inhibitors may also be useful in identifying the metabolites most 
important in apoptosis prevention. The othe'r metabolites of COX-2 induce different 
pathways involved in cell migration, proliferation, adhesion and survival (Nor et ai., 
1999; Carmeliet, 2000; Aoudjit et al .. 2001; Choi et ai., 2001; Giordano and Johnson, 
2001; Lin et al., 2001; Pai et al., 2001; Gately and Li, 2004; Basu et al., 2005). These 
other pathways induced by the other COX-2 metabolites may induce anti-apoptotic 
proteins e.g. xIAP or survivin, which may decrease the morphological changes observed 
in the present study (Chavakis and Dimmeler, 2002; Duval et aI., 2003). 
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To fully assess the potency of selective COX-2 inhibitors for inducing apoptosis a 
further dose response study would be carried out using lower concentrations than the 
present study. Furthennore, research into caspase expression and activation using 
western blots and colorimetric assays may be used to identify the pathways associated 
with selective COX-2 inhibitor induced apoptosis and the mechanisms behind VEGF 
and PGE2 prevention of apoptosis. However, the current study does imply that clinical 
use of selective COX-2 inhibitors e.g. DuP-697 is potentially dangerous. Induction of 
endothelial cell apoptosis would induce weakening of the vascular system. Inhibition 
of subsequent angiogenesis would prevent any repair to damaged blood vessels. Both 
the induction of apoptosis and inhibition of angiogenesis may leave the vascular system 
subject to increased stress and damage. 
Endothelial cells treated with natural products, curcumin and 6-shogaol, which have 
previously been shown to inhibit COX-2 activity (Tjendraputra et at., 2001; Chun et at., 
2003), induced a caspase-independent form of cell death which was not mediated by 
. 
COX-2 inhibition. Cell death was identified by chromatin condensation with no DNA 
laddering and no caspase 3 activation by curcumin in HUVECs and lurkat E6.1 cells. 
This is similar to the previously done studies, which also indicated no caspase 3 activity 
or DNA laddering in curcumin treated cells although there was chromatin condensation 
(Piwocka et at., 1999; Piwocka et at., 2001). Curcumin and 6-shogaol may possibly act 
through similar mechanisms due to the similarities in the structures of the compounds 
(Section 4.5). Both compounds caused chromatin condensation at concentrations far 
higher than was required to inhibit COX-2 (Zhang et at., 1999; Tjendraputra et at., 
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2001; Chun et al., 2003), but did not induce any other markers of apoptosis e.g. DNA 
laddering or caspase 3 activation. 
Whether the morphological changes induced by curcumin and 6-shogaol can be 
identified as apoptosis is unclear, but it is clear that these compounds induce a form of 
cell death similar to apoptosis without the intracellular signalling to activate the 
caspases. Explanations for this type of cell death are speculative but may indicate 
possible pathways that are induced following 6-shogaol and curcumin treatment. The 
observed caspase-independent cell death induced by 6-shogaol and curcumin may be 
due to secondary necrosis, which occurs after the initiation of apoptosis. 
Induction of secondary necrosis is initiated in cells which are undergoing apoptosis but 
fail to maintain ATP levels. Depletion of ATP inhibits full caspase activation 
preventing the caspase-cascade from completing the morphological changes associated 
with apoptosis and induces necrosis (Proskuryakov et al., 2003). Pathways behind this 
have been speculated to be due to the formation of large DNA breaks, by intracellular 
ROS production or direct DNA damage by anti-cancer drugs, which induce production 
of poly (ADP-ribose) polymerase (PARP). PARP induction causes an increase in 
production of the P ARP substrate (NAD+) resulting in depletion in ATP levels. This 
depletion then induces necrosis in the cells (Ha et aI., 1999; Walisser et al., 1999; 
Proskuryakov et aI., 2003). Alternatively, other studies have suggested that opening of 
the mitochondrial permeability transient pore (MPTP) may be responsible for the 
induction of necrosis or apoptosis. Upon cellular stress e.g. oxidative stress the MPTP, 
formed from the VDAC and ANT proteins, opens increasing mitochondrial swelling 
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and rupture of the outer mitochondrial membrane releasing cyt-c. This release of cyt-c 
would therefore activate caspase 9. However if the cellular insult is very severe the 
MPTP may remain open depleting ATP stores and induce necrosis instead of closing 
and inducing apoptosis (Halestrap, 2005). Both of the pathways suggested strongly 
indicate a role for ATP depletion in the activation of a caspase-independent cell death. 
Furthermore, both pathways indicate a possible reason for the activation of chromatin 
condensation and DNA breaks in curcumin and 6-shogaol treated cells without the other 
morphological changes. However, as curcumin did not inhibit mitochondrial activity 
as identified by the MTT assay, it does not appear that mitochondrial disruption is the 
cause of the cell death in this case, though further investigation into the release of cyt-c, 
caspase expression and the activation of P ARP would be required to confirm these 
mechanisms. 
Future investigation into how curcumin and 6-shogaol induce chromatin condensation 
may focus around other endonucleases in the cell. It has been shown that endonuclease 
G, which has been identified in the mitochondria, can fragment DNA with out requiring 
caspase activation in other eukaryotes (Lily et ai., 2001; Parrish et ai., 2001). Other 
studies into the morphological changes e.g. annexin V binding to phosphatidylserine, 
organelle shrinking, and trypan blue exclusion could also be investigated to assess 
which pathways and enzymes are activated. 
Clinically these compounds may be of some use to reduce angiogenesis. Induction of 
COX-2 independent chromatin condensation in HUVECs only occurs at high 
concentrations of curcumin and 6-shogaol, which may not be achievable in vivo, but 
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COX-2 activity would still be inhibited at low concentrations and possibly prevent 
angiogenesis (Yawaza et al., 2005 and results chapter 4). Support for this hypothesis is 
indicated by previous studies which have shown the prevention of HUVEC replication 
by curcumin and 6-shogaol at concentration similar to this study (25-50IlM) (Smith, 
2004). Curcumin has also been shown to inhibit HUVECs forming capillary-like 
tubules in vitro (0-25IlM) and angiogenesis in vivo (lOmM) (Thaloor et al., 1998; 
Gururaj et al., 2002). 6-Shogaol is more potent in the inhibition of COX-2 activity, 
ICso= 2.1IlM, than curcumin (Tjendraputra et al., 2001) and this may indicate that this 
compound is more effective at inhibiting angiogenesis and could be further investigated 
through in vitro capillary-tubule formation assays and in vivo angiogenesis research 
using lower concentrations than were studied in this thesis. 
The investigated effects of the ARC protein are unclear in HUVECs, though this study 
does indicate that ARC may possibly be expressed in the vasculature. Further work 
would include the further identification of the native HUVEC and transfected protein as 
ARC by protein sequencing. Investigation into transcription of the ARC gene may be 
studied through RT -PCR using ARC specific primers and subsequent sequencing of the 
cDNA produced. Mechanisms of tissue culture induced inhibition of ARC expression 
could also be addressed by these methods. The anti-apoptotic effects of ARC would 
have to be reassessed using a stimulus that is known to be blocked by the protein ARC 
e.g. FasL, to prove the protein activity. Furthermore, different strategies for the 
transfection of ARC may have to be considered e.g. adenovirus (Wheeler-Jones, 2005, 
personal communication), to prevent cytotoxicity in the cells induced during 
transfection with pCDNA3-ARC. It is possible that the transfection increased the 
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requirement for supplemented medium (Section 6.5) and it was the incubation with 
SFM that caused the increase in chromatin condensation observed. Possible 
mechanisms for this may be similar to the secondary necrosis pathways discussed 
above, with a decrease in ATP inducing chromatin condensation. However this would 
require further investigation as suggested previously. 
In summary this study indicates the pathways of apoptosis activated in endothelial cells 
have been shown to be dependent on the stimulus used, e.g. actinomycin-D, curcumin 
and 6-shogaol, DuP-697 or indomethacin (results chapter3, 4 and 5). The different 
pathways identified were similar to previous studies, which proposed that certain 
pathways of cell death induced different morphological and biochemical changes in the 
cells with some of the changes associated with apoptosis, e.g. DNA fragmentation and 
caspase activation, not occurring (Collins et al., 1992; Oberhammer et al., 1993; Zakeri 
et at., 1993; Taylor et at., 2001). Three different pathways of cell death have been 
identified in this study; (1) caspase-dependent apoptosis that gives the associated 
morphological and biochemical changes e.g. DNA "laddering", chromatin condensation 
and membrane blebbing, (2) caspase-independent cell death with chromatin 
condensation and no DNA laddering or smearing, (3) necrosis, which was assessed 
positive by trypan blue staining of the cells and by DNA smearing when visualised by 
agarose gel electrophoresis. 
The present study also identified that COX-2 inhibition may not be the only stimulus 
required to induce cell death in endothelial cells, though COX-l inhibition has no effect 
on endothelial cell apoptosis. However selective COX-2 inhibitors induced caspase-
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dependent apoptosis through one or more mechanisms that can be inhibited by PGE2. 
COX-2 inhibition is required to inhibit in vitro capillary-like tubule formation and cell 
replication with PGE2 having a specific role in angiogenesis. 
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9.0 Appendix A: Products and S'uppJier List 
Product 
Primary antibodies 
Anti apoptosis repressor with CARD polyclonal rabbit IgG 
Anti Caspase-3 monoclonal mouse IgG 
Anti Caspase-8 monoclonal mouse IgG 
Anti Caspase-9 monoclonal mouse IgG 
Anti Cyclooxygenase-2 polyclonal goat IgG 
Secondary antibodies 
Anti goat IgG-HRP conjugate 
Anti mouse IgG-HRP conjugate 
Anti rabbit IgG-HRP conjugate 
Assay kits 
BCA protein assay kit 
Caspase-3 cellular activity assay kit 
DNA suicide track ® kit 
JetPEI-HUVEC transfection reagent 
PGE2 ELISA Kit 
228 
Supplier 
Merck 
Biosciences 
Merck 
Biosciences 
Merck 
Biosciences 
Merck 
Biosciences 
Santa Cruz 
Santa Cruz 
Merck 
Biosciences 
Merck 
Biosciences 
Pierce 
Merck 
Biosciences 
Merck 
Biosciences 
Autogen Bioclear 
R&D Systems 
Cell culture and isolation 
Collagenase (type 2a) 
Endothelial cell growth factor 
Foetal bovine serum 
Gelatin 
L-Glutamine 
Media 199 
Penicillin/streptomycin 
RPMI 1640 media 
Trypsin-EOTA 
Matrigel 
Cytospinning and cell staining 
Acridine orange 
Glycerol 
Glass slides 
Gel electrophoresis and western blotting 
Acrylamidel Bisacrylamide (37.5: I) 
Ammonium persulphate 
Bromophenol blue 
Bovine serum albumin 
Photographic developer 
Oithiothreitol 
Enhanced Chemiluminescence Reagents 
EeL photographic film 
Photographic fixer 
229 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Menzel-Glaser 
Sigma 
BDH 
BOH 
Sigma 
Amersham 
Phannacia 
Biotech 
BDH 
Amersham 
Phannacia 
Biotech 
Kodak 
Amersham 
Phannacia 
Biotech 
Glycine 
Methanol 
Nitrocellulose membrane 
Non fat dried milk 
Phosphate buffered saline tablets 
Polyoxyethylene sorbitan monolaurate!Tween 20 
Sodium dodecyl sulphate (SOS) 
TetramethlethylendiamineiTEMEO 
Trizma -Base 
M isce llaneous 
Actinomycin-D 
Agarose 
CHO-OEVD (specific caspase 3 inhibitor) 
Curcumin 
OuP-697 
Ethidium bromide 
Hydrogen peroxide 
Indomethacin 
Lipopolysaccaride (LPS) 
Paclitaxel (Taxol (8:') 
Paracetamol 
6-Shogaol 
Sodium chloride 
230 
BDH 
Fischer Scientific 
Biorad 
Marvel 
Sigma 
Sigma 
Sigma 
BDH 
BDH 
BDH 
Sigma 
Sigma 
Sigma 
Tocris Cookson 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
BDH 
10.0 Appendix B: Solutions and Reagents 
E.coli Gro\\1h Media ' 
I 
LB Agar Tryptone 109! L 
Yeast extract I Sg! L 
NaCI 109! L 
Bacterial agar N°. 1 20g! L 
i 
LB Broth Tryptone 109! L 
Yeast extract Sg! L 
NaCI 109!L 
AmQicillin SOmg!ml diluted to SO ~g/ml 
DNA gel analxsis 
Final Concentration 
TAE buffer Tris (base) 4.84g! L 0.04M 
EDTA 0.372g! L O.OOIM 
I 
pH 8.0 with glacial acetic acid 
i 
TE buffer 1M Tris-Hc1 pH7.4 10 ml O.OIM 
O.SM EDTA pHS.O 2 ml O.OOIM 
231 
Western Blotting 
~ I Final Concentration 
, 
SDS-PAGE Tris (Base) 6g1 L 0.05M 
Electrode Buffer . Glycine 28.8g1 L 0.384 M 
SDS 191 L 0.1 % (w/v) 
Blotting Buffer Tris (Base) 3.03g1 L 25mM 
Glycine 14.41g1 L 192mM 
I I Methanol 0.2 LI L 20% (v/v) 
SDS-PAGE gels 
Resolving gel {xl} 12.5% acrylamide 
15% acrylamide 
1.875 M Tris-Hcl 2 ml 2 ml 
pH 8.8 
DistiJled H2O 3.65 ml 
2.85 ml 
30% Acrylamide/ 4.2 ml 
5 ml 
Bis-acrylamide 
10% SDS (w/v) 100 Jll 100 Jll 
1 O~,~ ammonium 50 III 50 III 
persulphate (w/v) 
232 
SDS-P AGE gels 
Stacking gel (x2) 4% acrylamide 
0.6 M Tris-Hcl pH 0.5 ml 
6.8 
Distilled H2O 3.75 ml 
30% Acrylamidel 0.68 ml 
Bis-acrylamide 
10% SDS (w/v) 50 ~l 
10% ammonium 25 ~l 
persulphate (w/v) 
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